Heterocyclic compounds for medical treatment
Abstract
The present invention provides heterocyclic compounds that bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation in a human or other host. The present invention also provides compounds that can be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
Term
13.4 yearsto projected expiry
Projected expiry 6 March 2040, counted from filing; an application has no term until it is granted.
- Priority and filed
- Published
- Today
- Projected expiry
14 claims: 11 independent, 3 dependent
- 1A compound selected from the group consisting of:or a pharmaceutically acceptable salt thereof;wherein: m is 0, 1, or 2;A 1 is selected from the group consisting of -O-, -S-, -CH 2 -, -CF 2 - and -NH-, and A 2 is -CH 2 -;or A 1 is selected from the group consisting of -O-, -S-, -CH 2 -, and -CF 2 -, and A 2 is-NH-;W is CH or N;X 1 is selected from bond, NR 34 , CH 2 , CHR 34 , C(R 34 ) 2 , O, and S;X 22 is halo, -NH 2 , -NHR 34 , -N(R 34 ) 2 , hydroxyl, thiol, -B(OH) 2 , -Sn(R 36 ) 3 , -Si(R 36 ) 3 , -OS(O) 2 alkyl, -OS(O) 2 haloalkyl, alkenyl, alkynyl, ethynyl, ethenyl, -C(O)H, -NR 34 C(O)alkene, -NR 34 C(O)alkyne, cyano, -SC(O)alkyl, OC(O)alkyl, heterocycle, -C(O)OH, hydrogen, alkyl, aryl, heteroaryl, aliphatic, heteroaliphatic, or carbocyclic;R 2 is independently selected at each occurrence from: -(CH 2 ) 0-1 -(C 3-7 cycloalkyl)-aryl substituted by R 10 ;-(CH 2 ) 0-1 -(C 3-7 cycloalkyl)-aryl;-(CH 2 ) 0-1 -aryl substituted by R 10 ;-(CH 2 ) 0-1 -aryl;-(CH 2 ) 0-1 -C 3-7 cycloalkyl substituted by R 10 ;-(CH 2 ) 0-1 -C 3-7 cycloalkyl;-(CH 2 ) 0-1 -heteroaryl substituted by R 9 ;-(CH 2 ) 0-1 -heteroaryl;-C(=O)C 1-6 alkyl;-C(=O)-N(R 7 ,R 8 );-C(=O)OC 1-6 alkyl;-C 1-6 alkoxy;-C 1-6 alkyl;-CH 2 -O-(CH 2 ) 0-1 -aryl substituted by R 10 ;-CH 2 -O-(CH 2 ) 0-1 -aryl;-O-(CH 2 ) 0-1 -aryl;-halogen;-halogen-C 1-6 alkyl;-hydroxy-C 1-6 alkyl;-N(R 5 ,R 6 );-NO 2 ;-NH-C(=O)C 1-6 alkyl;and -SO 2 -N(R 5 ,R 6 );R 3 is independently selected at each occurrence from: -(CH 2 ) 0-1 -(C 3-7 cycloalkyl)-aryl substituted by R 10 ;-(CH 2 ) 0-1 -(C 3-7 cycloalkyl)-aryl;-(CH 2 ) 0-1 -aryl substituted by R 10 ;-(CH 2 ) 0-1 -aryl;-(CH 2 ) 0-1 -C 3-7 cycloalkyl substituted by R 10 ;-(CH 2 ) 0-1 -C 3-7 cycloalkyl;-(CH 2 ) 0-1 -heteroaryl substituted by R 9 ;-(CH 2 ) 0-1 -heteroaryl;-(CH 2 ) 0-1 -heterocycloalkyl;-C(=O)C 1-6 alkyl;-(CH 2 ) 0-2 -C(=O)-N(R 7 ,R 8 );-C(=O)OC 1-6 alkyl;-C 1-6 alkoxy;-C 1-6 alkyl;-OH;-NO 2 ;-C 1-6 alkyl-N(R 11 )-C(=O)-R 12 ;-CH 2 -O-(CH 2 ) 0-1 -aryl substituted by R 10 ;-CH 2 -O-(CH 2 ) 0-1 -aryl;-O-(CH 2 ) 0-1 -aryl;-halogen;-halogen-C 1-6 alkyl;-hydroxy-C 1-6 alkyl;-hydroxy-C 1-6 alkyl-aryl;-N(R 5 ,R 6 );-NH-C(=O)C 1-6 alkyl;and -NH-C(=O)OC 1-6 alkyl;R 4 is independently selected at each occurrence from: -(CH 2 ) 0-1 -(C 3-7 cycloalkyl)-aryl substituted by R 10 ;-(CH 2 ) 0-1 -(C 3-7 cycloalkyl)-aryl;-(CH 2 ) 0-1 -aryl substituted by R 10 ;-(CH 2 ) 0-1 -aryl;-(CH 2 ) 0-1 -C 3-7 cycloalkyl substituted by R 10 ;-(CH 2 ) 0-1 -C 3-7 cycloalkyl;-(CH 2 ) 0-1 -heteroaryl substituted by R 9 ;-(CH 2 ) 0-1 -heteroaryl;=O as allowed by valence;-C(=O)C 1-6 alkyl;-C(=O)-N(R 7 ,R 8 );-C(=O)OC 1-6 alkyl;-C 1-6 alkoxy;-C 1-6 alkyl;-CH 2 -O-(CH 2 ) 0-1 -aryl substituted by R 10 ;-CH 2 -O-(CH 2 ) 0-1 -aryl;-halogen;-halogen-C 1-6 alkyl;-hydroxy-C 1-6 alkyl;-N(R 5 ,R 6 );and -NH-C(=O)C 1-6 alkyl;R 5 and R 6 are independently selected at each occurrence from H, C 1-6 alkyl and phenyl;or R 5 and R 6 , taken together with the nitrogen to which they are attached, form a heterocycloalkyl ring;R 7 and R 8 are independently selected at each occurrence from Hand C 1-6 alkyl;or R 7 and R 8 , taken together with the nitrogen to which they are attached, form a heterocycloalkyl ring;R 9 is independently selected at each occurrence from C 1-6 alkoxy, C 1-6 alkyl, halogen, halogen-C 1-6 alkyl, heteroaryl, and heteroaryl substituted by C 1-6 alkyl or C 1-6 alkoxy;R 10 is independently selected at each occurrence from C 1-6 alkoxy, C 1-6 alkyl, C 1-6 alkyl-C 1-6 alkoxy, halogen, and halogen-C 1-6 alkyl;R 11 is independently selected at each occurrence from Hand C 1-6 alkyl;R 12 is independently selected at each occurrence from H, C 1-6 alkyl and C 3-7 cycloalkyl. R 34 and R 34' are independently selected at each occurrence from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 3 -C 6 heterocycle, aryl, heteroaryl, -(CO)R 36 , -(CS)R 36 , -(C=NH)R 36 , -(SO)R 36 , and -(SO 2 )R 36 ;R 36 is independently selected at each occurrence from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 3 -C 6 heterocycle, aryl, heteroaryl, hydroxyl, C 1 -C 6 alkoxy, thio, C 1 -C 6 thioalkyl, -NH 2 , -NH(C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 heterocycle, aryl, or heteroaryl), and -N(independently C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 heterocycle, aryl, or heteroaryl) 2 ;R 20 , R 21 , R 22 , R 23 , and R 24 are independently selected from a covalent bond, alkyl, -C(O)-, -C(O)O-, -OC(O)-, -C(O)alkyl, -C(O)Oalkyl, -C(S)-, -SO 2 -, -S(O)-, -C(S)-, -C(O)NH-, -NHC(O)-, -N(alkyl)C(O)-, -C(O)N(alkyl)-, -O-, -S-, -NH-, -N(alkyl)-, -CH(-O-R 26 )-, -CH(-NR 34 R 34' )-, -C(-O-R 26 )alkyl-, -C(-NR 34 R 34' )alkyl-, -C(R 40 R 40 )-, -alkyl(R 27 )-alkyl(R 28 )-, -C(R 27 R 28 )-, -P(O)(OR 26 )O-, -P(O)(OR 26 )-, -NR 34 C(O)NR 34' -, alkene, haloalkyl, alkoxy, alkyneheteroarylalkyl, aryl, arylalkyl, heterocycle, aliphatic, heteroaliphatic, heteroaryl, lactic acid, glycolic acid, carbocycle, -(ethylene glycol) 1-6 -, -(lactic-co-glycolic acid) 1-6 -, -(propylene glycol) 1-6 -, -O-(CH 2 ) 1-12 -O-, -NH-(CH 2 ) 1-12 -NH-, -NH-(CH 2 ) 1-12 -O-, -O-(CH 2 ) 1-12 -NH-, -S-(CH 2 ) 1-12 -O-, -O-(CH 2 ) 1-12 -S-, -S-(CH 2 ) 1-12 -S-, -S-(CH 2 ) 1-12 -NH-, and -NH-(CH 2 ) 1-12 -S-;each of which R 20 , R 21 , R 22 , R 23 , and R 24 is optionally substituted with one or more substituents selected from R 101 ;wherein at least one of R 20 , R 21 , R 22 , R 23 , and R 24 is not a bond;R 101 is independently selected at each occurrence from hydrogen, alkyl, alkene, alkyne, haloalkyl, alkoxy, hydroxyl, aryl, heteroaryl, heterocycle, arylalkyl, heteroarylalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, CN, -COOalkyl, COOH, NO 2 , F, Cl, Br, I, CF 3 , NH 2 , NHalkyl, N(alkyl) 2 , aliphatic, and heteroaliphatic;R 26 is selected from hydrogen, alkyl, silane, arylalkyl, heteroarylalkyl, alkene, alkyne, aryl, heteroaryl, heterocyclic, aliphatic and heteroaliphatic;R 27 and R 28 are independently selected from hydrogen, alkyl, amine, or together with the carbon atom to which they are attached, form C(O), C(S), C=CH 2 , a C 3 -C 6 spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O, or form a 1 or 2 carbon bridged ring;and R 40 is selected at each instance from: hydrogen, alkyl, alkene, alkyne, halogen, hydroxyl, alkoxy, azide, amino, cyano, -NH(alkyl), -N(alkyl) 2 , -NHSO 2 (alkyl), -N(alkyl)SO 2 alkyl, -NHSO 2 (aryl, heteroaryl or heterocyclic), -N(alkyl)SO 2 (aryl, heteroaryl or heterocyclic) -NHSO 2 alkenyl, -N(alkyl)SO 2 alkenyl, -NHSO 2 alkynyl, -N(alkyl)SO 2 alkynyl, haloalkyl, aliphatic, heteroaliphatic, aryl, heteroaryl, heteroalkyl, heterocyclic, and carbocyclic.
- 9The compound of any one of claims 1-2 and 4-7, wherein R 3 is independently selected at each occurrence from:-C(=O)C 1-6 alkyl;-(CH 2 ) 0-2 -C(=O)-N(R 7 ,R 8 );-C(=O)OC 1-6 alkyl;-C 1-6 alkoxy;-C 1-6 alkyl;-OH;-NO 2 ;-C 1-6 alkyl-N(R 11 )-C(=O)-R 12 ;-CH 2 -O-(CH 2 ) 0-1 -aryl substituted by R 10 ;-CH 2 -O-(CH 2 ) 0-1 -aryl;-O-(CH 2 ) 0-1 -aryl;-halogen;-halogen-C 1-6 alkyl;-hydroxy-C 1-6 alkyl;-hydroxy-C 1-6 alkyl-aryl;-N(R 5 ,R 6 );-NH-C(=O)C 1-6 alkyl;and -NH-C(=O)OC 1-6 alkyl.
Independent claims11
664 paragraphs in 8 sections, as filed
CROSS-REFERENCE TO RELATED APPLICATION
0001This application claims the benefit of provisional <patcit id="pcit0001" dnum="US62814706"><text>U.S. Application No. 62/814,706 filed March 6, 2019</text></patcit>. The entirety of the application is incorporated herein by reference.
FIELD OF THE INVENTION
0002The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN), which can alter the substrate specificity of the CRBNE3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins that mediate disease. The present invention also provides compounds that can be used as synthetic intermediates in the preparation of bifunctional compounds for use in targeted protein degradation. The present compounds are thus useful for the treatment or prophylaxis of abnormal cellular proliferation, including tumors and cancer.
BACKGROUND OF THE INVENTION
0003Protein degradation is a highly regulated and essential process that maintains cellular homeostasis. The selective identification and removal of damaged, misfolded, or excess proteins is achieved via the ubiquitin-proteasome pathway (UPP). The UPP is central to the regulation of almost all cellular processes, including antigen processing, apoptosis, biogenesis of organelles, cell cycling, DNA transcription and repair, differentiation and development, immune response and inflammation, neural and muscular degeneration, morphogenesis of neural networks, modulation of cell surface receptors, ion channels and the secretory pathway, the response to stress and extracellular modulators, ribosome biogenesis and viral infection.
0004Covalent attachment of multiple ubiquitin molecules by an E3 ubiquitin ligase to a terminal lysine residue marks the protein for proteasome degradation, where the protein is digested into small peptides and eventually into its constituent amino acids that serve as building blocks for new proteins. Defective proteasomal degradation has been linked to a variety of clinical disorders including Alzheimer's disease, Parkinson's disease, Huntington's disease, muscular dystrophies, cardiovascular disease, and cancer among others.
0005Cereblon is a protein that in humans is encoded by the CRBN gene. CRBN orthologs are highly conserved from plants to humans, which underscores its physiological importance. Cereblon forms part of an E3 ubiquitin ligase protein complex which interacts with damaged DNA binding protein 1 (DDB1), forming an E3 ubiquitin ligase complex with Cullin 4 (CUL4A) and the E2-binding protein ROC1 (also known as RBX1) where it functions as a substrate receptor to select proteins for ubiquitination. Through a mechanism that has not been completely elucidated, cereblon ubiquitination of target proteins results in increased levels of fibroblast growth factor 8 (FGF8) and fibroblast growth factor 10 (FGF10). FGF8 in turn regulates a number of developmental processes, such as limb and auditory vesicle formation. The net result is that this E3 ubiquitin ligase complex is important for limb outgrowth in embryos. In the absence of cereblon, DDB 1 forms a complex with DDB2 that functions as a DNA damage-binding protein.
0006In unrelated parallel research, <nplcit id="ncit0001" npl-type="s"><text>Ito et al. (Science 2010, 327, 1345-1350</text></nplcit>) titled "Identification of a Primary Target of Thalidomide Teratogenicity", described that cereblon is a thalidomide binding protein. The study revealed that thalidomide-cereblon binding in vivo may be responsible for thalidomide teratogenicity. After the discovery that thalidomide causes teratogenicity in the mid-1960's, the compound and certain related structures were notwithstanding found to be useful as anti-inflammatory, anti-angiogenic and anti-cancer agents (see <nplcit id="ncit0002" npl-type="s"><text>Bartlett et al. (Nat. Rev. Cancer 2004, 4, 314-322) titled "The Evolution of Thalidomide and Its Imid Derivatives as Anticancer Agents</text></nplcit>"). Thalidomide has been approved for the treatment of certain neoplastic diseases, including multiple myeloma, and is currently under investigation for use in treating a variety of other types of cancer along with the structural derivatives lenalidomide and pomalidomide (see<nplcit id="ncit0003" npl-type="s"><text> Martiniani, R. et al. "Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma" Adv Hematol, 2012, 2012:842945</text></nplcit>; and <nplcit id="ncit0004" npl-type="s"><text>Terpos, E. et al. "Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma" Oncotargets and Therapy, 2013, 6:531</text></nplcit>).
0007The disclosure that thalidomide binds to the cereblon E3 ubiquitin ligase led to research to investigate incorporating thalidomide and certain derivatives into compounds for the targeted destruction of proteins. Celgene has disclosed imids for similar uses, including those in <patcit id="pcit0002" dnum="US6045501A"><text>U.S. Patents 6,045,501</text></patcit>; <patcit id="pcit0003" dnum="US6315720B"><text>6,315,720</text></patcit>; <patcit id="pcit0004" dnum="US6395754B"><text>6,395,754</text></patcit>; <patcit id="pcit0005" dnum="US6561976B"><text>6,561,976</text></patcit>; <patcit id="pcit0006" dnum="US6561977B"><text>6,561,977</text></patcit>; <patcit id="pcit0007" dnum="US6755784B"><text>6,755,784</text></patcit>; <patcit id="pcit0008" dnum="US6869399B"><text>6,869,399</text></patcit>; <patcit id="pcit0009" dnum="US6908432B"><text>6,908,432</text></patcit>; <patcit id="pcit0010" dnum="US7141018B"><text>7,141,018</text></patcit>; <patcit id="pcit0011" dnum="US7230012B"><text>7,230,012</text></patcit>; <patcit id="pcit0012" dnum="US7820697B"><text>7,820,697</text></patcit>; <patcit id="pcit0013" dnum="US7874984B"><text>7,874,984</text></patcit>; <patcit id="pcit0014" dnum="US7959566B"><text>7,959,566</text></patcit>; <patcit id="pcit0015" dnum="US8204763B"><text>8,204,763</text></patcit>; <patcit id="pcit0016" dnum="US8315886B"><text>8,315,886</text></patcit>; <patcit id="pcit0017" dnum="US8589188B"><text>8,589,188</text></patcit>; <patcit id="pcit0018" dnum="US8626531B"><text>8,626,531</text></patcit>; <patcit id="pcit0019" dnum="US8673939B"><text>8,673,939</text></patcit>; <patcit id="pcit0020" dnum="US8735428B"><text>8,735,428</text></patcit>; <patcit id="pcit0021" dnum="US8741929B"><text>8,741,929</text></patcit>; <patcit id="pcit0022" dnum="US8828427B"><text>8,828,427</text></patcit>; <patcit id="pcit0023" dnum="US9056120B"><text>9,056,120</text></patcit>; <patcit id="pcit0024" dnum="US9101621B"><text>9,101,621</text></patcit>; and <patcit id="pcit0025" dnum="US9101622B"><text>9,101,622</text></patcit>.
0008Patent applications filed by C4 Therapeutics, Inc., that describe compounds capable of binding to an E3 ubiquitin ligase include: <patcit id="pcit0026" dnum="WO2019236483A"><text>WO 2019/236483</text></patcit> titled "Spirocyclic Compounds"; <patcit id="pcit0027" dnum="WO2019191112A"><text>WO 2019/191112</text></patcit> titled "Cereblon Binders for the Degradation of Ikaros"; <patcit id="pcit0028" dnum="WO2019099868A"><text>WO 2019/099868</text></patcit> titled "Degraders and Degrons for Targeted Protein Degradation"; <patcit id="pcit0029" dnum="WO2018237026A"><text>WO 2018/237026</text></patcit> titled "N/O-Linked Degrons and Degronimers for Protein Degradation"; <patcit id="pcit0030" dnum="WO2017197051A"><text>WO 2017/197051</text></patcit> titled "Amine-Linked C3-Glutarimide Degronimers for Target Protein Degradation"; <patcit id="pcit0031" dnum="WO2017197055A"><text>WO 2017/197055</text></patcit> titled "Heterocyclic Degronimers for Target Protein Degradation"; <patcit id="pcit0032" dnum="WO2017197036A"><text>WO 2017/197036</text></patcit> titled "Spirocyclic Degronimers for Target Protein Degradation"; <patcit id="pcit0033" dnum="WO201719704620A"><text>WO 2017/197046 20</text></patcit> titled "C3-Carbon Linked Glutarimide Degronimers for Target Protein Degradation"; and <patcit id="pcit0034" dnum="WO2017197056A"><text>WO 2017/197056</text></patcit> titled "Bromodomain Targeting Degronimers for Target Protein Degradation."
0009Patent applications filed by C4 Therapeutics, Inc. and Hoffmann-La Roche that describe compounds capable of binding to an E3 ubiquitin ligase include <patcit id="pcit0035" dnum="WO2019121562A"><text>WO 2019/121562</text></patcit> titled "Bifunctional Inhibitors with EGFR having a E3 Ubiquitin Ligase Moiety"; <patcit id="pcit0036" dnum="WO2019149922A"><text>WO 2019/149922</text></patcit> titled "Compounds Which Cause Degradation of EGFR, for use Against Cancer"; <patcit id="pcit0037" dnum="WO2018220149A"><text>WO 2018/220149</text></patcit> titled "Compounds"; and <patcit id="pcit0038" dnum="WO2018115218A"><text>WO 2018/115218</text></patcit> titled "2-Benzopyrazinyl-N-Heteroaryl-2-Phenyl-Acetamide Compounds."
0010Additional compound publications include: <patcit id="pcit0039" dnum="WO2011035124A"><text>WO 2011/035124</text></patcit>; <patcit id="pcit0040" dnum="WO02072576A"><text>WO 02/072576</text></patcit>; <patcit id="pcit0041" dnum="WO2010085684A"><text>WO 2010/085684</text></patcit>; <patcit id="pcit0042" dnum="WO2014134240A"><text>WO 2014/134240</text></patcit>; <patcit id="pcit0043" dnum="WO2011130628A"><text>WO 2011/130628</text></patcit>; <patcit id="pcit0044" dnum="WO2007065518A"><text>WO 2007/065518</text></patcit>; <patcit id="pcit0045" dnum="WO2016176640A"><text>WO 2016/176640</text></patcit>; <patcit id="pcit0046" dnum="WO2009135651A"><text>WO 2009/135651</text></patcit>; <patcit id="pcit0047" dnum="WO2011156245A"><text>WO 2011/156245</text></patcit>; <patcit id="pcit0048" dnum="WO2017046318A"><text>WO 2017/046318</text></patcit>; <patcit id="pcit0049" dnum="WO2010130794A"><text>WO 2010/130794</text></patcit>; <patcit id="pcit0050" dnum="WO2012021382A"><text>WO 2012/021382</text></patcit>; <patcit id="pcit0051" dnum="WO2005060967A"><text>WO 2005/060967</text></patcit>; <patcit id="pcit0052" dnum="WO2012174199A"><text>WO 2012/174199</text></patcit>; <patcit id="pcit0053" dnum="EP385850A"><text>EP385850</text></patcit>; <patcit id="pcit0054" dnum="WO2016176449A"><text>WO 2016/176449</text></patcit>; <patcit id="pcit0055" dnum="WO2016040508A"><text>WO 2016/040508</text></patcit>; <patcit id="pcit0056" dnum="WO0020358A"><text>WO 00/20358</text></patcit>; <patcit id="pcit0057" dnum="EP125678A"><text>EP125678</text></patcit>; <patcit id="pcit0058" dnum="WO2006058338A"><text>WO 2006/058338</text></patcit>; <patcit id="pcit0059" dnum="WO2004108133A"><text>WO 2004/108133</text></patcit>; <patcit id="pcit0060" dnum="WO2010108817A"><text>WO 2010/108817</text></patcit>; <patcit id="pcit0061" dnum="WO2005113489A"><text>WO 2005/113489</text></patcit>; <patcit id="pcit0062" dnum="WO2012061708A"><text>WO 2012/061708</text></patcit>; <patcit id="pcit0063" dnum="WO2010023161A"><text>WO 2010/023161</text></patcit>; <patcit id="pcit0064" dnum="WO2007041598A"><text>WO 2007/041598</text></patcit>; <patcit id="pcit0065" dnum="WO2009050232A"><text>WO 2009/050232</text></patcit>; <patcit id="pcit0066" dnum="WO201893569A"><text>WO 2018/93569</text></patcit>;<nplcit id="ncit0005" npl-type="s"><text> Terefenk et al. Bioorg. Med. Chem. Lett. 2005, 15(15):3600-03</text></nplcit>; <nplcit id="ncit0006" npl-type="s"><text>Smolyar et al. Russian Journal of Organic Chemistry 2011, 47(8):119-3</text></nplcit>;<nplcit id="ncit0007" npl-type="s"><text> Jun Yon Choi et al. J. Med. Chem. 2012, 55(13):852-70</text></nplcit>.
0011There is a need for new compounds, compositions, and uses thereof that bind to the E3 ligase protein cereblon to treat various medical conditions, notably abnormal cellular proliferation. There is also a need for new compounds that may be used in the preparation of bifunctional molecules that are used in the degradation of proteins that are involved in disease processes.
SUMMARY OF THE INVENTION
0012In a first aspect, compounds and their uses and manufacture are provided that bind to cereblon and modify the ubiquitination of proteins by a cereblon-containing E3 ubiquitin ligase. In a second aspect, compounds are provided that contain a chemical moiety capable of binding to cereblon, which can be used as synthetic intermediates in the preparation of bifunctional compounds that cause degradation of a selected protein via the ubiquitin proteosome pathway (UPP).
0013The compounds described herein can be administered to a host, for example, a human, in need thereof, in an effective amount, optionally as a pharmaceutically acceptable salt, and optionally in a pharmaceutically acceptable composition. The compounds can be administered for any therapeutic indication which can be treated by modulating the function or activity of the cereblon-containing E3 Ubiquitin Ligase Protein Complex, including but not limited to the treatment of abnormal cell proliferation, such as cancer or a tumor, or other uses known for the cereblon binders thalidomide, pomalidomide, and lenalidomide. In certain embodiments, the compounds as described herein can modulate the natural activity of cereblon.
0014The invention includes new compounds of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, and Formulas XIII-a to XIII-I. In addition, the invention includes the use of compounds generally in Formula XIV for the treatment of a therapeutic condition that can be treated by modulating the function or activity of the cereblon-containing E3 Ubiquitin Ligase Protein Complex. The invention also includes the use of compounds generally in Formula XIV(1) in the preparation of bifunctional compounds that degrade a target protein by the ubiquitin proteasome pathway (UPP). The invention also includes compounds of Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-1, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), and Formulas XIII(1)-a to XIII(1)-i.
0015In one aspect, a compound is provided of Formula I: <chemistry id="chem0001" num="0001"><img file="EP4470618A2_D0001.tif" /></chemistry> or a pharmaceutically acceptable salt thereof; wherein: <ul id="ul0001" list-style="none" compact="compact"><li>A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, -CF<sub>2</sub>- and -NH-, and A<sup>2</sup> is -CH<sub>2</sub>-; or</li><li>A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, and -CF<sub>2</sub>-, and A<sup>2</sup> is-NH-;</li><li>W isCH orN;</li><li>R<sup>3</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl substituted by R<sup>9</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl; -(CH<sub>2</sub>)<sub>0-1</sub>-heterocycloalkyl; -C(=O)C<sub>1-6</sub>alkyl; -(CH<sub>2</sub>)<sub>0-2</sub>-C(=0)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -OH; -NO<sub>2</sub>; -C<sub>1-6</sub>alkyl-N(R<sup>11</sup>)-C(=O)-R<sup>12</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl-aryl; -N(R<sup>5</sup>,R<sup>6</sup>); -NH-C(=O)C<sub>1-6</sub>alkyl; -NH-C(=O)OC<sub>1-6</sub>alkyl; and =O as allowed by valence;</li><li>m is 0, 1, or 2;</li><li>R<sup>5</sup> and R<sup>6</sup> are independently selected at each occurrence from H, C<sub>1-6</sub>alkyl and phenyl;</li><li>or R<sup>5</sup> and R<sup>6</sup>, taken together with the nitrogen to which they are attached, form a heterocycloalkyl ring;</li><li>R<sup>7</sup> and R<sup>8</sup> are independently selected at each occurrence from Hand C<sub>1-6</sub>alkyl;</li><li>or R<sup>7</sup> and R<sup>8</sup>, taken together with the nitrogen to which they are attached, form a heterocycloalkyl ring;</li><li>R<sup>9</sup> is independently selected at each occurrence from C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkyl, halogen, halogen-C<sub>1-6</sub>alkyl, heteroaryl, and heteroaryl substituted by C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkoxy;</li><li>R<sup>10</sup> is independently selected at each occurrence from C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl-C<sub>1-6</sub>alkoxy, halogen, and halogen-C<sub>1-6</sub>alkyl;</li><li>R<sup>11</sup> is independently selected at each occurrence from Hand C<sub>1-6</sub>alkyl; and</li><li>R<sup>12</sup> is independently selected at each occurrence from H, C<sub>1-6</sub>alkyl and C<sub>3-7</sub>cycloalkyl.</li></ul>
0016In another aspect, a compound is provided of one of the following formulas: <chemistry id="chem0002" num="0002"><img file="EP4470618A2_D0002.tif" /></chemistry><chemistry id="chem0003" num="0003"><img file="EP4470618A2_D0003.tif" /></chemistry><chemistry id="chem0004" num="0004"><img file="EP4470618A2_D0004.tif" /></chemistry><chemistry id="chem0005" num="0005"><img file="EP4470618A2_D0005.tif" /></chemistry><chemistry id="chem0006" num="0006"><img file="EP4470618A2_D0006.tif" /></chemistry> and <chemistry id="chem0007" num="0007"><img file="EP4470618A2_D0007.tif" /></chemistry> or a pharmaceutically acceptable salt thereof; wherein: <ul id="ul0002" list-style="none" compact="compact"><li>R<sup>4</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl substituted by R<sup>9</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl; =O as allowed by valence; -C(=O)C<sub>1-6</sub>alkyl; -C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>;-CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -N(R<sup>5</sup>,R<sup>6</sup>); and -NH-C(=O)C<sub>1-6</sub>alkyl;</li><li>n is 1 or 2; and</li><li>all other variables are as defined herein.</li></ul>
0017In another aspect, a compound is provided of Formula III: <chemistry id="chem0008" num="0008"><img file="EP4470618A2_D0008.tif" /></chemistry><ul id="ul0003" list-style="none" compact="compact"><li>or a pharmaceutically acceptable salt thereof;</li><li>wherein all variables are as defined herein.</li></ul>
0018In another aspect, a compound is provided of one of the following formulas: <chemistry id="chem0009" num="0009"><img file="EP4470618A2_D0009.tif" /></chemistry><chemistry id="chem0010" num="0010"><img file="EP4470618A2_D0010.tif" /></chemistry><chemistry id="chem0011" num="0011"><img file="EP4470618A2_D0011.tif" /></chemistry><chemistry id="chem0012" num="0012"><img file="EP4470618A2_D0012.tif" /></chemistry><chemistry id="chem0013" num="0013"><img file="EP4470618A2_D0013.tif" /></chemistry><ul id="ul0004" list-style="none" compact="compact"><li>or a pharmaceutically acceptable salt thereof;</li><li>wherein all variables are as defined herein.</li></ul>
0019In another aspect, a compound is provided of Formula V: <chemistry id="chem0014" num="0014"><img file="EP4470618A2_D0014.tif" /></chemistry><ul id="ul0005" list-style="none" compact="compact"><li>or a pharmaceutically acceptable salt thereof;</li><li>wherein all variables are as defined herein.</li></ul>
0020In another aspect, a compound is provided of Formula VI: <chemistry id="chem0015" num="0015"><img file="EP4470618A2_D0015.tif" /></chemistry> or a pharmaceutically acceptable salt thereof; wherein: <ul id="ul0006" list-style="none" compact="compact"><li>R<sup>2</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl substituted by R<sup>9</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl; -C(=O)C<sub>1-6</sub>alkyl; -C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -N(R<sup>5</sup>,R<sup>6</sup>); -NO<sub>2</sub>; -NH-C(=O)C<sub>1-6</sub>alkyl; and -SO<sub>2</sub>-N(R<sup>5</sup>,R<sup>6</sup>); and</li><li>all other variables are as defined herein.</li></ul>
0021In another aspect, a compound is provided of one of the following formulas: <chemistry id="chem0016" num="0016"><img file="EP4470618A2_D0016.tif" /></chemistry><chemistry id="chem0017" num="0017"><img file="EP4470618A2_D0017.tif" /></chemistry> and <chemistry id="chem0018" num="0018"><img file="EP4470618A2_D0018.tif" /></chemistry><ul id="ul0007" list-style="none" compact="compact"><li>or a pharmaceutically acceptable salt thereof;</li><li>wherein all variables are as defined herein.</li></ul>
0022In another aspect, a compound is provided of one of the following formulas: <chemistry id="chem0019" num="0019"><img file="EP4470618A2_D0019.tif" /></chemistry><chemistry id="chem0020" num="0020"><img file="EP4470618A2_D0020.tif" /></chemistry><chemistry id="chem0021" num="0021"><img file="EP4470618A2_D0021.tif" /></chemistry><chemistry id="chem0022" num="0022"><img file="EP4470618A2_D0022.tif" /></chemistry> and <chemistry id="chem0023" num="0023"><img file="EP4470618A2_D0023.tif" /></chemistry><ul id="ul0008" list-style="none" compact="compact"><li>or a pharmaceutically acceptable salt thereof;</li><li>wherein all variables are as defined herein.</li></ul>
0023In another aspect, a compound is provided of one of the following formulas: <chemistry id="chem0024" num="0024"><img file="EP4470618A2_D0024.tif" /></chemistry><chemistry id="chem0025" num="0025"><img file="EP4470618A2_D0025.tif" /></chemistry><chemistry id="chem0026" num="0026"><img file="EP4470618A2_D0026.tif" /></chemistry><chemistry id="chem0027" num="0027"><img file="EP4470618A2_D0027.tif" /></chemistry><chemistry id="chem0028" num="0028"><img file="EP4470618A2_D0028.tif" /></chemistry><ul id="ul0009" list-style="none" compact="compact"><li>or a pharmaceutically acceptable salt thereof;</li><li>wherein all variables are as defined herein.</li></ul>
0024In another aspect, a compound is provided of one of the following formulas: <chemistry id="chem0029" num="0029"><img file="EP4470618A2_D0029.tif" /></chemistry><chemistry id="chem0030" num="0030"><img file="EP4470618A2_D0030.tif" /></chemistry><chemistry id="chem0031" num="0031"><img file="EP4470618A2_D0031.tif" /></chemistry><chemistry id="chem0032" num="0032"><img file="EP4470618A2_D0032.tif" /></chemistry> and <chemistry id="chem0033" num="0033"><img file="EP4470618A2_D0033.tif" /></chemistry><ul id="ul0010" list-style="none" compact="compact"><li>or a pharmaceutically acceptable salt thereof;</li><li>wherein all variables are as defined herein.</li></ul>
0025In another aspect, a compound is provided of one of the following formulas: <chemistry id="chem0034" num="0034"><img file="EP4470618A2_D0034.tif" /></chemistry><chemistry id="chem0035" num="0035"><img file="EP4470618A2_D0035.tif" /></chemistry><chemistry id="chem0036" num="0036"><img file="EP4470618A2_D0036.tif" /></chemistry><chemistry id="chem0037" num="0037"><img file="EP4470618A2_D0037.tif" /></chemistry> and <chemistry id="chem0038" num="0038"><img file="EP4470618A2_D0038.tif" /></chemistry><ul id="ul0011" list-style="none" compact="compact"><li>or a pharmaceutically acceptable salt thereof;</li><li>wherein all variables are as defined herein.</li></ul>
0026In another aspect, a compound is provided of Formula XII: <chemistry id="chem0039" num="0039"><img file="EP4470618A2_D0039.tif" /></chemistry> or a pharmaceutically acceptable salt thereof; wherein: <ul id="ul0012" list-style="none" compact="compact"><li>A is selected from: aryl optionally substituted with one or two R<sup>2</sup> groups; heteroaryl optionally substituted with one or two R<sup>3</sup> groups; heterocycloalkyl optionally substituted with one or two R<sup>4</sup> groups; -NH-C(=O)-C<sub>1-6</sub>alkyl; and cycloalkyl; and</li><li>all other variables are as defined herein.</li></ul>
0027In another aspect, a compound is provided of one of the following formulas: <chemistry id="chem0040" num="0040"><img file="EP4470618A2_D0040.tif" /></chemistry><chemistry id="chem0041" num="0041"><img file="EP4470618A2_D0041.tif" /></chemistry><chemistry id="chem0042" num="0042"><img file="EP4470618A2_D0042.tif" /></chemistry><chemistry id="chem0043" num="0043"><img file="EP4470618A2_D0043.tif" /></chemistry> and <chemistry id="chem0044" num="0044"><img file="EP4470618A2_D0044.tif" /></chemistry><ul id="ul0013" list-style="none" compact="compact"><li>or a pharmaceutically acceptable salt thereof;</li><li>wherein all variables are as defined herein.</li></ul>
0028In another aspect, the use of a compound for the treatment of a therapeutic condition which can be treated by modulating the function or activity of the cereblon-containing E3 Ubiquitin Ligase Protein Complex is provided of Formula XIV: <chemistry id="chem0045" num="0045"><img file="EP4470618A2_D0045.tif" /></chemistry> or a pharmaceutically acceptable salt thereof; <ul id="ul0014" list-style="none" compact="compact"><li>wherein Z is selected from: a covalent bond; carbonyl; -(CH<sub>2</sub>)<sub>0-2</sub>-NR<sup>1</sup>-(CH<sub>2</sub>)<sub>0-2</sub>-; -(NR<sup>1</sup>)<sub>0-1</sub>-C(=O)-(NR<sup>1</sup>)<sub>0-1</sub>- -(NR<sup>1</sup>)<sub>0-1</sub>-C(=O)-(CH<sub>2</sub>)<sub>1-3</sub>-; -O-(CH<sub>2</sub>)<sub>0-2</sub>-C(=O)-NR<sup>1</sup>-; -(CH<sub>2</sub>)<sub>1-3</sub>-; -(CH<sub>2</sub>)<sub>1-3</sub>-; -(CH<sub>2</sub>)<sub>0-2</sub>-O-(CH<sub>2</sub>)<sub>0-2</sub>; and -(NR<sup>1</sup>)<sub>0-1</sub>-SO<sub>0,2</sub>-(NR<sup>1</sup>)<sub>0-1</sub>-; or</li><li>in an alternative embodiment, Z is selected from alkylene, alkenylene, alkynylene, arylene, heteroarylene, heterocyclyl, or carbocyclyl;</li><li>each occurrence of R<sup>1</sup> is independently selected from H or C<sub>1-6</sub>alkyl; and all other variables are as defined herein.</li></ul>
0029The compounds of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, and Formula IV can activate, decrease, or change the natural activity of cereblon. These compounds of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, and Formula XIV are useful as therapeutic agents when administered in an effective amount to a host, typically a human, for the treatment of a medical disorder including, but not limited to, abnormal cellular proliferation, including a tumor or cancer, or a myelo- or lymphoproliferative disorder such as B- or T-cell lymphomas, multiple myeloma, Waldenstrom's macroglobulinemia, Wiskott-Aldrich syndrome, or a post-transplant lymphoproliferative disorder; an immune disorder, including autoimmune disorder such as Addison disease, Celiac disease, Dermatomyositis, Graves disease, thyroiditis, multiple sclerosis, pernicious anemia, reactive arthritis, lupus, or type I diabetes; a disease of cardiologic malfunction including hypercholesterolemia; an infectious disease including viral or bacterial infections; inflammatory conditions including asthma, chronic peptic ulcers, tuberculosis, rheumatoid arthritis, periodontitis, ulcerative colitis, Crohn's disease, or hepatitis; or any disorder than can be treated with thalidomide, pomalidomide, or lenalidomide.
0030In certain embodiments, the present invention provides the administration of an effective amount of a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, or Formula XIV to treat a patient, for example a human, having an infectious disease, wherein the therapy acts via binding to cereblon or its E3 Ubiquitin Ligase or acts through an independent mechanism, optionally in combination with another bioactive agent. The disease state or condition may be caused by a microbial agent or other exogenous agent such as a virus (as non-limiting examples, HIV, HBV, HCV, HSV, HPV, RSV, CMV, Ebola, Flavivirus, Pestivirus, Rotavirus, Influenza, Coronavirus, EBV, viral pneumonia, drug-resistant viruses, Bird Flu, RNA virus, DNA virus, adenovirus, poxvirus, Picornavirus, Togavirus, Orthomyxovirus, Retrovirus, or Hepadovirus), bacterial (including but not limited to Gram-negative, Gram-positive, Atypical, Staphylococcus, Streptococcus, E. Coli, Salmonella, Helicobacter pylori, meningitis, gonorrhea, Chlamydiaceae, Mycoplasmataceae, etc.), fungus, protozoa, helminth, worm, prion, parasite, or other microbe.
0031In another aspect, the compounds disclosed can be used as synthetic intermediates in the preparation of bifunctional compounds that cause degradation of a selected protein via the ubiquitin proteosome pathway (UPP) is provided. These compounds contain a functional group that can react with a second compound, wherein the second compound is capable of binding to a selected protein of interest, to create a bifunctional compound as described above that can cause the degradation of the selected protein via the UPP.
0032Thus, compounds of Formula XIV(1), or a pharmaceutically acceptable salt thereof, which can be used in the preparation of bifunctional compounds that cause degradation of a selected protein via the UPP are provided: <chemistry id="chem0046" num="0046"><img file="EP4470618A2_D0046.tif" /></chemistry> wherein: <ul id="ul0015" list-style="none" compact="compact"><li>A<sup>B</sup> is selected from arylene optionally substituted with one or two R<sup>2</sup> groups, heteroarylene optionally substituted with one or two R<sup>3</sup> groups; heterocycloalkylene optionally substituted with one or two R<sup>4</sup> groups, -NH-C(=O)-C<sub>1-6</sub>alkylene-, and cycloalkylene;</li><li>"Tail" is a chemical moiety that contains a reactive functional group that can covalently bind to a protein binding moiety to produce a targeted protein degrader, or</li><li>"Tail" is a chemical moiety that can be used to modify the properties of the compound such as hydrophobicity, hydrophilicity, solubility, drug delivery, pharmacokinetics, or other properties such as charge, polarity, or fit within the active pocket;</li><li>in one embodiment, "Tail" is <chemistry id="chem0047" num="0047"><img file="EP4470618A2_D0047.tif" /></chemistry></li><li>X<sup>1</sup> is selected from bond, NR<sup>34</sup>, CH<sub>2</sub>, CHR<sup>34</sup>, C(R<sup>34</sup>)<sub>2</sub>, O, and S;</li><li>X<sup>22</sup> is a functional group that can be used as a linking group to a protein binding moiety; or X<sup>22</sup> is a group that caps the valence and is not typically a linking group; representative examples of X<sup>22</sup> include, but are not limited to, halo, -NH<sub>2</sub>, -NHR<sup>34</sup>, -N(R<sup>34</sup>)<sub>2</sub>, hydroxyl, thiol, -B(OH)<sub>2</sub>, -Sn(R<sup>36</sup>)<sub>3</sub>, -Si(R<sup>36</sup>)<sub>3</sub>, -OS(O)<sub>2</sub>alkyl, -OS(O)<sub>2</sub>haloalkyl, alkenyl, alkynyl, ethynyl, ethenyl, -C(O)H, -NR<sup>34</sup>C(O)alkene, -NR<sup>34</sup>C(O)alkyne, cyano, -SC(O)alkyl, OC(O)alkyl, heterocycle, -C(O)OH, hydrogen, alkyl, aryl, heteroaryl, aliphatic, heteroaliphatic, and carbocyclic;</li><li>R<sup>34</sup> and R<sup>34</sup> are independently selected at each occurrence from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl (for example methyl, ethyl, cyclopropyl, or C<sub>1</sub>-C<sub>3</sub>alkyl), C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, C<sub>3</sub>-C<sub>6</sub>heterocycle, aryl, heteroaryl, -(CO)R<sup>36</sup>, -(CS)R<sup>36</sup>, -(C=NH)R<sup>36</sup>, -(SO)R<sup>36</sup>, and -(SO<sub>2</sub>)R<sup>36</sup>;</li><li>R<sup>36</sup> is independently selected at each occurrence from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, C<sub>3</sub>-C<sub>6</sub>heterocycle, aryl, heteroaryl, hydroxyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, thio, C<sub>1</sub>-C<sub>6</sub>thioalkyl, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, C<sub>3</sub>-C<sub>7</sub>heterocycle, aryl, or heteroaryl), and -N(independently C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, C<sub>3</sub>-C<sub>7</sub>heterocycle, aryl, or heteroaryl)<sub>2</sub>;</li><li>R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> are independently a divalent or mutltivalent linking group, including but not limited to a covalent bond, alkyl, -C(O)-, -C(O)O-, -OC(O)-, -C(O)alkyl, -C(O)Oalkyl, -C(S)-, -SO<sub>2</sub>-, -S(O)-, -C(S)-, -C(O)NH-, -NHC(O)-, -N(alkyl)C(O)-, -C(O)N(alkyl)-, -O-, -S-, -NH-, -N(alkyl)-, -CH(-O-R<sup>26</sup>)-, -CH(-NR<sup>34</sup>R<sup>34'</sup>)-, -C(-O-R<sup>26</sup>)alkyl-, -C(-NR<sup>34</sup>R<sup>34')</sup>alkyl-, -C(R<sup>40</sup>R<sup>40</sup>)-, -C(R<sup>27</sup>R<sup>28</sup>)-, -P(O)(OR<sup>26</sup>)O-, -P(O)(OR<sup>26</sup>)-, -NR<sup>34</sup>C(O)NR<sup>34'</sup>-, alkene, haloalkyl, alkoxy, alkyneheteroarylalkyl, aryl, arylalkyl, heterocycle, aliphatic, heteroaliphatic, heteroaryl, lactic acid, glycolic acid, carbocycle, -(ethylene glycol)<sub>1-6</sub>-, -(lactic-co-glycolic acid)<sub>1-6</sub>-, -(propylene glycol)<sub>1-6</sub>-, -O-(CH<sub>2</sub>)<sub>1-12</sub>-O-, -NH-(CH<sub>2</sub>)<sub>1-12</sub>-NH-, -NH-(CH<sub>2</sub>)<sub>1-12</sub>-O-, -O-(CH<sub>2</sub>)<sub>1-12</sub>-NH-, -S-(CH<sub>2</sub>)<sub>1-12</sub>-O-, -O-(CH<sub>2</sub>)<sub>1-12</sub>-S-, -S-(CH<sub>2</sub>)<sub>1-12</sub>-S-, -S-(CH<sub>2</sub>)<sub>1-12</sub>-NH-, and -NH-(CH<sub>2</sub>)<sub>1-12</sub>-S-, wherein the 1-6 can be independently 1, 2, 3, 4, 5, or 6, wherein the 1-12 can be independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, and wherein one or more of the CH<sub>2</sub> or NH groups can be modified by substitution of a H for a methyl, ethyl, cyclopropyl, F (if on carbon), etc, as described herein, and optionally, a heteroatom, heteroalkyl, aryl, heteroaryl or cycloaliphatic group is interspersed in the chain. Certain non-limiting examples include -O-CH(CH<sub>3</sub>)-CH(CH<sub>3</sub>)CH-O-, -O-CH<sub>2</sub>-CH(CH<sub>3</sub>)CH-O-, -O-CH(CH<sub>3</sub>)-CH<sub>2</sub>CH-O-, etc.</li><li>each of which R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> is optionally substituted with one or more substituents selected from R<sup>101</sup> or alternatively as described in the Definitions section; wherein at least one of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> is not a bond;</li><li>R<sup>101</sup> is independently selected at each occurrence from hydrogen, alkyl, alkene, alkyne, haloalkyl, alkoxy, hydroxyl, aryl, heteroaryl, heterocycle, arylalkyl, heteroarylalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, CN, -COOalkyl, COOH, NO<sub>2</sub>, F, Cl, Br, I, CF<sub>3</sub>, NH<sub>2</sub>, NHalkyl, N(alkyl)<sub>2</sub>, aliphatic, and heteroaliphatic;</li><li>R<sup>26</sup> is selected from hydrogen, alkyl, silane, arylalkyl, heteroarylalkyl, alkene, alkyne, aryl, heteroaryl, heterocyclic, aliphatic and heteroaliphatic;</li><li>R<sup>27</sup> and R<sup>28</sup> are independently selected from hydrogen, alkyl, amine, or together with the carbon atom to which they are attached, form C(O), C(S), C=CH<sub>2</sub>, a C<sub>3</sub>-C<sub>6</sub> spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O, or form a 1 or 2 carbon bridged ring;</li><li>R<sup>40</sup> is selected at each instance from: hydrogen, alkyl, alkene, alkyne, halogen, hydroxyl, alkoxy, azide, amino, cyano, -NH(aliphatic, including alkyl), -N(aliphatic, including alkyl)<sub>2</sub>, -NHSO<sub>2</sub>(aliphatic, including alkyl), -N(aliphatic, including alkyl)SO<sub>2</sub>alkyl, -NHSO<sub>2(</sub>aryl, heteroaryl or heterocyclic), -N(alkyl)SO<sub>2</sub>(aryl, heteroaryl or heterocyclic) -NHSO<sub>2</sub>alkenyl, -N(alkyl)SO<sub>2</sub>alkenyl, -NHSO<sub>2</sub>alkynyl, -N(alkyl)SO<sub>2</sub>alkynyl, haloalkyl, aliphatic, heteroaliphatic, aryl, heteroaryl, heteroalkyl, heterocyclic, and carbocyclic; and</li><li>all other variables are as defined herein.</li></ul>
0033In another aspect, new compounds are provided comprising the compounds of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, and Formulas XIII-a to XIII-I, wherein one of the free hydrogens on the molecule has been replaced by a "Tail" group as defined herein. Thus, new compounds are also provided of Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), and Formulas XIII(1)-a to XIII(1)-i.
0034In one aspect, a compound is provided of Formula I(1) <chemistry id="chem0048" num="0048"><img file="EP4470618A2_D0048.tif" /></chemistry> wherein all variables are as defined herein.
0035In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0049" num="0049"><img file="EP4470618A2_D0049.tif" /></chemistry><chemistry id="chem0050" num="0050"><img file="EP4470618A2_D0050.tif" /></chemistry><chemistry id="chem0051" num="0051"><img file="EP4470618A2_D0051.tif" /></chemistry><chemistry id="chem0052" num="0052"><img file="EP4470618A2_D0052.tif" /></chemistry><chemistry id="chem0053" num="0053"><img file="EP4470618A2_D0053.tif" /></chemistry><chemistry id="chem0054" num="0054"><img file="EP4470618A2_D0054.tif" /></chemistry><chemistry id="chem0055" num="0055"><img file="EP4470618A2_D0055.tif" /></chemistry><chemistry id="chem0056" num="0056"><img file="EP4470618A2_D0056.tif" /></chemistry><chemistry id="chem0057" num="0057"><img file="EP4470618A2_D0057.tif" /></chemistry><chemistry id="chem0058" num="0058"><img file="EP4470618A2_D0058.tif" /></chemistry> and <chemistry id="chem0059" num="0059"><img file="EP4470618A2_D0059.tif" /></chemistry> wherein all variables are as defined herein.
0036In one aspect, a compound is provided of Formula III(1): <chemistry id="chem0060" num="0060"><img file="EP4470618A2_D0060.tif" /></chemistry> wherein all variables are as defined herein.
0037In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0061" num="0061"><img file="EP4470618A2_D0061.tif" /></chemistry><chemistry id="chem0062" num="0062"><img file="EP4470618A2_D0062.tif" /></chemistry><chemistry id="chem0063" num="0063"><img file="EP4470618A2_D0063.tif" /></chemistry><chemistry id="chem0064" num="0064"><img file="EP4470618A2_D0064.tif" /></chemistry><chemistry id="chem0065" num="0065"><img file="EP4470618A2_D0065.tif" /></chemistry><chemistry id="chem0066" num="0066"><img file="EP4470618A2_D0066.tif" /></chemistry><chemistry id="chem0067" num="0067"><img file="EP4470618A2_D0067.tif" /></chemistry><chemistry id="chem0068" num="0068"><img file="EP4470618A2_D0068.tif" /></chemistry><chemistry id="chem0069" num="0069"><img file="EP4470618A2_D0069.tif" /></chemistry><chemistry id="chem0070" num="0070"><img file="EP4470618A2_D0070.tif" /></chemistry> wherein all variables are as defined herein.
0038In one aspect, a compound is provided of Formula V(1): <chemistry id="chem0071" num="0071"><img file="EP4470618A2_D0071.tif" /></chemistry> wherein all variables are as defined herein.
0039In one aspect, a compound is provided of Formula VI(1): <chemistry id="chem0072" num="0072"><img file="EP4470618A2_D0072.tif" /></chemistry> wherein all variables are as defined herein.
0040In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0073" num="0073"><img file="EP4470618A2_D0073.tif" /></chemistry><chemistry id="chem0074" num="0074"><img file="EP4470618A2_D0074.tif" /></chemistry><chemistry id="chem0075" num="0075"><img file="EP4470618A2_D0075.tif" /></chemistry><chemistry id="chem0076" num="0076"><img file="EP4470618A2_D0076.tif" /></chemistry> and <chemistry id="chem0077" num="0077"><img file="EP4470618A2_D0077.tif" /></chemistry> wherein all variables are as defined herein.
0041In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0078" num="0078"><img file="EP4470618A2_D0078.tif" /></chemistry><chemistry id="chem0079" num="0079"><img file="EP4470618A2_D0079.tif" /></chemistry><chemistry id="chem0080" num="0080"><img file="EP4470618A2_D0080.tif" /></chemistry><chemistry id="chem0081" num="0081"><img file="EP4470618A2_D0081.tif" /></chemistry><chemistry id="chem0082" num="0082"><img file="EP4470618A2_D0082.tif" /></chemistry><chemistry id="chem0083" num="0083"><img file="EP4470618A2_D0083.tif" /></chemistry><chemistry id="chem0084" num="0084"><img file="EP4470618A2_D0084.tif" /></chemistry><chemistry id="chem0085" num="0085"><img file="EP4470618A2_D0085.tif" /></chemistry> and <chemistry id="chem0086" num="0086"><img file="EP4470618A2_D0086.tif" /></chemistry> wherein all variables are as defined herein.
0042In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0087" num="0087"><img file="EP4470618A2_D0087.tif" /></chemistry><chemistry id="chem0088" num="0088"><img file="EP4470618A2_D0088.tif" /></chemistry><chemistry id="chem0089" num="0089"><img file="EP4470618A2_D0089.tif" /></chemistry><chemistry id="chem0090" num="0090"><img file="EP4470618A2_D0090.tif" /></chemistry><chemistry id="chem0091" num="0091"><img file="EP4470618A2_D0091.tif" /></chemistry><chemistry id="chem0092" num="0092"><img file="EP4470618A2_D0092.tif" /></chemistry><chemistry id="chem0093" num="0093"><img file="EP4470618A2_D0093.tif" /></chemistry><chemistry id="chem0094" num="0094"><img file="EP4470618A2_D0094.tif" /></chemistry><chemistry id="chem0095" num="0095"><img file="EP4470618A2_D0095.tif" /></chemistry> and <chemistry id="chem0096" num="0096"><img file="EP4470618A2_D0096.tif" /></chemistry> wherein all variables are as defined herein.
0043In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0097" num="0097"><img file="EP4470618A2_D0097.tif" /></chemistry><chemistry id="chem0098" num="0098"><img file="EP4470618A2_D0098.tif" /></chemistry><chemistry id="chem0099" num="0099"><img file="EP4470618A2_D0099.tif" /></chemistry><chemistry id="chem0100" num="0100"><img file="EP4470618A2_D0100.tif" /></chemistry><chemistry id="chem0101" num="0101"><img file="EP4470618A2_D0101.tif" /></chemistry><chemistry id="chem0102" num="0102"><img file="EP4470618A2_D0102.tif" /></chemistry><chemistry id="chem0103" num="0103"><img file="EP4470618A2_D0103.tif" /></chemistry><chemistry id="chem0104" num="0104"><img file="EP4470618A2_D0104.tif" /></chemistry> and <chemistry id="chem0105" num="0105"><img file="EP4470618A2_D0105.tif" /></chemistry> wherein all variables are as defined herein.
0044In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0106" num="0106"><img file="EP4470618A2_D0106.tif" /></chemistry><chemistry id="chem0107" num="0107"><img file="EP4470618A2_D0107.tif" /></chemistry><chemistry id="chem0108" num="0108"><img file="EP4470618A2_D0108.tif" /></chemistry><chemistry id="chem0109" num="0109"><img file="EP4470618A2_D0109.tif" /></chemistry><chemistry id="chem0110" num="0110"><img file="EP4470618A2_D0110.tif" /></chemistry><chemistry id="chem0111" num="0111"><img file="EP4470618A2_D0111.tif" /></chemistry><chemistry id="chem0112" num="0112"><img file="EP4470618A2_D0112.tif" /></chemistry><chemistry id="chem0113" num="0113"><img file="EP4470618A2_D0113.tif" /></chemistry> and <chemistry id="chem0114" num="0114"><img file="EP4470618A2_D0114.tif" /></chemistry> wherein all variables are as defined herein.
0045In one aspect, a compound is provided of Formula XII(1): <chemistry id="chem0115" num="0115"><img file="EP4470618A2_D0115.tif" /></chemistry> wherein all variables are as defined herein.
0046In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0116" num="0116"><img file="EP4470618A2_D0116.tif" /></chemistry><chemistry id="chem0117" num="0117"><img file="EP4470618A2_D0117.tif" /></chemistry><chemistry id="chem0118" num="0118"><img file="EP4470618A2_D0118.tif" /></chemistry><chemistry id="chem0119" num="0119"><img file="EP4470618A2_D0119.tif" /></chemistry><chemistry id="chem0120" num="0120"><img file="EP4470618A2_D0120.tif" /></chemistry><chemistry id="chem0121" num="0121"><img file="EP4470618A2_D0121.tif" /></chemistry><chemistry id="chem0122" num="0122"><img file="EP4470618A2_D0122.tif" /></chemistry><chemistry id="chem0123" num="0123"><img file="EP4470618A2_D0123.tif" /></chemistry> and <chemistry id="chem0124" num="0124"><img file="EP4470618A2_D0124.tif" /></chemistry> wherein all variables are as defined herein.
0047In a first aspect, the present invention provides compounds of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VΠI(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1) as defined herein for use as a therapeutically active substance.
0048In a further aspect, the present invention provides pharmaceutical compositions comprising a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VΠI(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) as defined herein and a therapeutically inert carrier.
0049In certain embodiments, the compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1) has at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i. e., enriched. In one embodiment, the compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) includes a deuterium or multiple deuterium atoms.
0050Other features and advantages of the present application will be apparent from the following detailed description and claims.
0051The present invention therefore includes at least the following features: <ol id="ol0001" compact="compact"><li>a) a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or a pharmaceutically acceptable salt thereof;</li><li>b) use of a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1), or a pharmaceutically acceptable salt thereof, in an effective amount in the treatment of a patient, typically a human, with a disorder that responds to such treatment, including by modulating the cereblon-based ubiquitination of a protein, such as for example, abnormal cellular proliferation such as a tumor or cancer, an immune or autoimmune or inflammatory disorder, a cardiologic disorder, an infectious disease, or other disorder that responds to such treatment;</li><li>c) use of a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a medical disorder, as further described herein;</li><li>d) a method for manufacturing a medicament intended for the therapeutic treatment of a disorder in a host, characterized in that a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) is used in the manufacture;</li><li>e) a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1), or a pharmaceutically acceptable salt thereof, that is useful in the treatment of an abnormal cellular proliferation such as cancer in a host, including any of the cancers described herein;</li><li>f) use of a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an abnormal cellular proliferation such as cancer, including any of the cancers described herein;</li><li>g) a method for manufacturing a medicament intended for the therapeutic use to treat an abnormal cellular proliferation such as cancer in a host, including any of the cancers described herein, characterized in that a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) is used in the manufacture;</li><li>h) a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1), or a pharmaceutically acceptable salt thereof, that is useful in the treatment of a tumor in a host, including any of the tumors described herein;</li><li>i) use of a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a tumor in a host, including any of the tumors described herein;</li><li>j) a method for manufacturing a medicament intended for the therapeutic use to treat a tumor in a host, including any of the tumors described herein, characterized in that a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1) is used in the manufacture;</li><li>k) a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1), or a pharmaceutically acceptable salt thereof, that is useful in the treatment of an immune, autoimmune, or inflammatory disorder in a host;</li><li>l) use of a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an immune, autoimmune, or inflammatory disorder in a host;</li><li>m) a method for manufacturing a medicament intended for the therapeutic use to treat an immune, autoimmune, or inflammatory disorder in a host, characterized in that a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VΠI(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1) is used in the manufacture;</li><li>n) a pharmaceutical formulation comprising an effective host-treating amount of a compound of a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1), or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier or diluent;</li><li>o) a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) as described herein in enantiomerically or diastereomerically (as relevant) enriched form, including an isolated enantiomer or diastereomer (i.e., greater than 85, 90, 95, 97, or 99% pure);</li><li>p) a process for the preparation of therapeutic products that contain an effective amount of a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VΠI(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1), or a pharmaceutically acceptable salt thereof; and</li><li>q) a process for the preparation of a bifunctional compound that causes degradation of a selected protein via the ubiquitin proteasome pathway, characterized in that a compound of Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) is used in the preparation of the bifunctional compound.</li></ol>
DETAILED DESCRIPTION OF THE INVENTION
I. Definitions
0052Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. In the specification, singular forms also include the plural unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference. The references cited herein are not admitted to be prior art to the claimed application. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.
0053Compounds are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.
0054The compounds in any of the Formulas described herein may be in the form of a racemate, enantiomer, mixture of enantiomers, diastereomer, mixture of diastereomers, tautomer, N-oxide, isomer, such as rotamer, as if each is specifically described unless specifically excluded by context.
0055The terms "a" and "an" do not denote a limitation of quantity, but rather denote the presence of at least one of the reference item. The term "or" means "and/or". Recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The endpoints of all ranges are included within the range and are independently combinable. All methods described herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of example, or exemplary language (e.g., "such as"), is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed.
0056The compounds of the present invention may form a solvate with a solvent (including water). Therefore, in one non-limiting embodiment, the invention includes a solvated form of the compound. The term "solvate" refers to a molecular complex of a compound of the present invention (including a salt thereof) with one or more solvent molecules. Non-limiting examples of solvents are water, ethanol, isopropanol, dimethyl sulfoxide, acetone and other common organic solvents. The term "hydrate" refers to a molecular complex comprising a compound of the invention and water. Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent may be isotopically substituted, e.g. D<sub>2</sub>O, d<sub>6</sub>-acetone, d<sub>6</sub>-DMSO. A solvate can be in a liquid or solid form.
0057A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -(C=O)NH<sub>2</sub> is attached through the carbon of the carbonyl (C=O) group.
0058The following definitions of the general terms used in the present description apply irrespectively of whether the terms in question appear alone or in combination with other groups.
0059Unless otherwise stated, the following terms used in this Application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms "a", "an," and "the" include plural referents unless the context clearly dictates otherwise.
0060The term "C<sub>1-6</sub>-alkyl", alone or in combination with other groups, stands for a hydrocarbon radical which may be linear or branched, with single or multiple branching, wherein the alkyl group in general comprises 1 to 6 carbon atoms, for example, methyl (Me), ethyl (Et), propyl, isopropyl (i-propyl), n-butyl, i-butyl (isobutyl), 2-butyl (sec-butyl), t-butyl (tert-butyl), isopentyl, 2-ethyl-propyl (2-methyl-propyl), 1,2-dimethyl-propyl and the like. A specific group is methyl.
0061The term "halogen-C<sub>1-6</sub>-alkyl", alone or in combination with other groups, refers to C<sub>1-6</sub>-alkyl as defined herein, which is substituted by one or multiple halogen, particularly 1-5 halogen, more particularly 1-3 halogen. Particular halogen is fluoro. Particular "halogen-C<sub>1-6</sub>-alkyl" is fluoro-C<sub>1-6</sub>-alkyl and a particular "halogen-C<sub>1-3</sub>-alkyl" is fluoro-C<sub>1-3</sub>-alkyl. Examples are trifluoromethyl, difluoromethyl, fluoromethyl and the like.
0062In one embodiment "halogen-C<sub>1-6</sub>-alkyl" has one carbon.
0063In one embodiment "halogen-C<sub>1-6</sub>-alkyl" has one carbon and one halogen.
0064In one embodiment "halogen-C<sub>1-6</sub>-alkyl" has one carbon and two halogens.
0065In one embodiment "halogen-C<sub>1-6</sub>-alkyl" has one carbon and three halogens.
0066In one embodiment "halogen-C<sub>1-6</sub>-alkyl" has two carbons.
0067In one embodiment "halogen-C<sub>1-6</sub>-alkyl" has three carbons.
0068In one embodiment "halogen-C<sub>1-6</sub>-alkyl" has four carbons.
0069In one embodiment "halogen-C<sub>1-6</sub>-alkyl" has five carbons.
0070In one embodiment "halogen-C<sub>1-6</sub>-alkyl" has six carbons.
0071Non-limiting examples of "halogen-C<sub>1-6</sub>-alkyl" include: <chemistry id="chem0125" num="0125"><img file="EP4470618A2_D0125.tif" /></chemistry>
0072Additional non-limiting examples of "halogen-C<sub>1-6</sub>-alkyl" include: <chemistry id="chem0126" num="0126"><img file="EP4470618A2_D0126.tif" /></chemistry><chemistry id="chem0127" num="0127"><img file="EP4470618A2_D0127.tif" /></chemistry>
0073Additional non-limiting examples of "halogen-C<sub>1-6</sub>-alkyl" include: <chemistry id="chem0128" num="0128"><img file="EP4470618A2_D0128.tif" /></chemistry> and <chemistry id="chem0129" num="0129"><img file="EP4470618A2_D0129.tif" /></chemistry>
0074Additional non-limiting examples of "halogen-C<sub>1-6</sub>-alkyl" include: <chemistry id="chem0130" num="0130"><img file="EP4470618A2_D0130.tif" /></chemistry> and <chemistry id="chem0131" num="0131"><img file="EP4470618A2_D0131.tif" /></chemistry>
0075The term "hydroxy-C<sub>1-6</sub>-alkyl", alone or in combination with other groups, refers to C<sub>1-6</sub>-alkyl as defined herein, which is substituted by one or multiple hydroxy groups, particularly by 1 hydroxy group. Examples are -CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OH and the like.
0076The term "cycloalkyl" denotes a monovalent saturated monocyclic or bicyclic hydrocarbon group of 3 to 10 ring carbon atoms, particularly a monovalent saturated monocyclic hydrocarbon group of 3 to 8 ring carbon atoms. Bicyclic means consisting of two carbocycles having one or more carbon atoms in common, while one carbocycle is saturated, the other one may be aromatic. Particular cycloalkyl groups are monocyclic. Examples for monocyclic cycloalkyl are "C<sub>3</sub>-<sub>7</sub>cycloalkyl" such as cyclopropyl, cyclobutanyl, cyclopentyl, cyclohexyl or cycloheptyl. Examples for saturated bicyclic cycloalkyl are bicyclo[2.2.1]heptanyl, or bicyclo[2.2.2]octanyl. Examples for bicyclic cycloalkyl wherein one ring is aromatic are 1<i>H</i>-indenyl or 1,2,3,4-tetrahydronaphthalenyl.
0077The term "hydroxy", alone or in combination with other groups, refers to OH.
0078The term "Bz" stands for benzyl (i.e., phenyl-CH<sub>2</sub>-).
0079The term "halogen", alone or in combination with other groups, denotes chloro (Cl), iodo (I), fluoro (F) and bromo (Br). A specific group is F.
0080The term "heteroaryl" denotes a monovalent heterocyclic mono- or bicyclic ring system of 5 to 12 ring atoms, comprising 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon and in which at least one ring is aromatic. Examples of heteroaryl moieties include pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, azepinyl, diazepinyl, isoxazolyl, benzofuranyl, isothiazolyl, benzothienyl, indolinyl, indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzooxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, or 2,3-dihydropyrrolo[2,3-b]pyridinyl. Specific examples include benzimidazolyl, pyridinyl, thiazolyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, 3,4-dihydroquinolinyl, benzofuranyl, furanyl, imidazolyl, isoindolyl, and quinolinyl.
0081In one embodiment "heteroaryl" is a 5 membered aromatic group containing 1, 2, 3, or 4 nitrogen atoms.
0082Non-limiting examples of 5 membered "heteroaryl" groups include pyrrole, furan, thiophene, pyrazole, imidazole, triazole, tetrazole, isoxazole, oxazole, oxadiazole, oxatriazole, isothiazole, thiazole, thiadiazole, and thiatriazole.
0083Additional non-limiting examples of 5 membered "heteroaryl" groups include: <chemistry id="chem0132" num="0132"><img file="EP4470618A2_D0132.tif" /></chemistry><chemistry id="chem0133" num="0133"><img file="EP4470618A2_D0133.tif" /></chemistry><chemistry id="chem0134" num="0134"><img file="EP4470618A2_D0134.tif" /></chemistry>
0084In one embodiment "heteroaryl" is a 6 membered aromatic group containing 1, 2, or 3 nitrogen atoms (i.e. pyridinyl, pyridazinyl, triazinyl, pyrimidinyl, and pyrazinyl).
0085Non-limiting examples of 6 membered "heteroaryl" groups with 1 or 2 nitrogen atoms include: <chemistry id="chem0135" num="0135"><img file="EP4470618A2_D0135.tif" /></chemistry> and <chemistry id="chem0136" num="0136"><img file="EP4470618A2_D0136.tif" /></chemistry>
0086In one embodiment "heteroaryl" is a 9 membered bicyclic aromatic group containing 1 or 2 atoms selected from nitrogen, oxygen, and sulfur.
0087Non-limiting examples of "heteroaryl" groups that are bicyclic include indole, benzofuran, isoindole, indazole, benzimidazole, azaindole, azaindazole, purine, isobenzofuran, benzothiophene, benzoisoxazole, benzoisothiazole, benzooxazole, and benzothiazole.
0088Additional non-limiting examples of "heteroaryl" groups that are bicyclic include: <chemistry id="chem0137" num="0137"><img file="EP4470618A2_D0137.tif" /></chemistry>
0089Additional non-limiting examples of "heteroaryl" groups that are bicyclic include: <chemistry id="chem0138" num="0138"><img file="EP4470618A2_D0138.tif" /></chemistry>
0090Additional non-limiting examples of "heteroaryl" groups that are bicyclic include: <chemistry id="chem0139" num="0139"><img file="EP4470618A2_D0139.tif" /></chemistry>
0091In one embodiment "heteroaryl" is a 10 membered bicyclic aromatic group containing 1 or 2 atoms selected from nitrogen, oxygen, and sulfur.
0092Non-limiting examples of "heteroaryl" groups that are bicyclic include quinoline, isoquinoline, quinoxaline, phthalazine, quinazoline, cinnoline, and naphthyridine.
0093Additional non-limiting examples of "heteroaryl" groups that are bicyclic include: <chemistry id="chem0140" num="0140"><img file="EP4470618A2_D0140.tif" /></chemistry>
0094In another embodiment "heteroaryl" is "optionally substituted" with 1, 2, 3, or 4 subsituents.
0095The term "heterocycloalkyl" denotes a monovalent saturated or partly unsaturated mono- or bicyclic ring system of 4 to 9 ring atoms, comprising 1, 2, or 3 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Examples for monocyclic saturated heterocycloalkyl are azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, or oxazepanyl. Examples for bicyclic saturated heterocycloalkyl are 8-aza-bicyclo[3.2.1]octyl, quinuclidinyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, 9-aza-bicyclo[3.3.1]nonyl, 3-oxa-9-aza-bicyclo[3.3.1]nonyl, or 3-thia-9-aza-bicyclo[3.3.1]nonyl. Examples for partly unsaturated heterocycloalkyl are dihydrofuryl, imidazolinyl, dihydro-oxazolyl, tetrahydro-pyridinyl, or dihydropyranyl. Specific examples include piperazinyl, piperidinyl, pyrrolidinyl and 3,8-diazabicyclo[3.2.1]octanyl.
0096In one embodiment "heterocycloalkyl" refers to a cyclic ring with one nitrogen and 3, 4, 5, 6, 7, or 8 carbon atoms.
0097In one embodiment "heterocycloalkyl" refers to a cyclic ring with one nitrogen and one oxygen and 3, 4, 5, 6, 7, or 8 carbon atoms.
0098In one embodiment "heterocycloalkyl" refers to a cyclic ring with two nitrogens and 3, 4, 5, 6, 7, or 8 carbon atoms.
0099In one embodiment "heterocycloalkyl" refers to a cyclic ring with one oxygen and 3, 4, 5, 6, 7, or 8 carbon atoms.
0100In one embodiment "heterocycloalkyl" refers to a cyclic ring with one sulfur and 3, 4, 5, 6, 7, or 8 carbon atoms.
0101Non-limiting examples of "heterocycloalkyl" include aziridine, oxirane, thiirane, azetidine, 1,3-diazetidine, oxetane, and thietane.
0102Additional non-limiting examples of "heterocycloalkyl" include pyrrolidine, 3-pyrroline, 2-pyrroline, pyrazolidine, and imidazolidine.
0103Additional non-limiting examples of "heterocycloalkyl" include tetrahydrofuran, 1,3-dioxolane, tetrahydrothiophene, 1,2-oxathiolane, and 1,3-oxathiolane.
0104Additional non-limiting examples of "heterocycloalkyl" include piperidine, piperazine, tetrahydropyran, 1,4-dioxane, thiane, 1,3-dithiane, 1,4-dithiane, morpholine, and thiomorpholine.
0105Additional non-limiting examples of "heterocycloalkyl" include indoline, tetrahydroquinoline, tetrahydroisoquinoline, and dihydrobenzofuran wherein the point of attachment for each group is on the heterocyclic ring.
0106For example, <chemistry id="chem0141" num="0141"><img file="EP4470618A2_D0141.tif" /></chemistry> is a "heterocycloalkyl" group.
0107However, <chemistry id="chem0142" num="0142"><img file="EP4470618A2_D0142.tif" /></chemistry> is an "aryl" group.
0108Non-limiting examples of "heterocycloalkyl" also include: <chemistry id="chem0143" num="0143"><img file="EP4470618A2_D0143.tif" /></chemistry>
0109Additional non-limiting examples of "heterocycloalkyl" include: <chemistry id="chem0144" num="0144"><img file="EP4470618A2_D0144.tif" /></chemistry>
0110Additional non-limiting examples of "heterocycloalkyl" include: <chemistry id="chem0145" num="0145"><img file="EP4470618A2_D0145.tif" /></chemistry>
0111Non-limiting examples of "heterocycloalkyl" also include: <chemistry id="chem0146" num="0146"><img file="EP4470618A2_D0146.tif" /></chemistry>
0112Non-limiting examples of "heterocycloalkyl" also include: <chemistry id="chem0147" num="0147"><img file="EP4470618A2_D0147.tif" /></chemistry>
0113Additional non-limiting examples of "heterocycloalkyl" include: <chemistry id="chem0148" num="0148"><img file="EP4470618A2_D0148.tif" /></chemistry>
0114Additional non-limiting examples of "heterocycloalkyl" include: <chemistry id="chem0149" num="0149"><img file="EP4470618A2_D0149.tif" /></chemistry>
0115In another embodiment "heterocycloalkyl" is "optionally substituted" with 1, 2, 3, or 4 substituents.
0116The term "C<sub>1-6</sub>-alkoxy", alone or in combination with other groups, stands for an -O-C<sub>1-6</sub>-alkyl radical which may be linear or branched, with single or multiple branching, wherein the alkyl group in general comprises 1 to 6 carbon atoms, for example, methoxy (OMe, MeO), ethoxy (OEt), propoxy, isopropoxy (i-propoxy), n-butoxy, i-butoxy (iso-butoxy), 2-butoxy (sec-butoxy), t-butoxy (<i>tert</i>-butoxy), isopentyloxy (i-pentyloxy) and the like. Particular "C<sub>1-6</sub>-alkoxy" are groups with 1 to 4 carbon atoms. A specific group is methoxy.
0117The term "aryl" denotes a monovalent aromatic carbocyclic mono- or bicyclic ring system comprising 6 to 10 carbon ring atoms. Examples of aryl moieties include phenyl (Ph), and naphthyl. Specific "aryl" is phenyl.
0118In one embodiment "aryl" is a 6 carbon aromatic group (phenyl)
0119In one embodiment "aryl" is a 10 carbon aromatic group (napthyl)
0120In one embodiment "aryl" is a 6 carbon aromatic group fused to a heterocycle wherein the point of attachment is the aryl ring. Non-limiting examples of "aryl" include indoline, tetrahydroquinoline, tetrahydroisoquinoline, and dihydrobenzofuran wherein the point of attachment for each group is on the aromatic ring.
0121For example <chemistry id="chem0150" num="0150"><img file="EP4470618A2_D0150.tif" /></chemistry> is an "aryl" group.
0122However, <chemistry id="chem0151" num="0151"><img file="EP4470618A2_D0151.tif" /></chemistry> is a "heterocycloalkyl" group.
0123In one embodiment "aryl" is a 6 carbon aromatic group fused to a cycloalkyl wherein the point of attachment is the aryl ring. Non-limiting examples of "aryl" include dihydro-indene and tetrahydronaphthalene wherein the point of attachment for each group is on the aromatic ring.
0124For example <chemistry id="chem0152" num="0152"><img file="EP4470618A2_D0152.tif" /></chemistry> is an "aryl" group.
0125However, <chemistry id="chem0153" num="0153"><img file="EP4470618A2_D0153.tif" /></chemistry> is a "cycloalkyl" group.
0126In another embodiment "aryl" is "optionally substituted" with 1, 2, 3, or 4 substitutents.
0127The term "optionally substituted" denotes the substitution of a group herein by a moiety including, but not limited to, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>3</sub>-C<sub>12</sub> cycloalkyl, C<sub>3</sub>-C<sub>12</sub> cycloalkenyl, C<sub>1</sub>-C<sub>12</sub> heterocycloalkyl, C<sub>3</sub>-C<sub>12</sub> heterocycloalkenyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, amino, C<sub>1</sub>-C<sub>10</sub> alkylamino, C<sub>1</sub>-C<sub>10</sub> dialkylamino, arylamino, diarylamino, C<sub>1</sub>-C<sub>10</sub> alkylsulfonamino, arylsulfonamino, C<sub>1</sub>-C<sub>10</sub> alkylimino, arylimino, C<sub>1</sub>-C<sub>10</sub> alkylsulfonimino, arylsulfonimino, hydroxyl, halo, thio, C<sub>1</sub>-C<sub>10</sub> alkylthio, arylthio, C<sub>1</sub>-C<sub>10</sub> alkylsulfonyl, arylsulfonyl, acylamino, aminoacyl, aminothioacyl, amidino, guanidine, ureido, cyano, nitro, azido, acyl, thioacyl, acyloxy, carboxyl, and carboxylic ester.
0128In another embodiment any suitable group may be present on a "substituted" or "optionally substituted" position if indicated that forms a stable molecule and meets the desired purpose of the invention and includes, but is not limited to, e.g., halogen (which can independently be F, Cl, Br or I); cyano; hydroxyl; nitro; azido; alkanoyl (such as a C<sub>2</sub>-C<sub>6</sub> alkanoyl group); carboxamide; alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy such as phenoxy; thioalkyl including those having one or more thioether linkages; alkylsulfinyl; alkylsulfonyl groups including those having one or more sulfonyl linkages; aminoalkyl groups including groups having more than one N atoms; aryl (e.g., phenyl, biphenyl, naphthyl, or the like, each ring either substituted or unsubstituted); arylalkyl having for example, 1 to 3 separate or fused rings and from 6 to about 14 or 18 ring carbon atoms, with benzyl being an exemplary arylalkyl group; arylalkoxy, for example, having 1 to 3 separate or fused rings with benzyloxy being an exemplary arylalkoxy group; or a saturated or partially unsaturated heterocycle having 1 to 3 separate or fused rings with one or more N, O or S atoms, or a heteroaryl having 1 to 3 separate or fused rings with one or more N, O or S atoms, e.g. coumarinyl, quinolinyl, isoquinolinyl, quinazolinyl, pyridyl, pyrazinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, triazinyl, oxazolyl, isoxazolyl, imidazolyl, indolyl, benzofuranyl, benzothiazolyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholinyl, piperazinyl, and pyrrolidinyl. Such groups may be further substituted, e.g. with hydroxy, alkyl, alkoxy, halogen and amino. In certain embodiments "optionally substituted" includes one or more substituents independently selected from halogen, hydroxyl, amino, cyano, -CHO, -COOH, -CONH<sub>2</sub>, alkyl including C<sub>1</sub>-C<sub>6</sub>alkyl, alkenyl including C<sub>2</sub>-C<sub>6</sub>alkenyl, alkynyl including C<sub>2</sub>-C<sub>6</sub>alkynyl, -C<sub>1</sub>-C<sub>6</sub>alkoxy, alkanoyl including C<sub>2</sub>-C<sub>6</sub>alkanoyl, C<sub>1</sub>-C<sub>6</sub>alkylester, (mono- and di-C<sub>1</sub>-C<sub>6</sub>alkylamino)Co-C<sub>2</sub>alkyl, haloalkyl including C<sub>1</sub>-C<sub>6</sub>haloalkyl, hydoxyC<sub>1</sub>-C<sub>6</sub>alkyl, ester, carbamate, urea, sulfonamide,-C<sub>1</sub>-C<sub>6</sub>alkyl(heterocyclo), C<sub>1</sub>-C<sub>6</sub>alkyl(heteroaryl), -C<sub>1</sub>-C<sub>6</sub>alkyl(C<sub>3</sub>-C<sub>7</sub>cycloalkyl), O-C<sub>1</sub>-C<sub>6</sub>alkyl(C<sub>3</sub>-C<sub>7</sub>cycloalkyl), B(OH)<sub>2</sub>, phosphate, phosphonate and haloalkoxy including C<sub>1</sub>-C<sub>6</sub>haloalkoxy. In some embodiments, the suitable group present on a "substituted" or "optionally substituted" is divalent including, but not limited to, oxo (=O), =S, =CH<sub>2</sub>, etc. The suitable group on a "substituted" or "optional substituted" position may be monovalent, divalent, or trivalent such that it forms a stable molecule and meets the desired purpose of the invention.
0129In one embodiment a group described herein that can be substituted with 1, 2, 3, or 4 substituents is substituted with one substituent.
0130In one embodiment a group described herein that can be substituted with 1, 2, 3, or 4 substituents is substituted with two substituents.
0131In one embodiment a group described herein that can be substituted with 1, 2, 3, or 4 substituents is substituted with three substituents.
0132In one embodiment a group described herein that can be substituted with 1, 2, 3, or 4 substituents is substituted with four substituents.
0133Terms like "a-b-x substituted by R" means that the "x" portion of the moiety is substituted by R. For example, "-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>" means that the "aryl" portion of the moiety is substituted by R<sup>10</sup>; "-(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>" means that the "aryl" portion fo the moiety is substituted by R<sup>10</sup>; "-(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl substituted by R<sup>9</sup>" means that the "heteroaryl" portion of the moiety is substituted by R<sup>9</sup>; and "-CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>" means that the "aryl" portion of the moiety is substituted by R<sup>10</sup>.
0134The term "pharmaceutically acceptable" denotes an attribute of a material which is useful in preparing a pharmaceutical composition that is generally safe, not unacceptable toxic, and neither biologically nor otherwise undesirable. In one aspect, the material is acceptable for veterinary as well as human pharmaceutical use.
0135The term "a pharmaceutically acceptable salt" refers to a salt that is suitable for use in contact with the tissues of humans and animals. Examples of suitable salts with inorganic and organic acids are, but are not limited to acetic acid, citric acid, formic acid, fumaric acid, hydrochloric acid, lactic acid, maleic acid, malic acid, methane-sulfonic acid, nitric acid, phosphoric acid, p-toluenesulphonic acid, succinic acid, sulfuric acid (sulphuric acid), tartaric acid, trifluoroacetic acid and the like. Particular acids are formic acid, trifluoroacetic acid and hydrochloric acid. Specific acids are hydrochloric acid, trifluoroacetic acid and fumaric acid.
0136Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC-(CH<sub>2</sub>)<sub>n</sub>-COOH where n is 0-4, and the like, or using a different acid that produces the same counterion. Lists of additional suitable salts may be found, e.g., in <nplcit id="ncit0008" npl-type="b"><text>Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985</text></nplcit>).
0137The terms "pharmaceutically acceptable auxiliary substance" refer to carriers and auxiliary substances such as diluents or excipients that are compatible with the other ingredients of the formulation.
0138"Therapeutically effective amount", when administered to a subject for treating a disease state, will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors.
0139The term "as defined herein" and "as described herein" when referring to a variable incorporates by reference the broad definition of the variable as well as particularly, more particularly and most particularly definitions, if any.
0140The terms "treating", "contacting" and "reacting" when referring to a chemical reaction means adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
0141The term "aromatic" denotes the conventional idea of aromaticity as defined in the literature, in particular in <nplcit id="ncit0009" npl-type="b"><text>IUPAC - Compendium of Chemical Terminology, 2nd Edition, A. D. McNaught & A. Wilkinson (Eds). Blackwell Scientific Publications, Oxford (1997</text></nplcit>).
0142The term "pharmaceutically acceptable excipient" denotes any ingredient having no therapeutic activity and being non-toxic such as disintegrators, binders, fillers, solvents, buffers, tonicity agents, stabilizers, antioxidants, surfactants or lubricants used in formulating pharmaceutical products.
0143All separate embodiments may be combined.
0144The term "treatment" as used herein includes: (1) inhibiting the state, disorder or condition (e.g. arresting, reducing or delaying the development of the disease, or a relapse thereof in case of maintenance treatment, of at least one clinical or subclinical symptom thereof); and/or (2) relieving the condition (i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms). However, it will be appreciated that when a medicament is administered to a patient to treat a disease, the outcome may not always be effective treatment.
0145The term "prophylaxis" as used herein includes: preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a mammal and especially a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition.
Isotopic Substitution
0146The present invention includes compounds of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e., enriched. Isotopes are atoms having the same atomic number but different mass numbers, i.e., the same number of protons but a different number of neutrons.
0147Examples of isotopes that can be incorporated into compound of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, chlorine and iodine such as <sup>2</sup>H, <sup>3</sup>H, <sup>11</sup>C, <sup>13</sup>C, <sup>14</sup>C, <sup>15</sup>N, <sup>17</sup>0, <sup>18</sup>0, <sup>18</sup>F, <sup>35</sup>S, <sup>36</sup>Cl, and <sup>125</sup>I respectively. In one non-limiting embodiment, isotopically labelled compounds can be used in metabolic studies (with, for example <sup>14</sup>C), reaction kinetic studies (with, for example <sup>2</sup>H or <sup>3</sup>H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an <sup>18</sup>F labeled compound may be particularly desirable for PET or SPECT studies. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
0148Isotopic substitutions, for example deuterium substitutions, can be partial or complete. Partial deuterium substitution means that at least one hydrogen is substituted with deuterium. In certain embodiments, the isotope is 90, 95, or 99% or more enriched in an isotope at any location of interest. In one non-limiting embodiment, deuterium is 90, 95, or 99% enriched at a desired location.
0149In one non-limiting embodiment, the substitution of a hydrogen atom for a deuterium atom can be provided in any compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XΠI(1)-i, or Formula XIV(1). In one non-limiting embodiment, the substitution of a hydrogen atom for a deuterium atom occurs within one or more groups selected from the variables described herein. For example, when any of the groups are, or contain for example through substitution, methyl, ethyl, or methoxy, the alkyl residue may be deuterated (in non-limiting embodiments, CDH<sub>2</sub>, CD<sub>2</sub>H, CD<sub>3</sub>, CH<sub>2</sub>CD<sub>3</sub>, CD<sub>2</sub>CD<sub>3</sub>, CHDCH<sub>2</sub>D, CHDCHD<sub>2</sub>, OCDH<sub>2</sub>, OCD<sub>2</sub>H, or OCD<sub>3</sub>, etc.). In certain other embodiments, when two substitutions are combined to form a cycle, the unsubstituted carbons may be deuterated.
II. Compounds of the Present Invention
0150The present invention provides compounds of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, and pharmaceutically acceptable salts thereof. The invention also provides the use of compounds of Formula XIV or Formula XIV(1) as further described herein.
Embodiments of Formulas I-XIII
0151In one embodiment, a compound of Formula I is provided: <chemistry id="chem0154" num="0154"><img file="EP4470618A2_D0154.tif" /></chemistry> wherein all variables are as defined herein.
0152In one embodiment, a compound of Formula I is provided selected from: <chemistry id="chem0155" num="0155"><img file="EP4470618A2_D0155.tif" /></chemistry><chemistry id="chem0156" num="0156"><img file="EP4470618A2_D0156.tif" /></chemistry> and <chemistry id="chem0157" num="0157"><img file="EP4470618A2_D0157.tif" /></chemistry> Wherein all variables are as defined herein.
0153In one embodiment, a compound of Formula I is selected from: <chemistry id="chem0158" num="0158"><img file="EP4470618A2_D0158.tif" /></chemistry><chemistry id="chem0159" num="0159"><img file="EP4470618A2_D0159.tif" /></chemistry> wherein all variables are defined as herein.
0154In one embodiment of Formula I, <chemistry id="chem0160" num="0160"><img file="EP4470618A2_D0160.tif" /></chemistry> is selected from: <chemistry id="chem0161" num="0161"><img file="EP4470618A2_D0161.tif" /></chemistry><chemistry id="chem0162" num="0162"><img file="EP4470618A2_D0162.tif" /></chemistry><chemistry id="chem0163" num="0163"><img file="EP4470618A2_D0163.tif" /></chemistry><chemistry id="chem0164" num="0164"><img file="EP4470618A2_D0164.tif" /></chemistry> wherein all variables are defined as herein.
0155In one embodiment, a compound is provided of Formula II-c and Formula II-d: <chemistry id="chem0165" num="0165"><img file="EP4470618A2_D0165.tif" /></chemistry> wherein all variables are defined as herein.
0156In one embodiment, a compound is provided of one of the following formulas: <chemistry id="chem0166" num="0166"><img file="EP4470618A2_D0166.tif" /></chemistry><chemistry id="chem0167" num="0167"><img file="EP4470618A2_D0167.tif" /></chemistry><chemistry id="chem0168" num="0168"><img file="EP4470618A2_D0168.tif" /></chemistry> and <chemistry id="chem0169" num="0169"><img file="EP4470618A2_D0169.tif" /></chemistry> wherein all variables are defined as herein.
0157In any one embodiment of Formulas II-a to II-k, <chemistry id="chem0170" num="0170"><img file="EP4470618A2_D0170.tif" /></chemistry> is selected from: <chemistry id="chem0171" num="0171"><img file="EP4470618A2_D0171.tif" /></chemistry>
0158In one embodiment, a compound is provided of Formula III: <chemistry id="chem0172" num="0172"><img file="EP4470618A2_D0172.tif" /></chemistry> wherein all variables are as defined herein.
0159In one embodiment, a compound of Formula III is selected from: <chemistry id="chem0173" num="0173"><img file="EP4470618A2_D0173.tif" /></chemistry><chemistry id="chem0174" num="0174"><img file="EP4470618A2_D0174.tif" /></chemistry> and <chemistry id="chem0175" num="0175"><img file="EP4470618A2_D0175.tif" /></chemistry> wherein all variables are defined as herein.
0160In one embodiment, a compound of Formula III is selected from: <chemistry id="chem0176" num="0176"><img file="EP4470618A2_D0176.tif" /></chemistry><chemistry id="chem0177" num="0177"><img file="EP4470618A2_D0177.tif" /></chemistry> Wherein all variables are defined as herein.
0161In one embodiment of Formula III, <chemistry id="chem0178" num="0178"><img file="EP4470618A2_D0178.tif" /></chemistry> is selected from: <chemistry id="chem0179" num="0179"><img file="EP4470618A2_D0179.tif" /></chemistry><chemistry id="chem0180" num="0180"><img file="EP4470618A2_D0180.tif" /></chemistry><chemistry id="chem0181" num="0181"><img file="EP4470618A2_D0181.tif" /></chemistry>
0162In one embodiment, a compound is provided of Formula IV-a and Formula IV-b: <chemistry id="chem0182" num="0182"><img file="EP4470618A2_D0182.tif" /></chemistry> wherein all variables are as defined herein.
0163In one embodiment, a compound is provided of one of the following formulas: <chemistry id="chem0183" num="0183"><img file="EP4470618A2_D0183.tif" /></chemistry><chemistry id="chem0184" num="0184"><img file="EP4470618A2_D0184.tif" /></chemistry> wherein all variables are as defined herein.
0164In one embodiment, a compound is provided selected Formula IV-g and Formula IV-h: <chemistry id="chem0185" num="0185"><img file="EP4470618A2_D0185.tif" /></chemistry> wherein all variables are as defined herein.
0165In one embodiment, a compound is provided selected from Formula IV-i and Formula IV-j: <chemistry id="chem0186" num="0186"><img file="EP4470618A2_D0186.tif" /></chemistry> wherein all variables are as defined herein.
0166In some embodiments of any one of Formula IV-a to IV-j, <chemistry id="chem0187" num="0187"><img file="EP4470618A2_D0187.tif" /></chemistry> or <chemistry id="chem0188" num="0188"><img file="EP4470618A2_D0188.tif" /></chemistry> is selected from: <chemistry id="chem0189" num="0189"><img file="EP4470618A2_D0189.tif" /></chemistry><chemistry id="chem0190" num="0190"><img file="EP4470618A2_D0190.tif" /></chemistry>
0167In one embodiment, a compound is provided of Formula V: <chemistry id="chem0191" num="0191"><img file="EP4470618A2_D0191.tif" /></chemistry> wherein all variables are as defined herein.
0168In one embodiment, a compound of Formula V is selected from: <chemistry id="chem0192" num="0192"><img file="EP4470618A2_D0192.tif" /></chemistry><chemistry id="chem0193" num="0193"><img file="EP4470618A2_D0193.tif" /></chemistry> and <chemistry id="chem0194" num="0194"><img file="EP4470618A2_D0194.tif" /></chemistry>
0169In one embodiment, a compound of Formula V is selected from: <chemistry id="chem0195" num="0195"><img file="EP4470618A2_D0195.tif" /></chemistry><chemistry id="chem0196" num="0196"><img file="EP4470618A2_D0196.tif" /></chemistry>
0170In one embodiment of Formula V, <chemistry id="chem0197" num="0197"><img file="EP4470618A2_D0197.tif" /></chemistry> is selected from: <chemistry id="chem0198" num="0198"><img file="EP4470618A2_D0198.tif" /></chemistry> and <chemistry id="chem0199" num="0199"><img file="EP4470618A2_D0199.tif" /></chemistry>
0171In one embodiment, a compound is provided of Formula VI: <chemistry id="chem0200" num="0200"><img file="EP4470618A2_D0200.tif" /></chemistry> wherein all variables are as defined herein.
0172In one embodiment, a compound of Formula VI is selected from: <chemistry id="chem0201" num="0201"><img file="EP4470618A2_D0201.tif" /></chemistry><chemistry id="chem0202" num="0202"><img file="EP4470618A2_D0202.tif" /></chemistry> and <chemistry id="chem0203" num="0203"><img file="EP4470618A2_D0203.tif" /></chemistry> wherein all variables are as defined herein.
0173In one embodiment, a compound of Formula VI is selected from: <chemistry id="chem0204" num="0204"><img file="EP4470618A2_D0204.tif" /></chemistry><chemistry id="chem0205" num="0205"><img file="EP4470618A2_D0205.tif" /></chemistry> wherein all variables are as defined herein.
0174In one embodiment of Formula VI, <chemistry id="chem0206" num="0206"><img file="EP4470618A2_D0206.tif" /></chemistry> is selected from: <chemistry id="chem0207" num="0207"><img file="EP4470618A2_D0207.tif" /></chemistry><chemistry id="chem0208" num="0208"><img file="EP4470618A2_D0208.tif" /></chemistry>
0175In one embodiment, a compound of Formula VII-a is selected from: <chemistry id="chem0209" num="0209"><img file="EP4470618A2_D0209.tif" /></chemistry><chemistry id="chem0210" num="0210"><img file="EP4470618A2_D0210.tif" /></chemistry> and <chemistry id="chem0211" num="0211"><img file="EP4470618A2_D0211.tif" /></chemistry> wherein all variables are as defined herein.
0176In one embodiment, a compound is provided of Formula VII-b, Formula VII-c, and Formula VII-d: <chemistry id="chem0212" num="0212"><img file="EP4470618A2_D0212.tif" /></chemistry> and <chemistry id="chem0213" num="0213"><img file="EP4470618A2_D0213.tif" /></chemistry> wherein all variables are as defined herein.
0177In one embodiment, a compound is provided of Formula VII-e: <chemistry id="chem0214" num="0214"><img file="EP4470618A2_D0214.tif" /></chemistry> wherein all variables are as defined herein.
0178In one embodiment of any one of Formula VII-a to VII-e, <chemistry id="chem0215" num="0215"><img file="EP4470618A2_D0215.tif" /></chemistry> is selected from: <chemistry id="chem0216" num="0216"><img file="EP4470618A2_D0216.tif" /></chemistry>
0179In one embodiment, a compound is provided of one of the following formulas: <chemistry id="chem0217" num="0217"><img file="EP4470618A2_D0217.tif" /></chemistry><chemistry id="chem0218" num="0218"><img file="EP4470618A2_D0218.tif" /></chemistry> wherein all variables are as defined herein.
0180In one embodiment, a compound is provided of Formula VIII-e): <chemistry id="chem0219" num="0219"><img file="EP4470618A2_D0219.tif" /></chemistry> wherein all variables are as defined herein.
0181In one embodiment, a compound is provided of Formula VIII-f and Formula VIII-g: <chemistry id="chem0220" num="0220"><img file="EP4470618A2_D0220.tif" /></chemistry> wherein all variables are as defined herein.
0182In one embodiment, a compound is provided of Formula VIII-h and VIII-i: <chemistry id="chem0221" num="0221"><img file="EP4470618A2_D0221.tif" /></chemistry> wherein all variables are as defined herein.
0183In one embodiment of any one of Formula VIII-a to VIII-i, <chemistry id="chem0222" num="0222"><img file="EP4470618A2_D0222.tif" /></chemistry> is selected from: <chemistry id="chem0223" num="0223"><img file="EP4470618A2_D0223.tif" /></chemistry><chemistry id="chem0224" num="0224"><img file="EP4470618A2_D0224.tif" /></chemistry><chemistry id="chem0225" num="0225"><img file="EP4470618A2_D0225.tif" /></chemistry><chemistry id="chem0226" num="0226"><img file="EP4470618A2_D0226.tif" /></chemistry>
0184In one embodiment, a compound is provided of one of the following formulas: <chemistry id="chem0227" num="0227"><img file="EP4470618A2_D0227.tif" /></chemistry><chemistry id="chem0228" num="0228"><img file="EP4470618A2_D0228.tif" /></chemistry> wherein all variables are as defined herein.
0185In one embodiment, a compound is provided of Formula IX-e: <chemistry id="chem0229" num="0229"><img file="EP4470618A2_D0229.tif" /></chemistry> wherein all variables are as defined herein.
0186In one embodiment, a compound is provided of Formula IX-f and IX-g: <chemistry id="chem0230" num="0230"><img file="EP4470618A2_D0230.tif" /></chemistry> wherein all variables are as defined herein.
0187In one embodiment, a compound is provided of Formula IX-h and IX-i: <chemistry id="chem0231" num="0231"><img file="EP4470618A2_D0231.tif" /></chemistry> wherein all variables are as defined herein.
0188In one embodiment, a compound is provided of Formula IX-j: <chemistry id="chem0232" num="0232"><img file="EP4470618A2_D0232.tif" /></chemistry> wherein all variables are as defined herein.
0189In one embodiment, a compound is provided of one of the following formulas: <chemistry id="chem0233" num="0233"><img file="EP4470618A2_D0233.tif" /></chemistry> and <chemistry id="chem0234" num="0234"><img file="EP4470618A2_D0234.tif" /></chemistry> wherein all variables are as defined herein.
0190In one embodiment, a compound is provided of Formula X-d or X-e: <chemistry id="chem0235" num="0235"><img file="EP4470618A2_D0235.tif" /></chemistry> wherein all variables are as defined herein.
0191In one embodiment, a compound is provided of one of the following formulas: <chemistry id="chem0236" num="0236"><img file="EP4470618A2_D0236.tif" /></chemistry> and <chemistry id="chem0237" num="0237"><img file="EP4470618A2_D0237.tif" /></chemistry> wherein all variables are as defined herein.
0192In one embodiment, a compound is provided of Formula X-i: <chemistry id="chem0238" num="0238"><img file="EP4470618A2_D0238.tif" /></chemistry> wherein all variables are as defined herein.
0193In one embodiment, a compound is provided of one of the following formulas: <chemistry id="chem0239" num="0239"><img file="EP4470618A2_D0239.tif" /></chemistry><chemistry id="chem0240" num="0240"><img file="EP4470618A2_D0240.tif" /></chemistry> and <chemistry id="chem0241" num="0241"><img file="EP4470618A2_D0241.tif" /></chemistry> wherein all variables are as defined herein.
0194In one embodiment, a compound is provided of one of the following Formulas: <chemistry id="chem0242" num="0242"><img file="EP4470618A2_D0242.tif" /></chemistry><chemistry id="chem0243" num="0243"><img file="EP4470618A2_D0243.tif" /></chemistry> wherein all variables are as defined herein.
0195In one embodiment, a compound is provided of Formula XI-i: <chemistry id="chem0244" num="0244"><img file="EP4470618A2_D0244.tif" /></chemistry> wherein all variables are as defined herein.
0196In one embodiment, a compound is provided of Formula XII: <chemistry id="chem0245" num="0245"><img file="EP4470618A2_D0245.tif" /></chemistry> wherein all variables are as defined herein.
0197In one embodiment, a compound is provided of Formula XII selected from: <chemistry id="chem0246" num="0246"><img file="EP4470618A2_D0246.tif" /></chemistry><chemistry id="chem0247" num="0247"><img file="EP4470618A2_D0247.tif" /></chemistry> and <chemistry id="chem0248" num="0248"><img file="EP4470618A2_D0248.tif" /></chemistry>
0198In one embodiment, a compound is provided of Formula XII selected from: <chemistry id="chem0249" num="0249"><img file="EP4470618A2_D0249.tif" /></chemistry><chemistry id="chem0250" num="0250"><img file="EP4470618A2_D0250.tif" /></chemistry>
0199In one embodiment, a compound is provided of one of the following formulas: <chemistry id="chem0251" num="0251"><img file="EP4470618A2_D0251.tif" /></chemistry><chemistry id="chem0252" num="0252"><img file="EP4470618A2_D0252.tif" /></chemistry> wherein all variables are as defined herein.
0200In one embodiment, a compound is provided of Formula XIII-e: <chemistry id="chem0253" num="0253"><img file="EP4470618A2_D0253.tif" /></chemistry> wherein all variables are as defined herein.
0201In one embodiment, a compound is provided of one of the following formulas: <chemistry id="chem0254" num="0254"><img file="EP4470618A2_D0254.tif" /></chemistry> and <chemistry id="chem0255" num="0255"><img file="EP4470618A2_D0255.tif" /></chemistry> wherein all variables are as defined herein.
0202In one embodiment, a compound is provided of Formula XIII-i: <chemistry id="chem0256" num="0256"><img file="EP4470618A2_D0256.tif" /></chemistry> wherein all variables are as defined herein.
0203In any one embodiment of Formulas IX-a to IX-j, X-a to X-i, XI-a to XI-i, or XIII-a to XIII-I, <chemistry id="chem0257" num="0257"><img file="EP4470618A2_D0257.tif" /></chemistry> can be selected from: <chemistry id="chem0258" num="0258"><img file="EP4470618A2_D0258.tif" /></chemistry><chemistry id="chem0259" num="0259"><img file="EP4470618A2_D0259.tif" /></chemistry>
Embodiments of Formula XIV
0204In a first aspect (A1), the present invention provides a compound of Formula XIV <chemistry id="chem0260" num="0260"><img file="EP4470618A2_D0260.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein: wherein all variables are as defined herein.
0205The invention also provides the following enumerated Embodiments (E): <ul id="ul0016" list-style="none" compact="compact"><li>E1: In one embodiment, the present invention provides a compound of Formula XIV according to A1, or a pharmaceutically acceptable salt thereof, wherein Z is selected from the group consisting of: <ol id="ol0002" compact="compact"><li>i) a covalent bond,</li><li>ii) carbonyl,</li><li>iii) -NR<sup>1</sup>-,</li><li>iv) -O-CH<sub>2</sub>-C(=O)-NR<sup>1</sup>-,</li><li>v) -C(=O)-NR<sup>1</sup>-, and</li><li>vi) -NR<sup>1</sup>-C(=O)-.</li></ol></li><li>E2: In one embodiment, the present invention provides a compound of Formula XIV according to any one of A1 or E1, or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is hydrogen.</li><li>E3: In one embodiment, the present invention provides a compound of Formula XIV according to any one of A1 and E1 to E2, or a pharmaceutically acceptable salt thereof, wherein each R<sup>2</sup> is -C<sub>1-6</sub>alkyl or -N(R<sup>5</sup>,R<sup>6</sup>).</li><li>E4: In one aspect, the present invention provides a compound of Formula XIV according to any one of A1 and E1 to E2, or a pharmaceutically acceptable salt thereof, wherein each R<sup>2</sup> is methyl or -N(R<sup>5</sup>,R<sup>6</sup>).</li><li>E5: In one embodiment, the present invention provides a compound of Formula XIV according to any one of A1 and E1 to E4, or a pharmaceutically acceptable salt thereof, wherein each R<sup>3</sup> is selected from the group consisting of -C(=O)-N(R<sup>7</sup>,R<sup>8</sup>), -C<sub>1-6</sub>alkyl, -OH, and -NO<sub>2</sub>.</li><li>E6: In one embodiment, the present invention provides a compound of Formula XIV according to any one of A1 and E1 to E4, or a pharmaceutically acceptable salt thereof, wherein each R<sup>3</sup> is selected from the group consisting of -C(=O)-N(R<sup>7</sup>,R<sup>8</sup>), isopropyl, -OH, and -NO<sub>2</sub>.</li><li>E7: In one embodiment, the present invention provides a compound of Formula XIV according to any one of A1 and E1 to E6, or a pharmaceutically acceptable salt thereof, wherein each R<sup>4</sup> is -C(=O)C<sub>1-6</sub>alkyl.</li><li>E8: In one aspect, the present invention provides a compound of Formula XIV according to any one of A1 and E1 to E6, or a pharmaceutically acceptable salt thereof, wherein each R<sup>4</sup> is acetyl.</li><li>E9: In one embodiment, the present invention provides a compound of Formula XIV according to any one of A1 and E1 to E8, or a pharmaceutically acceptable salt thereof, wherein each R<sup>5</sup> is hydrogen.</li><li>E10: In one embodiment, the present invention provides a compound of Formula XIV according to any one of A1 and E1 to E9, or a pharmaceutically acceptable salt thereof, wherein each R<sup>6</sup> is hydrogen.</li><li>E11: In one embodiment, the present invention provides a compound of Formula XIV according to any one of A1 and E1 to E10, or a pharmaceutically acceptable salt thereof, wherein each R<sup>7</sup> is C<sub>1-6</sub>alkyl.</li><li>E12: In one embodiment, the present invention provides a compound of Formula XIV according to any one of A1 and E1 to E10, or a pharmaceutically acceptable salt thereof, wherein each R<sup>7</sup> is methyl.</li><li>E13: In one embodiment, the present invention provides a compound of Formula XIV according to any one of A1 and E1 to E12, or a pharmaceutically acceptable salt thereof, wherein each R<sup>8</sup> is hydrogen.</li><li>E14: In one embodiment, the present invention provides a compound of Formula XIV according to any one of A1 and E1 to E13, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of: <ol id="ol0003" compact="compact"><li>i) aryl substituted with R<sup>2</sup>,</li><li>ii) aryl,</li><li>iii) heteroaryl substituted with one or two R<sup>3</sup>,</li><li>iv) heteroaryl, and</li><li>v) heterocycloalkyl substituted with R<sup>4</sup>.</li></ol></li><li>E15: In one aspect, the present invention provides a compound of Formula XIV according to any one of A1 and E1 to E13, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of: <ol id="ol0004" compact="compact"><li>i) phenyl substituted with R<sup>2</sup>,</li><li>ii) phenyl,</li><li>iii) tetralin-1-yl,</li><li>iv) benzimidazol-1-yl substituted with one or two R<sup>3</sup>,</li><li>v) isoindolin-2-yl substituted with R<sup>3</sup>,</li><li>vi) 2-furyl,</li><li>vii) indolin-1-yl,</li><li>viii) benzofuran-3-yl,</li><li>ix) 2,3-dihydropyrrolo[2,3-b]pyridin-1-yl, and</li><li>x) 4-piperidyl substituted with R<sup>4</sup>.</li></ol></li><li>E16: In one embodiment, the present invention provides a compound of Formula XIV according to A1, or a pharmaceutically acceptable salt thereof, wherein: <ul id="ul0017" list-style="none" compact="compact"><li>A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, -CF<sub>2</sub>- and -NH-; and A<sup>2</sup> is - CH<sub>2</sub>-; or</li><li>A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, and -CF<sub>2</sub>-; and A<sup>2</sup> is -NH-; Z is selected from the group consisting of: <ol id="ol0005" compact="compact"><li>i) a covalent bond,</li><li>ii) carbonyl,</li><li>iii) -NH-,</li><li>iv) -O-CH<sub>2</sub>-C(=O)-NH-,</li><li>v) -C(=O)-NH-, and</li><li>vi) -NH-C(=O)-;</li></ol></li><li>W is CH or N;</li><li>A is selected from the group consisting of: <ol id="ol0006" compact="compact"><li>i) aryl substituted with R<sup>2</sup>,</li><li>ii) aryl,</li><li>iii) heteroaryl substituted with one or two R<sup>3</sup>,</li><li>iv) heteroaryl, and</li><li>v) heterocycloalkyl substituted with R<sup>4</sup>;</li></ol></li><li>R<sup>2</sup> is -C<sub>1-6</sub>alkyl or -NH<sub>2</sub>;</li><li>R<sup>3</sup> is selected from the group consisting of -C(=O)-NH-C<sub>1-6</sub>alkyl, -C<sub>1-6</sub>alkyl, -OH, and - NO<sub>2</sub>; and</li><li>R<sup>4</sup> is -C(=O)C<sub>1-6</sub>alkyl.</li></ul></li><li>E17: In one aspect, the present invention provides a compound of Formula XIV according to A1, or a pharmaceutically acceptable salt thereof, wherein: <ul id="ul0018" list-style="none" compact="compact"><li>A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, -CF<sub>2</sub>- and -NH-; and A<sup>2</sup> is - CH<sub>2</sub>-; or</li><li>A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, and -CF<sub>2</sub>-; and A<sup>2</sup> is -NH-;</li><li>Z is selected from the group consisting of: <ol id="ol0007" compact="compact"><li>i) a covalent bond,</li><li>ii) carbonyl,</li><li>iii) -NH-,</li><li>iv) -O-CH<sub>2</sub>-C(=O)-NH-,</li><li>v) -C(=O)-NH-, and</li><li>vi) -NH-C(=O)-;</li></ol></li><li>W is CH or N;</li><li>A is selected from the group consisting of: <ol id="ol0008" compact="compact"><li>i) phenyl substituted with R<sup>2</sup>,</li><li>ii) phenyl,</li><li>iii) tetralin-1-yl,</li><li>iv) benzimidazol-1-yl substituted with one or two R<sup>3</sup>,</li><li>v) isoindolin-2-yl substituted with R<sup>3</sup>,</li><li>vi) 2-furyl,</li><li>vii) indolin-1-yl,</li><li>viii) benzofuran-3-yl,</li><li>ix) 2,3-dihydropyrrolo[2,3-b]pyridin-1-yl, and</li><li>x) 4-piperidyl substituted with R<sup>4</sup>;</li></ol></li><li>R<sup>2</sup> is methyl or -NH<sub>2</sub>;</li><li>R<sup>3</sup> is selected from the group consisting of -C(=O)-NH-CH<sub>3</sub>, isopropyl, -OH, and -NO<sub>2</sub>; and</li><li>R<sup>4</sup> is acetyl.</li></ul></li><li>E18: In one embodiment, the present invention provides a compound of Formula XIV according to A1, or a pharmaceutically acceptable salt thereof, wherein: <ul id="ul0019" list-style="none" compact="compact"><li>A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, -CF<sub>2</sub>- and -NH-; and A<sup>2</sup> is - CH<sub>2</sub>-; or</li><li>A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, and -CF<sub>2</sub>-; and A<sup>2</sup> is -NH-; and</li><li>W is CH or N.</li></ul></li><li>E19: In one embodiment, the present invention provides a compound of Formula XIV according to A1, or a pharmaceutically acceptable salt thereof, wherein: <ul id="ul0020" list-style="none" compact="compact"><li>A is selected from the group consisting of: <ol id="ol0009" compact="compact"><li>i) aryl substituted with R<sup>2</sup>,</li><li>ii) aryl,</li><li>iii) heteroaryl substituted with one or two R<sup>3</sup>,</li><li>iv) heteroaryl, and</li><li>v) heterocycloalkyl substituted with R<sup>4</sup>;</li></ol></li><li>R<sup>2</sup> is -C<sub>1-6</sub>alkyl or -NH<sub>2</sub>;</li><li>R<sup>3</sup> is selected from the group consisting of -C(=O)-NH-C<sub>1-6</sub>alkyl, -C<sub>1-6</sub>alkyl, -OH, and - NO<sub>2</sub>; and</li><li>R<sup>4</sup> is -C(=O)C<sub>1-6</sub>alkyl.</li></ul></li><li>E20: In one aspect, the present invention provides a compound of Formula XIV according to A1, or a pharmaceutically acceptable salt thereof, wherein: <ul id="ul0021" list-style="none" compact="compact"><li>A is selected from the group consisting of: <ol id="ol0010" compact="compact"><li>i) phenyl substituted with R<sup>2</sup>,</li><li>ii) phenyl,</li><li>iii) tetralin-1-yl,</li><li>iv) benzimidazol-1-yl substituted with one or two R<sup>3</sup>,</li><li>v) isoindolin-2-yl substituted with R<sup>3</sup>,</li><li>vi) 2-furyl,</li><li>vii) indolin-1-yl,</li><li>viii) benzofuran-3-yl,</li><li>ix) 2,3-dihydropyrrolo[2,3-b]pyridin-1-yl, and</li><li>x) 4-piperidyl substituted with R<sup>4</sup>;</li></ol></li><li>R<sup>2</sup> is methyl or -NH<sub>2</sub>;</li><li>R<sup>3</sup> is selected from the group consisting of -C(=O)-NH-CH<sub>3</sub>, isopropyl, -OH, and -NO<sub>2</sub>; and</li><li>R<sup>4</sup> is acetyl.</li></ul></li><li>E21: In one embodiment, the present invention provides a compound of Formula XIV according to A1, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula XIV is selected from the group consisting of: <ul id="ul0022" list-style="none" compact="compact"><li>2-Isopropyl-<i>N-</i>methyl-1-(2-oxoindolin-6-yl)benzimidazole-5-carboxamide;</li><li>2-Isopropyl-<i>N-</i>methyl-1-(2-oxoindolin-5-yl)benzimidazole-5-carboxamide;</li><li>6-(2-Aminoanilino)-3<i>H</i>-1,3 -benzothiazol-2-one;</li><li>6-(2-Isopropylbenzimidazol-1-yl)-3<i>H</i>-1,3-benzothiazol-2-one;</li><li>6-(2-Aminoanilino)-3<i>H</i>-1,3-benzoxazol-2-one;</li><li>6-(2-Isopropylbenzimidazol-1-yl)-3<i>H</i>-1,3-benzoxazol-2-one;</li><li><i>N</i>-(1-Acetyl-4-piperidyl)-2-oxo-3<i>H</i>-1,3-benzoxazole-6-carboxamide;</li><li>6-(2,3-Dihydropyrrolo[2,3-b]pyridine-1-carbonyl)-3<i>H</i>-1,3-benzoxazol-2-one;</li><li>6-(Indoline-1-carbonyl)-3<i>H</i>-1,3-benzothiazol-2-one;</li><li>5-(Indoline-1-carbonyl)indolin-2-one;</li><li>2-Oxo-<i>N</i>-phenyl-3<i>H</i>-oxazolo[4,5-b]pyridine-6-carboxamide;</li><li><i>N-</i>(1-Acetyl-4-piperidyl)-2-oxo-3<i>H</i>-oxazolo[4,5-b]pyridine-6-carboxamide;</li><li>5-(Indoline-1-carbonyl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one;</li><li>3,3-Difluoro-5-(2-isopropylbenzimidazol-1-yl)indolin-2-one;</li><li>6-(4-Hydroxyisoindoline-2-carbonyl)-3<i>H</i>-1,3-benzoxazol-2-one;</li><li>6-(4-Nitroisoindoline-2-carbonyl)-3<i>H</i>-1,3-benzoxazol-2-one;</li><li><i>N</i>-(3,3-Difluoro-2-oxo-indolin-5-yl)tetralin-1-carboxamide;</li><li><i>N-</i>(3,3-Difluoro-2-oxo-indolin-5-yl)benzofuran-3-carboxamide;</li><li>2-Isopropyl-<i>N-</i>methyl-1-(2-oxo-1,3-dihydropyrrolo[2,3-b]pyridin-5-yl)benzimidazole-5-carboxamide;</li><li>5-(2-Isopropylbenzimidazol-1-yl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one;</li><li>N-(2-Oxo-3H-1,3-benzoxazol-6-yl)benzamide;</li><li>N-(2-Oxoindolin-5-yl)furan-2-carboxamide;</li><li>2-(2-Methylphenoxy)-N-(2-oxo-3H-1,3-benzothiazol-6-yl)acetamide;</li><li>2-Oxo-N-phenylindoline-5-carboxamide;</li><li>2-Oxo-N-phenyl-3H-1,3 -benzoxazole-6-carboxamide;</li><li>6-(Indoline-1-carbonyl)-3H-1,3-benzoxazol-2-one; and</li><li>2-Oxo-N-phenyl-3H-1,3-benzothiazole-6-carboxamide.</li></ul></li><li>E22: In one embodiment, the present invention provides a compound of Formula XIV according to A1, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula XIV is selected from the group consisting of: <ul id="ul0023" list-style="none" compact="compact"><li>2-Isopropyl-<i>N-</i>methyl-1-(2-oxoindolin-6-yl)benzimidazole-5-carboxamide;</li><li>2-Isopropyl-<i>N</i>-methyl-1-(2-oxoindolin-5-yl)benzimidazole-5-carboxamide;</li><li>6-(2-Aminoanilino)-3<i>H</i>-1,3 -benzothiazol-2-one;</li><li>6-(2-Isopropylbenzimidazol-1-yl)-3<i>H</i>-1,3-benzothiazol-2-one;</li><li>6-(2-Isopropylbenzimidazol-1-yl)-3<i>H</i>-1,3-benzoxazol-2-one;</li><li><i>N</i>-(1-Acetyl-4-piperidyl)-2-oxo-3<i>H</i>-1,3-benzoxazole-6-carboxamide;</li><li>6-(2,3-Dihydropyrrolo[2,3-b]pyridine-1-carbonyl)-3<i>H</i>-1,3-benzoxazol-2-one;</li><li>6-(Indoline-1-carbonyl)-3<i>H</i>-1,3-benzothiazol-2-one;</li><li>2-Oxo-<i>N</i>-phenyl-3<i>H</i>-oxazolo[4,5-b]pyridine-6-carboxamide;</li><li><i>N-</i>(1-Acetyl-4-piperidyl)-2-oxo-3<i>H</i>-oxazolo[4,5-b]pyridine-6-carboxamide;</li><li>5-(Indoline-1-carbonyl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one;</li><li>3,3-Difluoro-5-(2-isopropylbenzimidazol-1-yl)indolin-2-one;</li><li>6-(4-Hydroxyisoindoline-2-carbonyl)-3<i>H</i>-1,3-benzoxazol-2-one;</li><li>6-(4-Nitroisoindoline-2-carbonyl)-3<i>H</i>-1,3-benzoxazol-2-one;</li><li><i>N</i>-(3,3-Difluoro-2-oxo-indolin-5-yl)tetralin-1-carboxamide;</li><li><i>N-</i>(3,3-Difluoro-2-oxo-indolin-5-yl)benzofuran-3-carboxamide;</li><li>2-Isopropyl-<i>N-</i>methyl-1-(2-oxo-1,3-dihydropyrrolo[2,3-b]pyridin-5-yl)benzimidazole-5-carboxamide; and</li><li>5-(2-Isopropylbenzimidazol-1-yl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one.</li></ul></li><li>E23: In one embodiment, R<sup>3</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; -(CH<sub>2</sub>)<sub>0-1</sub>-heterocycloalkyl; -C(=O)C<sub>1-6</sub>alkyl; -(CH<sub>2</sub>)<sub>0-2</sub>-C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -OH; -NO<sub>2</sub>; -C<sub>1-6</sub>alkyl-N(R<sup>11</sup>)-C(=O)-R<sup>12</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -N(R<sup>5</sup>,R<sup>6</sup>); -NH-C(=O)C<sub>1-6</sub>alkyl; and -NH-C(=O)OC<sub>1-6</sub>alkyl.</li><li>E24: In one embodiment, R<sup>2</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; -(CH<sub>2</sub>)<sub>0-1</sub>-heterocycloalkyl; -C(=O)C<sub>1-6</sub>alkyl; -(CH<sub>2</sub>)<sub>0-2</sub>-C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -OH; -NO<sub>2</sub>; -C<sub>1-6</sub>alkyl-N(R<sup>11</sup>)-C(=O)-R<sup>12</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -N(R<sup>5</sup>,R<sup>6</sup>); -NH-C(=O)C<sub>1-6</sub>alkyl; and -NH-C(=O)OC<sub>1-6</sub>alkyl.</li><li>E25: The compound of any one of the above embodiments, wherein A<sup>1</sup> is selected from the group consisting of -O- and -NH-, and A<sup>2</sup> is -CH<sub>2</sub>-.</li><li>E26: The compound of any one of the above embodiments, wherein A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, -CF<sub>2</sub>-, and A<sup>2</sup> is-NH-.</li><li>E27: The compound of any one of the above embodiments, wherein W is CH.</li><li>E28: The compound of any one of the above embodiments, wherein W is N.</li><li>E29: The compound of any one of the above embodiments, wherein R<sup>2</sup> is independently selected at each occurrence from: -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -N(R<sup>5</sup>,R<sup>6</sup>); -NO<sub>2</sub>; -NH-C(=O)C<sub>1-6</sub>alkyl; and -SO<sub>2</sub>-N(R<sup>5</sup>,R<sup>6</sup>).</li><li>E30: The compound of any one of the above embodiments, wherein R<sup>2</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; - C(=O)C<sub>1-6</sub>alkyl; -C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; and -O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl.</li><li>E31: The compound of any one of the above embodiments, wherein R<sup>3</sup> is independently selected at each occurrence from:-C(=O)C<sub>1-6</sub>alkyl; -(CH<sub>2</sub>)<sub>0-2</sub>-C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -OH; -NO<sub>2</sub>; -C<sub>1-6</sub>alkyl-N(R<sup>11</sup>)-C(=O)-R<sup>12</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl-aryl; -N(R<sup>5</sup>,R<sup>6</sup>); -NH-C(=O)C<sub>1-6</sub>alkyl; -NH-C(=O)OC<sub>1-6</sub>alkyl; and =O.</li><li>E32: The compound of any one of the above embodiments, wherein R<sup>3</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; - (CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl substituted by R<sup>9</sup>; and -(CH<sub>2</sub>)<sub>0-1</sub>-heterocycloalkyl.</li><li>E33: The compound of any one of the above embodiments, wherein R<sup>4</sup> is independently selected at each occurrence from: -C(=O)C<sub>1-6</sub>alkyl; -C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup><sub>;</sub>-CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -N(R<sup>5</sup>,R<sup>6</sup>); and -NH-C(=O)C<sub>1-6</sub>alkyl.</li><li>E34: The compound of any one of the above embodiments, wherein R<sup>4</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; and -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl.</li><li>E35: The compound of any one of the above embodiments, wherein R<sup>5</sup> and R<sup>6</sup> are independently selected at each occurrence from H, C<sub>1-6</sub>alkyl and phenyl.</li><li>E36: The compound of any one of the above embodiments, wherein R<sup>5</sup> and R<sup>6</sup>, taken together with the nitrogen to which they are attached, form a heterocycloalkyl ring.</li><li>E37: The compound of any one of the above embodiments, wherein R<sup>7</sup> and R<sup>8</sup> are independently selected at each occurrence from Hand C<sub>1-6</sub>alkyl.</li><li>E38: The compound of any one of the above embodiments, wherein R<sup>7</sup> and R<sup>8</sup>, taken together with the nitrogen to which they are attached, form a heterocycloalkyl ring.</li><li>E39: The compound of any one of the above embodiments, wherein X<sup>1</sup> is selected from bond or NR<sup>34</sup>.</li><li>E40: The compound of any one of the above embodiments, wherein X<sup>22</sup> is selected from halo, -NH<sub>2</sub>, -NHR<sup>34</sup>, -N(R<sup>34</sup>)<sub>2</sub>, hydroxyl, thiol, -B(OH)<sub>2</sub>, -Sn(R<sup>36</sup>)<sub>3</sub>, -Si(R<sup>36</sup>)<sub>3</sub>, -OS(O)<sub>2</sub>alkyl, - OS(O)<sub>2</sub>haloalkyl, alkenyl, alkynyl, ethynyl, ethenyl, -C(O)H, -NR<sup>34</sup>C(O)alkene, -NR<sup>34</sup>C(O)alkyne, cyano, -SC(O)alkyl, OC(O)alkyl, heterocycle, -C(O)OH, hydrogen, alkyl, aryl, heteroaryl, aliphatic, heteroaliphatic, and carbocyclic.</li><li>E41: The compound of any one of the above embodiments, wherein R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> are independently selected from bond, alkyl, -C(O)-, -C(O)O-, -OC(O)-, -C(O)alkyl, - C(O)Oalkyl, -C(S)-, -SO<sub>2</sub>-, -S(O)-, -C(S)-, -C(O)NH-, -NHC(O)-, -N(alkyl)C(O)-, -C(O)N(alkyl)-, -O-, -S-, -NH-, -N(alkyl)-, -CH(-O-R<sup>26</sup>)-, -CH(-NR<sup>34</sup>R<sup>34'</sup>)-, -C(-O-R<sup>26</sup>)alkyl-, -C(-NR<sup>34</sup>R<sup>34'</sup>)alkyl-, -C(R<sup>40</sup>R<sup>40</sup>)-, -alkyl(R<sup>27</sup>)-alkyl(R<sup>28</sup>)-, -C(R<sup>27</sup>R<sup>28</sup>)-, -P(O)(OR<sup>26</sup>)O-, -P(O)(OR<sup>26</sup>)-, -N<sup>34</sup>C(O)NR<sup>34'</sup>-, alkene, haloalkyl, alkoxy, alkyneheteroarylalkyl, aryl, arylalkyl, heterocycle, aliphatic, heteroaliphatic, heteroaryl, lactic acid, glycolic acid, carbocycle, -(ethylene glycol)<sub>1-6</sub>-, -(lactic-co-glycolic acid)<sub>1-6</sub>-, -(propylene glycol)<sub>1-6</sub>-, -O-(CH<sub>2</sub>)<sub>1-12</sub>-O-, -NH-(CH<sub>2</sub>)<sub>1-12</sub>-NH-, -NH-(CH<sub>2</sub>)<sub>1-12</sub>-O-, -O-(CH<sub>2</sub>)<sub>1-12</sub>-NH-, -S-(CH<sub>2</sub>)<sub>1-12</sub>-O-, -O-(CH<sub>2</sub>)<sub>1-12</sub>-S-, -S-(CH<sub>2</sub>)<sub>1-12</sub>-S-, -S-(CH<sub>2</sub>)<sub>1-12</sub>-NH-, and -NH-(CH<sub>2</sub>)<sub>1-12</sub>-S-, wherein at least one of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> is not a bond.</li><li>E42: The compound of any one of the above embodiments, wherein at least two of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> are not a bond.</li><li>E43: The compound of any one of the above embodiments, wherein at least three of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> are not a bond.</li><li>E44: The compound of any one of the above embodiments, wherein at least four of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> are not a bond.</li></ul>
0206In one embodiment, the present invention provides pharmaceutically acceptable salts or esters of the compounds of Formula XIV as described herein. In a particular embodiment, the present invention provides pharmaceutically acceptable salts of the compounds according to Formula XIV as described herein, especially hydrochloride salts. In a further particular embodiment, the present invention provides pharmaceutically acceptable esters of the compounds according to Formula XIV as described herein. In yet a further particular embodiment, the present invention provides compounds according to Formula XIV as described herein.
0207Furthermore, the invention includes all optical isomers, i.e. diastereoisomers, diastereomeric mixtures, racemic mixtures, all their corresponding enantiomers and/or tautomers as well as their solvates of the compounds of Formula XIV.
0208The compounds of Formula XIV may contain one or more asymmetric centers and can therefore occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within this invention. The present invention is meant to encompass all such isomeric forms of these compounds. The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration. If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography.
0209In the embodiments, where optically pure enantiomers are provided, optically pure enantiomer means that the compound contains > 90% of the desired isomer by weight, particularly > 95% of the desired isomer by weight, or more particularly > 99% of the desired isomer by weight, said weight percent based upon the total weight of the isomer(s) of the compound. Chirally pure or chirally enriched compounds may be prepared by chirally selective synthesis or by separation of enantiomers. The separation of enantiomers may be carried out on the final product or alternatively on a suitable intermediate.
0210In one embodiment of Formula XIV, Z is a covalent bond.
0211In another embodiment of Formula XIV, Z is C(=O).
0212In another embodiment of Formula XIV, Z is selected from: <chemistry id="chem0261" num="0261"><img file="EP4470618A2_D0261.tif" /></chemistry><chemistry id="chem0262" num="0262"><img file="EP4470618A2_D0262.tif" /></chemistry>
0213In another embodiment of Formula XIV, Z is selected from: <chemistry id="chem0263" num="0263"><img file="EP4470618A2_D0263.tif" /></chemistry>
0214In another embodiment of Formula XIV, Z is selected from: <chemistry id="chem0264" num="0264"><img file="EP4470618A2_D0264.tif" /></chemistry><chemistry id="chem0265" num="0265"><img file="EP4470618A2_D0265.tif" /></chemistry>
0215In another embodiment of Formula XIV, Z is selected from: <chemistry id="chem0266" num="0266"><img file="EP4470618A2_D0266.tif" /></chemistry> and <chemistry id="chem0267" num="0267"><img file="EP4470618A2_D0267.tif" /></chemistry>
0216In another embodiment of Formula XIV, Z is selected from: <chemistry id="chem0268" num="0268"><img file="EP4470618A2_D0268.tif" /></chemistry>
0217In another embodiment of Formula XIV, Z is selected from: <chemistry id="chem0269" num="0269"><img file="EP4470618A2_D0269.tif" /></chemistry>
0218In another embodiment of Formula XIV, Z is selected from: <chemistry id="chem0270" num="0270"><img file="EP4470618A2_D0270.tif" /></chemistry>
0219In one embodiment of Formula XIV, <chemistry id="chem0271" num="0271"><img file="EP4470618A2_D0271.tif" /></chemistry>
0220In one embodiment of Formula XIV, <chemistry id="chem0272" num="0272"><img file="EP4470618A2_D0272.tif" /></chemistry>
0221In one embodiment of Formula XIV, <chemistry id="chem0273" num="0273"><img file="EP4470618A2_D0273.tif" /></chemistry> is selected from: <chemistry id="chem0274" num="0274"><img file="EP4470618A2_D0274.tif" /></chemistry><chemistry id="chem0275" num="0275"><img file="EP4470618A2_D0275.tif" /></chemistry> and <chemistry id="chem0276" num="0276"><img file="EP4470618A2_D0276.tif" /></chemistry>
0222In one embodiment of Formula XIV, <chemistry id="chem0277" num="0277"><img file="EP4470618A2_D0277.tif" /></chemistry> is selected from: <chemistry id="chem0278" num="0278"><img file="EP4470618A2_D0278.tif" /></chemistry><chemistry id="chem0279" num="0279"><img file="EP4470618A2_D0279.tif" /></chemistry> and <chemistry id="chem0280" num="0280"><img file="EP4470618A2_D0280.tif" /></chemistry>
0223In one embodiment of Formula XIV, <chemistry id="chem0281" num="0281"><img file="EP4470618A2_D0281.tif" /></chemistry> is selected from: <chemistry id="chem0282" num="0282"><img file="EP4470618A2_D0282.tif" /></chemistry>
0224In one embodiment of Formula XIV, <chemistry id="chem0283" num="0283"><img file="EP4470618A2_D0283.tif" /></chemistry> is selected from: <chemistry id="chem0284" num="0284"><img file="EP4470618A2_D0284.tif" /></chemistry>
0225In one embodiment of Formula XIV, <chemistry id="chem0285" num="0285"><img file="EP4470618A2_D0285.tif" /></chemistry> is selected from: <chemistry id="chem0286" num="0286"><img file="EP4470618A2_D0286.tif" /></chemistry>
0226In one embodiment of Formula XIV, <chemistry id="chem0287" num="0287"><img file="EP4470618A2_D0287.tif" /></chemistry> is selected from: <chemistry id="chem0288" num="0288"><img file="EP4470618A2_D0288.tif" /></chemistry>
0227In one embodiment of Formula XIV, <chemistry id="chem0289" num="0289"><img file="EP4470618A2_D0289.tif" /></chemistry> is selected from: <chemistry id="chem0290" num="0290"><img file="EP4470618A2_D0290.tif" /></chemistry>
0228In one embodiment of Formula XIV, <chemistry id="chem0291" num="0291"><img file="EP4470618A2_D0291.tif" /></chemistry> is selected from: <chemistry id="chem0292" num="0292"><img file="EP4470618A2_D0292.tif" /></chemistry>
0229In one embodiment of Formula XIV, <chemistry id="chem0293" num="0293"><img file="EP4470618A2_D0293.tif" /></chemistry> is selected from: <chemistry id="chem0294" num="0294"><img file="EP4470618A2_D0294.tif" /></chemistry> and <chemistry id="chem0295" num="0295"><img file="EP4470618A2_D0295.tif" /></chemistry>
Embodiments of Formula XIV(1)
0230In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0296" num="0296"><img file="EP4470618A2_D0296.tif" /></chemistry><chemistry id="chem0297" num="0297"><img file="EP4470618A2_D0297.tif" /></chemistry><chemistry id="chem0298" num="0298"><img file="EP4470618A2_D0298.tif" /></chemistry><chemistry id="chem0299" num="0299"><img file="EP4470618A2_D0299.tif" /></chemistry> and <chemistry id="chem0300" num="0300"><img file="EP4470618A2_D0300.tif" /></chemistry>
0231In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0301" num="0301"><img file="EP4470618A2_D0301.tif" /></chemistry><chemistry id="chem0302" num="0302"><img file="EP4470618A2_D0302.tif" /></chemistry><chemistry id="chem0303" num="0303"><img file="EP4470618A2_D0303.tif" /></chemistry> and <chemistry id="chem0304" num="0304"><img file="EP4470618A2_D0304.tif" /></chemistry>
0232In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0305" num="0305"><img file="EP4470618A2_D0305.tif" /></chemistry><chemistry id="chem0306" num="0306"><img file="EP4470618A2_D0306.tif" /></chemistry><chemistry id="chem0307" num="0307"><img file="EP4470618A2_D0307.tif" /></chemistry><chemistry id="chem0308" num="0308"><img file="EP4470618A2_D0308.tif" /></chemistry><chemistry id="chem0309" num="0309"><img file="EP4470618A2_D0309.tif" /></chemistry><chemistry id="chem0310" num="0310"><img file="EP4470618A2_D0310.tif" /></chemistry><chemistry id="chem0311" num="0311"><img file="EP4470618A2_D0311.tif" /></chemistry><chemistry id="chem0312" num="0312"><img file="EP4470618A2_D0312.tif" /></chemistry><chemistry id="chem0313" num="0313"><img file="EP4470618A2_D0313.tif" /></chemistry> and <chemistry id="chem0314" num="0314"><img file="EP4470618A2_D0314.tif" /></chemistry>
0233In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0315" num="0315"><img file="EP4470618A2_D0315.tif" /></chemistry><chemistry id="chem0316" num="0316"><img file="EP4470618A2_D0316.tif" /></chemistry><chemistry id="chem0317" num="0317"><img file="EP4470618A2_D0317.tif" /></chemistry><chemistry id="chem0318" num="0318"><img file="EP4470618A2_D0318.tif" /></chemistry><chemistry id="chem0319" num="0319"><img file="EP4470618A2_D0319.tif" /></chemistry><chemistry id="chem0320" num="0320"><img file="EP4470618A2_D0320.tif" /></chemistry><chemistry id="chem0321" num="0321"><img file="EP4470618A2_D0321.tif" /></chemistry><chemistry id="chem0322" num="0322"><img file="EP4470618A2_D0322.tif" /></chemistry><chemistry id="chem0323" num="0323"><img file="EP4470618A2_D0323.tif" /></chemistry> and <chemistry id="chem0324" num="0324"><img file="EP4470618A2_D0324.tif" /></chemistry>
0234In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0325" num="0325"><img file="EP4470618A2_D0325.tif" /></chemistry><chemistry id="chem0326" num="0326"><img file="EP4470618A2_D0326.tif" /></chemistry><chemistry id="chem0327" num="0327"><img file="EP4470618A2_D0327.tif" /></chemistry><chemistry id="chem0328" num="0328"><img file="EP4470618A2_D0328.tif" /></chemistry><chemistry id="chem0329" num="0329"><img file="EP4470618A2_D0329.tif" /></chemistry><chemistry id="chem0330" num="0330"><img file="EP4470618A2_D0330.tif" /></chemistry><chemistry id="chem0331" num="0331"><img file="EP4470618A2_D0331.tif" /></chemistry><chemistry id="chem0332" num="0332"><img file="EP4470618A2_D0332.tif" /></chemistry> and <chemistry id="chem0333" num="0333"><img file="EP4470618A2_D0333.tif" /></chemistry>
0235In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0334" num="0334"><img file="EP4470618A2_D0334.tif" /></chemistry><chemistry id="chem0335" num="0335"><img file="EP4470618A2_D0335.tif" /></chemistry><chemistry id="chem0336" num="0336"><img file="EP4470618A2_D0336.tif" /></chemistry><chemistry id="chem0337" num="0337"><img file="EP4470618A2_D0337.tif" /></chemistry><chemistry id="chem0338" num="0338"><img file="EP4470618A2_D0338.tif" /></chemistry><chemistry id="chem0339" num="0339"><img file="EP4470618A2_D0339.tif" /></chemistry><chemistry id="chem0340" num="0340"><img file="EP4470618A2_D0340.tif" /></chemistry> and <chemistry id="chem0341" num="0341"><img file="EP4470618A2_D0341.tif" /></chemistry>
0236In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0342" num="0342"><img file="EP4470618A2_D0342.tif" /></chemistry><chemistry id="chem0343" num="0343"><img file="EP4470618A2_D0343.tif" /></chemistry><chemistry id="chem0344" num="0344"><img file="EP4470618A2_D0344.tif" /></chemistry><chemistry id="chem0345" num="0345"><img file="EP4470618A2_D0345.tif" /></chemistry><chemistry id="chem0346" num="0346"><img file="EP4470618A2_D0346.tif" /></chemistry><chemistry id="chem0347" num="0347"><img file="EP4470618A2_D0347.tif" /></chemistry><chemistry id="chem0348" num="0348"><img file="EP4470618A2_D0348.tif" /></chemistry><chemistry id="chem0349" num="0349"><img file="EP4470618A2_D0349.tif" /></chemistry> and <chemistry id="chem0350" num="0350"><img file="EP4470618A2_D0350.tif" /></chemistry>
0237In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0351" num="0351"><img file="EP4470618A2_D0351.tif" /></chemistry><chemistry id="chem0352" num="0352"><img file="EP4470618A2_D0352.tif" /></chemistry><chemistry id="chem0353" num="0353"><img file="EP4470618A2_D0353.tif" /></chemistry><chemistry id="chem0354" num="0354"><img file="EP4470618A2_D0354.tif" /></chemistry><chemistry id="chem0355" num="0355"><img file="EP4470618A2_D0355.tif" /></chemistry><chemistry id="chem0356" num="0356"><img file="EP4470618A2_D0356.tif" /></chemistry><chemistry id="chem0357" num="0357"><img file="EP4470618A2_D0357.tif" /></chemistry><chemistry id="chem0358" num="0358"><img file="EP4470618A2_D0358.tif" /></chemistry><chemistry id="chem0359" num="0359"><img file="EP4470618A2_D0359.tif" /></chemistry> and <chemistry id="chem0360" num="0360"><img file="EP4470618A2_D0360.tif" /></chemistry>
0238In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0361" num="0361"><img file="EP4470618A2_D0361.tif" /></chemistry><chemistry id="chem0362" num="0362"><img file="EP4470618A2_D0362.tif" /></chemistry><chemistry id="chem0363" num="0363"><img file="EP4470618A2_D0363.tif" /></chemistry><chemistry id="chem0364" num="0364"><img file="EP4470618A2_D0364.tif" /></chemistry><chemistry id="chem0365" num="0365"><img file="EP4470618A2_D0365.tif" /></chemistry><chemistry id="chem0366" num="0366"><img file="EP4470618A2_D0366.tif" /></chemistry><chemistry id="chem0367" num="0367"><img file="EP4470618A2_D0367.tif" /></chemistry><chemistry id="chem0368" num="0368"><img file="EP4470618A2_D0368.tif" /></chemistry><chemistry id="chem0369" num="0369"><img file="EP4470618A2_D0369.tif" /></chemistry> and <chemistry id="chem0370" num="0370"><img file="EP4470618A2_D0370.tif" /></chemistry>
0239In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0371" num="0371"><img file="EP4470618A2_D0371.tif" /></chemistry><chemistry id="chem0372" num="0372"><img file="EP4470618A2_D0372.tif" /></chemistry><chemistry id="chem0373" num="0373"><img file="EP4470618A2_D0373.tif" /></chemistry><chemistry id="chem0374" num="0374"><img file="EP4470618A2_D0374.tif" /></chemistry><chemistry id="chem0375" num="0375"><img file="EP4470618A2_D0375.tif" /></chemistry><chemistry id="chem0376" num="0376"><img file="EP4470618A2_D0376.tif" /></chemistry><chemistry id="chem0377" num="0377"><img file="EP4470618A2_D0377.tif" /></chemistry><chemistry id="chem0378" num="0378"><img file="EP4470618A2_D0378.tif" /></chemistry><chemistry id="chem0379" num="0379"><img file="EP4470618A2_D0379.tif" /></chemistry> and <chemistry id="chem0380" num="0380"><img file="EP4470618A2_D0380.tif" /></chemistry>
0240In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0381" num="0381"><img file="EP4470618A2_D0381.tif" /></chemistry><chemistry id="chem0382" num="0382"><img file="EP4470618A2_D0382.tif" /></chemistry><chemistry id="chem0383" num="0383"><img file="EP4470618A2_D0383.tif" /></chemistry><chemistry id="chem0384" num="0384"><img file="EP4470618A2_D0384.tif" /></chemistry><chemistry id="chem0385" num="0385"><img file="EP4470618A2_D0385.tif" /></chemistry><chemistry id="chem0386" num="0386"><img file="EP4470618A2_D0386.tif" /></chemistry><chemistry id="chem0387" num="0387"><img file="EP4470618A2_D0387.tif" /></chemistry><chemistry id="chem0388" num="0388"><img file="EP4470618A2_D0388.tif" /></chemistry><chemistry id="chem0389" num="0389"><img file="EP4470618A2_D0389.tif" /></chemistry> and <chemistry id="chem0390" num="0390"><img file="EP4470618A2_D0390.tif" /></chemistry>
0241In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0391" num="0391"><img file="EP4470618A2_D0391.tif" /></chemistry><chemistry id="chem0392" num="0392"><img file="EP4470618A2_D0392.tif" /></chemistry><chemistry id="chem0393" num="0393"><img file="EP4470618A2_D0393.tif" /></chemistry><chemistry id="chem0394" num="0394"><img file="EP4470618A2_D0394.tif" /></chemistry><chemistry id="chem0395" num="0395"><img file="EP4470618A2_D0395.tif" /></chemistry><chemistry id="chem0396" num="0396"><img file="EP4470618A2_D0396.tif" /></chemistry><chemistry id="chem0397" num="0397"><img file="EP4470618A2_D0397.tif" /></chemistry><chemistry id="chem0398" num="0398"><img file="EP4470618A2_D0398.tif" /></chemistry><chemistry id="chem0399" num="0399"><img file="EP4470618A2_D0399.tif" /></chemistry> and <chemistry id="chem0400" num="0400"><img file="EP4470618A2_D0400.tif" /></chemistry>
0242In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0401" num="0401"><img file="EP4470618A2_D0401.tif" /></chemistry><chemistry id="chem0402" num="0402"><img file="EP4470618A2_D0402.tif" /></chemistry><chemistry id="chem0403" num="0403"><img file="EP4470618A2_D0403.tif" /></chemistry><chemistry id="chem0404" num="0404"><img file="EP4470618A2_D0404.tif" /></chemistry><chemistry id="chem0405" num="0405"><img file="EP4470618A2_D0405.tif" /></chemistry><chemistry id="chem0406" num="0406"><img file="EP4470618A2_D0406.tif" /></chemistry><chemistry id="chem0407" num="0407"><img file="EP4470618A2_D0407.tif" /></chemistry><chemistry id="chem0408" num="0408"><img file="EP4470618A2_D0408.tif" /></chemistry> and <chemistry id="chem0409" num="0409"><img file="EP4470618A2_D0409.tif" /></chemistry>
0243In one aspect, a compound of Formula XIV(1) selected from: <chemistry id="chem0410" num="0410"><img file="EP4470618A2_D0410.tif" /></chemistry><chemistry id="chem0411" num="0411"><img file="EP4470618A2_D0411.tif" /></chemistry><chemistry id="chem0412" num="0412"><img file="EP4470618A2_D0412.tif" /></chemistry><chemistry id="chem0413" num="0413"><img file="EP4470618A2_D0413.tif" /></chemistry><chemistry id="chem0414" num="0414"><img file="EP4470618A2_D0414.tif" /></chemistry><chemistry id="chem0415" num="0415"><img file="EP4470618A2_D0415.tif" /></chemistry><chemistry id="chem0416" num="0416"><img file="EP4470618A2_D0416.tif" /></chemistry><chemistry id="chem0417" num="0417"><img file="EP4470618A2_D0417.tif" /></chemistry><chemistry id="chem0418" num="0418"><img file="EP4470618A2_D0418.tif" /></chemistry> and <chemistry id="chem0419" num="0419"><img file="EP4470618A2_D0419.tif" /></chemistry>
Embodiments of Formulas I(1)-XIII(1)
0244In one aspect, a compound is provided of Formula I(1) <chemistry id="chem0420" num="0420"><img file="EP4470618A2_D0420.tif" /></chemistry> wherein all variables are as defined herein.
0245In one embodiment of Formula I(1), <chemistry id="chem0421" num="0421"><img file="EP4470618A2_D0421.tif" /></chemistry> is selected from: <chemistry id="chem0422" num="0422"><img file="EP4470618A2_D0422.tif" /></chemistry><chemistry id="chem0423" num="0423"><img file="EP4470618A2_D0423.tif" /></chemistry><chemistry id="chem0424" num="0424"><img file="EP4470618A2_D0424.tif" /></chemistry><chemistry id="chem0425" num="0425"><img file="EP4470618A2_D0425.tif" /></chemistry><chemistry id="chem0426" num="0426"><img file="EP4470618A2_D0426.tif" /></chemistry><chemistry id="chem0427" num="0427"><img file="EP4470618A2_D0427.tif" /></chemistry><chemistry id="chem0428" num="0428"><img file="EP4470618A2_D0428.tif" /></chemistry><chemistry id="chem0429" num="0429"><img file="EP4470618A2_D0429.tif" /></chemistry> and <chemistry id="chem0430" num="0430"><img file="EP4470618A2_D0430.tif" /></chemistry> wherein T is <chemistry id="chem0431" num="0431"><img file="EP4470618A2_D0431.tif" /></chemistry>
0246In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0432" num="0432"><img file="EP4470618A2_D0432.tif" /></chemistry><chemistry id="chem0433" num="0433"><img file="EP4470618A2_D0433.tif" /></chemistry><chemistry id="chem0434" num="0434"><img file="EP4470618A2_D0434.tif" /></chemistry><chemistry id="chem0435" num="0435"><img file="EP4470618A2_D0435.tif" /></chemistry><chemistry id="chem0436" num="0436"><img file="EP4470618A2_D0436.tif" /></chemistry><chemistry id="chem0437" num="0437"><img file="EP4470618A2_D0437.tif" /></chemistry><chemistry id="chem0438" num="0438"><img file="EP4470618A2_D0438.tif" /></chemistry><chemistry id="chem0439" num="0439"><img file="EP4470618A2_D0439.tif" /></chemistry><chemistry id="chem0440" num="0440"><img file="EP4470618A2_D0440.tif" /></chemistry><chemistry id="chem0441" num="0441"><img file="EP4470618A2_D0441.tif" /></chemistry> and <chemistry id="chem0442" num="0442"><img file="EP4470618A2_D0442.tif" /></chemistry> wherein all variables are as defined herein.
0247In any one embodiment of Formula II(1)a-II(1)-k, <chemistry id="chem0443" num="0443"><img file="EP4470618A2_D0443.tif" /></chemistry> is selected from: <chemistry id="chem0444" num="0444"><img file="EP4470618A2_D0444.tif" /></chemistry><chemistry id="chem0445" num="0445"><img file="EP4470618A2_D0445.tif" /></chemistry> and <chemistry id="chem0446" num="0446"><img file="EP4470618A2_D0446.tif" /></chemistry> wherein T is <chemistry id="chem0447" num="0447"><img file="EP4470618A2_D0447.tif" /></chemistry>
0248In one aspect, a compound is provided of Formula III(1): <chemistry id="chem0448" num="0448"><img file="EP4470618A2_D0448.tif" /></chemistry> wherein all variables are as defined herein.
0249In one embodiment of Formula III(1), <chemistry id="chem0449" num="0449"><img file="EP4470618A2_D0449.tif" /></chemistry> is selected from: <chemistry id="chem0450" num="0450"><img file="EP4470618A2_D0450.tif" /></chemistry><chemistry id="chem0451" num="0451"><img file="EP4470618A2_D0451.tif" /></chemistry><chemistry id="chem0452" num="0452"><img file="EP4470618A2_D0452.tif" /></chemistry><chemistry id="chem0453" num="0453"><img file="EP4470618A2_D0453.tif" /></chemistry><chemistry id="chem0454" num="0454"><img file="EP4470618A2_D0454.tif" /></chemistry><chemistry id="chem0455" num="0455"><img file="EP4470618A2_D0455.tif" /></chemistry><chemistry id="chem0456" num="0456"><img file="EP4470618A2_D0456.tif" /></chemistry><chemistry id="chem0457" num="0457"><img file="EP4470618A2_D0457.tif" /></chemistry> and <chemistry id="chem0458" num="0458"><img file="EP4470618A2_D0458.tif" /></chemistry> wherein T is <chemistry id="chem0459" num="0459"><img file="EP4470618A2_D0459.tif" /></chemistry>
0250In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0460" num="0460"><img file="EP4470618A2_D0460.tif" /></chemistry><chemistry id="chem0461" num="0461"><img file="EP4470618A2_D0461.tif" /></chemistry><chemistry id="chem0462" num="0462"><img file="EP4470618A2_D0462.tif" /></chemistry><chemistry id="chem0463" num="0463"><img file="EP4470618A2_D0463.tif" /></chemistry><chemistry id="chem0464" num="0464"><img file="EP4470618A2_D0464.tif" /></chemistry><chemistry id="chem0465" num="0465"><img file="EP4470618A2_D0465.tif" /></chemistry><chemistry id="chem0466" num="0466"><img file="EP4470618A2_D0466.tif" /></chemistry><chemistry id="chem0467" num="0467"><img file="EP4470618A2_D0467.tif" /></chemistry><chemistry id="chem0468" num="0468"><img file="EP4470618A2_D0468.tif" /></chemistry> and <chemistry id="chem0469" num="0469"><img file="EP4470618A2_D0469.tif" /></chemistry> wherein all variables are as defined herein.
0251In one embodiment of any one of Formulas IV(1)-a to IV(1)-J, <chemistry id="chem0470" num="0470"><img file="EP4470618A2_D0470.tif" /></chemistry> is selected from: <chemistry id="chem0471" num="0471"><img file="EP4470618A2_D0471.tif" /></chemistry><chemistry id="chem0472" num="0472"><img file="EP4470618A2_D0472.tif" /></chemistry><chemistry id="chem0473" num="0473"><img file="EP4470618A2_D0473.tif" /></chemistry><chemistry id="chem0474" num="0474"><img file="EP4470618A2_D0474.tif" /></chemistry><chemistry id="chem0475" num="0475"><img file="EP4470618A2_D0475.tif" /></chemistry> wherein T is <chemistry id="chem0476" num="0476"><img file="EP4470618A2_D0476.tif" /></chemistry>
0252In one aspect, a compound is provided of Formula V(1): <chemistry id="chem0477" num="0477"><img file="EP4470618A2_D0477.tif" /></chemistry> wherein all variables are as defined herein.
0253In one embodiment of Formula V(1), <chemistry id="chem0478" num="0478"><img file="EP4470618A2_D0478.tif" /></chemistry> is selected from: <chemistry id="chem0479" num="0479"><img file="EP4470618A2_D0479.tif" /></chemistry><chemistry id="chem0480" num="0480"><img file="EP4470618A2_D0480.tif" /></chemistry> wherein T is <chemistry id="chem0481" num="0481"><img file="EP4470618A2_D0481.tif" /></chemistry>
0254In one aspect, a compound is provided of Formula VI(1): <chemistry id="chem0482" num="0482"><img file="EP4470618A2_D0482.tif" /></chemistry> wherein all variables are as defined herein.
0255In one embodiment of Formula VI(1), <chemistry id="chem0483" num="0483"><img file="EP4470618A2_D0483.tif" /></chemistry> is selected from: <chemistry id="chem0484" num="0484"><img file="EP4470618A2_D0484.tif" /></chemistry><chemistry id="chem0485" num="0485"><img file="EP4470618A2_D0485.tif" /></chemistry><chemistry id="chem0486" num="0486"><img file="EP4470618A2_D0486.tif" /></chemistry><chemistry id="chem0487" num="0487"><img file="EP4470618A2_D0487.tif" /></chemistry><chemistry id="chem0488" num="0488"><img file="EP4470618A2_D0488.tif" /></chemistry> and <chemistry id="chem0489" num="0489"><img file="EP4470618A2_D0489.tif" /></chemistry> wherein T is <chemistry id="chem0490" num="0490"><img file="EP4470618A2_D0490.tif" /></chemistry>
0256In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0491" num="0491"><img file="EP4470618A2_D0491.tif" /></chemistry><chemistry id="chem0492" num="0492"><img file="EP4470618A2_D0492.tif" /></chemistry><chemistry id="chem0493" num="0493"><img file="EP4470618A2_D0493.tif" /></chemistry><chemistry id="chem0494" num="0494"><img file="EP4470618A2_D0494.tif" /></chemistry> and <chemistry id="chem0495" num="0495"><img file="EP4470618A2_D0495.tif" /></chemistry> wherein all variables are as defined herein.
0257In one embodiment of any one of Formulas VII(1)a-VII(1)e, <chemistry id="chem0496" num="0496"><img file="EP4470618A2_D0496.tif" /></chemistry> is selected from: <chemistry id="chem0497" num="0497"><img file="EP4470618A2_D0497.tif" /></chemistry><chemistry id="chem0498" num="0498"><img file="EP4470618A2_D0498.tif" /></chemistry> wherein T is <chemistry id="chem0499" num="0499"><img file="EP4470618A2_D0499.tif" /></chemistry>
0258In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0500" num="0500"><img file="EP4470618A2_D0500.tif" /></chemistry><chemistry id="chem0501" num="0501"><img file="EP4470618A2_D0501.tif" /></chemistry><chemistry id="chem0502" num="0502"><img file="EP4470618A2_D0502.tif" /></chemistry><chemistry id="chem0503" num="0503"><img file="EP4470618A2_D0503.tif" /></chemistry><chemistry id="chem0504" num="0504"><img file="EP4470618A2_D0504.tif" /></chemistry><chemistry id="chem0505" num="0505"><img file="EP4470618A2_D0505.tif" /></chemistry><chemistry id="chem0506" num="0506"><img file="EP4470618A2_D0506.tif" /></chemistry><chemistry id="chem0507" num="0507"><img file="EP4470618A2_D0507.tif" /></chemistry> and <chemistry id="chem0508" num="0508"><img file="EP4470618A2_D0508.tif" /></chemistry> wherein all variables are as defined herein.
0259In one embodiment of any one of Formulas VIII(1)-a to VIII(1)-I, In one embodiment, <chemistry id="chem0509" num="0509"><img file="EP4470618A2_D0509.tif" /></chemistry> is selected from: <chemistry id="chem0510" num="0510"><img file="EP4470618A2_D0510.tif" /></chemistry><chemistry id="chem0511" num="0511"><img file="EP4470618A2_D0511.tif" /></chemistry><chemistry id="chem0512" num="0512"><img file="EP4470618A2_D0512.tif" /></chemistry><chemistry id="chem0513" num="0513"><img file="EP4470618A2_D0513.tif" /></chemistry> wherein T is <chemistry id="chem0514" num="0514"><img file="EP4470618A2_D0514.tif" /></chemistry>
0260In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0515" num="0515"><img file="EP4470618A2_D0515.tif" /></chemistry><chemistry id="chem0516" num="0516"><img file="EP4470618A2_D0516.tif" /></chemistry><chemistry id="chem0517" num="0517"><img file="EP4470618A2_D0517.tif" /></chemistry><chemistry id="chem0518" num="0518"><img file="EP4470618A2_D0518.tif" /></chemistry><chemistry id="chem0519" num="0519"><img file="EP4470618A2_D0519.tif" /></chemistry><chemistry id="chem0520" num="0520"><img file="EP4470618A2_D0520.tif" /></chemistry><chemistry id="chem0521" num="0521"><img file="EP4470618A2_D0521.tif" /></chemistry><chemistry id="chem0522" num="0522"><img file="EP4470618A2_D0522.tif" /></chemistry><chemistry id="chem0523" num="0523"><img file="EP4470618A2_D0523.tif" /></chemistry> and <chemistry id="chem0524" num="0524"><img file="EP4470618A2_D0524.tif" /></chemistry> wherein all variables are as defined herein.
0261In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0525" num="0525"><img file="EP4470618A2_D0525.tif" /></chemistry><chemistry id="chem0526" num="0526"><img file="EP4470618A2_D0526.tif" /></chemistry><chemistry id="chem0527" num="0527"><img file="EP4470618A2_D0527.tif" /></chemistry><chemistry id="chem0528" num="0528"><img file="EP4470618A2_D0528.tif" /></chemistry><chemistry id="chem0529" num="0529"><img file="EP4470618A2_D0529.tif" /></chemistry><chemistry id="chem0530" num="0530"><img file="EP4470618A2_D0530.tif" /></chemistry><chemistry id="chem0531" num="0531"><img file="EP4470618A2_D0531.tif" /></chemistry><chemistry id="chem0532" num="0532"><img file="EP4470618A2_D0532.tif" /></chemistry> and <chemistry id="chem0533" num="0533"><img file="EP4470618A2_D0533.tif" /></chemistry> wherein all variables are as defined herein.
0262In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0534" num="0534"><img file="EP4470618A2_D0534.tif" /></chemistry><chemistry id="chem0535" num="0535"><img file="EP4470618A2_D0535.tif" /></chemistry><chemistry id="chem0536" num="0536"><img file="EP4470618A2_D0536.tif" /></chemistry><chemistry id="chem0537" num="0537"><img file="EP4470618A2_D0537.tif" /></chemistry><chemistry id="chem0538" num="0538"><img file="EP4470618A2_D0538.tif" /></chemistry><chemistry id="chem0539" num="0539"><img file="EP4470618A2_D0539.tif" /></chemistry><chemistry id="chem0540" num="0540"><img file="EP4470618A2_D0540.tif" /></chemistry><chemistry id="chem0541" num="0541"><img file="EP4470618A2_D0541.tif" /></chemistry><chemistry id="chem0542" num="0542"><img file="EP4470618A2_D0542.tif" /></chemistry> wherein all variables are as defined herein.
0263In one aspect, a compound is provided of Formula XII(1): <chemistry id="chem0543" num="0543"><img file="EP4470618A2_D0543.tif" /></chemistry> wherein all variables are as defined herein.
0264In one aspect, a compound is provided of one of the following formulas: <chemistry id="chem0544" num="0544"><img file="EP4470618A2_D0544.tif" /></chemistry><chemistry id="chem0545" num="0545"><img file="EP4470618A2_D0545.tif" /></chemistry><chemistry id="chem0546" num="0546"><img file="EP4470618A2_D0546.tif" /></chemistry><chemistry id="chem0547" num="0547"><img file="EP4470618A2_D0547.tif" /></chemistry> wherein all variables are as defined herein.
0265In one embodiment of any one compound of Formula IX(1)-1 to IX(1)-j, X(1)-a to X(1)-i, XI(1)-a to XI(1)-i, and XIII(1)-a to XIII(1)-i, <chemistry id="chem0548" num="0548"><img file="EP4470618A2_D0548.tif" /></chemistry> is selected from: <chemistry id="chem0549" num="0549"><img file="EP4470618A2_D0549.tif" /></chemistry><chemistry id="chem0550" num="0550"><img file="EP4470618A2_D0550.tif" /></chemistry><chemistry id="chem0551" num="0551"><img file="EP4470618A2_D0551.tif" /></chemistry><chemistry id="chem0552" num="0552"><img file="EP4470618A2_D0552.tif" /></chemistry> wherein T is <chemistry id="chem0553" num="0553"><img file="EP4470618A2_D0553.tif" /></chemistry>
III.
Tail Embodiments
0266In one embodiment, "Tail" is a moiety selected from Formula T-I, Formula T-II, Formula T-III, Formula T-IV, Formula T-V, Formula T-VI, and Formula T-VII: <chemistry id="chem0554" num="0554"><img file="EP4470618A2_D0554.tif" /></chemistry><chemistry id="chem0555" num="0555"><img file="EP4470618A2_D0555.tif" /></chemistry><chemistry id="chem0556" num="0556"><img file="EP4470618A2_D0556.tif" /></chemistry><chemistry id="chem0557" num="0557"><img file="EP4470618A2_D0557.tif" /></chemistry><chemistry id="chem0558" num="0558"><img file="EP4470618A2_D0558.tif" /></chemistry><chemistry id="chem0559" num="0559"><img file="EP4470618A2_D0559.tif" /></chemistry> and <chemistry id="chem0560" num="0560"><img file="EP4470618A2_D0560.tif" /></chemistry> wherein all variables are defined as above.
0267In an additional embodiment, "Tail" is a moiety selected from Formula T-VIII, T-IX, and T-X: <chemistry id="chem0561" num="0561"><img file="EP4470618A2_D0561.tif" /></chemistry><chemistry id="chem0562" num="0562"><img file="EP4470618A2_D0562.tif" /></chemistry> and <chemistry id="chem0563" num="0563"><img file="EP4470618A2_D0563.tif" /></chemistry> wherein all variables are defined as above.. In other embodiments of T-VIII, T-IX and T-X, a carbocyclic ring is used in place of the heterocycle.
0268The following are non-limiting examples of "Tail" moieties that can be used in this invention. Based on this elaboration, those of skill in the art will understand how to use the full breadth of "Tail" moieties that will accomplish the goal of the invention.
0269As certain non-limiting examples, Formula T-I, Formula T-II, Formula T-III, Formula T-IV, Formula T-V, Formula T-VI, or Formula T-VII include: <chemistry id="chem0564" num="0564"><img file="EP4470618A2_D0564.tif" /></chemistry><chemistry id="chem0565" num="0565"><img file="EP4470618A2_D0565.tif" /></chemistry><chemistry id="chem0566" num="0566"><img file="EP4470618A2_D0566.tif" /></chemistry><chemistry id="chem0567" num="0567"><img file="EP4470618A2_D0567.tif" /></chemistry><chemistry id="chem0568" num="0568"><img file="EP4470618A2_D0568.tif" /></chemistry><chemistry id="chem0569" num="0569"><img file="EP4470618A2_D0569.tif" /></chemistry><chemistry id="chem0570" num="0570"><img file="EP4470618A2_D0570.tif" /></chemistry><chemistry id="chem0571" num="0571"><img file="EP4470618A2_D0571.tif" /></chemistry><chemistry id="chem0572" num="0572"><img file="EP4470618A2_D0572.tif" /></chemistry><chemistry id="chem0573" num="0573"><img file="EP4470618A2_D0573.tif" /></chemistry><chemistry id="chem0574" num="0574"><img file="EP4470618A2_D0574.tif" /></chemistry><chemistry id="chem0575" num="0575"><img file="EP4470618A2_D0575.tif" /></chemistry><chemistry id="chem0576" num="0576"><img file="EP4470618A2_D0576.tif" /></chemistry>
0270In an additional embodiment "Tail" is selected from: <chemistry id="chem0577" num="0577"><img file="EP4470618A2_D0577.tif" /></chemistry><chemistry id="chem0578" num="0578"><img file="EP4470618A2_D0578.tif" /></chemistry><chemistry id="chem0579" num="0579"><img file="EP4470618A2_D0579.tif" /></chemistry>
0271In an additional embodiment "Tail" is selected from: <chemistry id="chem0580" num="0580"><img file="EP4470618A2_D0580.tif" /></chemistry><chemistry id="chem0581" num="0581"><img file="EP4470618A2_D0581.tif" /></chemistry><chemistry id="chem0582" num="0582"><img file="EP4470618A2_D0582.tif" /></chemistry><chemistry id="chem0583" num="0583"><img file="EP4470618A2_D0583.tif" /></chemistry>
0272Non-limiting examples of moieties of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> include: <chemistry id="chem0584" num="0584"><img file="EP4470618A2_D0584.tif" /></chemistry><chemistry id="chem0585" num="0585"><img file="EP4470618A2_D0585.tif" /></chemistry>
0273Additional non-limiting examples of moieties of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> include: <chemistry id="chem0586" num="0586"><img file="EP4470618A2_D0586.tif" /></chemistry><chemistry id="chem0587" num="0587"><img file="EP4470618A2_D0587.tif" /></chemistry><chemistry id="chem0588" num="0588"><img file="EP4470618A2_D0588.tif" /></chemistry><chemistry id="chem0589" num="0589"><img file="EP4470618A2_D0589.tif" /></chemistry><chemistry id="chem0590" num="0590"><img file="EP4470618A2_D0590.tif" /></chemistry>
0274Additional non-limiting examples of moieties of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> include: <chemistry id="chem0591" num="0591"><img file="EP4470618A2_D0591.tif" /></chemistry><chemistry id="chem0592" num="0592"><img file="EP4470618A2_D0592.tif" /></chemistry><chemistry id="chem0593" num="0593"><img file="EP4470618A2_D0593.tif" /></chemistry><chemistry id="chem0594" num="0594"><img file="EP4470618A2_D0594.tif" /></chemistry><chemistry id="chem0595" num="0595"><img file="EP4470618A2_D0595.tif" /></chemistry>
0275In additional embodiments, "Tail" is an optionally substituted ethylene glycol having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, ethylene glycol units, or optionally substituted alkyl groups interspersed with optionally substituted, O, N, S, P or Si atoms. In certain embodiments, "Tail" is flanked, substituted, or interspersed with an aryl, phenyl, benzyl, alkyl, alkylene, or heterocycle group. In certain embodiments, "Tail" may be asymmetric or symmetrical. In some embodiments, "Tail" is a substituted or unsubstituted polyethylene glycol group ranging in size from about 1 to about 12 ethylene glycol units, between 1 and about 10 ethylene glycol units, about 2 about 6 ethylene glycol units, between about 2 and 5 ethylene glycol units, between about 2 and 4 ethylene glycol units. In any of the embodiments of the compounds described herein, "Tail" group may be any suitable moiety as described herein.
0276In additional embodiments, the "Tail" is selected from: <ul id="ul0024" list-style="none" compact="compact"><li>-NR<sup>61</sup>(CH<sub>2</sub>)<sub>n1</sub>-(lower alkyl)-X<sup>22</sup>, -NR<sup>61</sup>(CH<sub>2</sub>)<sub>n1</sub>-(lower alkoxyl)-X<sup>22</sup>,</li><li>-NR<sup>61</sup>(CH<sub>2</sub>)<sub>n1</sub>-(lower alkoxyl)-OCH<sub>2</sub>-X<sup>22</sup>, -NR<sup>61</sup>(CH<sub>2</sub>)<sub>n1</sub>-(lower alkoxyl)-(lower alkyl)-OCH<sub>2</sub>-X<sup>22</sup>,</li><li>-NR<sup>61</sup>(CH<sub>2</sub>)<sub>n1</sub>(cycloalkyl)-(lower alkyl)-OCH<sub>2</sub>-X<sup>22</sup>, -NR<sup>61</sup>(CH<sub>2</sub>)<sub>n1</sub>-(heterocycloalkyl)-X<sup>22</sup>,</li><li>-NR<sup>61</sup>(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n1</sub>-(lower alkyl)-O-CH<sub>2</sub>-X<sup>22</sup>,</li><li>-NR<sup>61</sup>(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n1</sub>-(heterocycloalkyl)-O-CH<sub>2</sub>-X<sup>22</sup>,</li><li>-NR<sup>61</sup>(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n1</sub>-Aryl-O-CH<sub>2</sub>-X<sup>22</sup>, -NR<sup>61</sup>(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n1</sub>-(heteroaryl)-O-CH<sub>2</sub>-X<sup>22</sup>,</li><li>-NR<sup>61</sup>(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n1</sub>-(cycloalkyl)-O-(heteroaryl)-O-CH<sub>2</sub>-X<sup>22</sup>,</li><li>-N<sup>R61</sup>(CH<sub>2</sub>CH<sub>2</sub>O)m-(cycloalkyl)-O-Aryl-O-CH<sub>2</sub>-X<sup>22</sup>,</li><li>-NR<sup>61</sup>(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n1</sub>-(lower alkyl)-NH-Aryl-O- CH<sub>2</sub>-X<sup>22</sup>,</li><li>-NR<sup>61</sup>(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n1</sub>-(lower alkyl)-O-Aryl-CH<sub>2</sub>-X<sup>22</sup>,</li><li>-NR<sup>61</sup>(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n1</sub>-cycloalkyl-O-Aryl-X<sup>22</sup>, -NR<sup>61</sup>(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n1</sub>-cycloalkyl-O-heteroaryl-X<sup>22</sup>,</li><li>-NR<sup>61</sup>(CH<sub>2</sub>CH<sub>2</sub>)<sub>n1</sub>-(cycloalkyl)-O-(heterocycle)-CH<sub>2</sub>-X<sup>22</sup></li><li>-NR<sup>61</sup>(CH<sub>2</sub>CH<sub>2</sub>)<sub>n1</sub>-(heterocycle)-(heterocycle)-CH<sub>2</sub>-X<sup>22</sup>, and -NR<sup>61</sup>-(heterocycle)-CH<sub>2</sub>-X<sup>22</sup>;</li><li>wherein n1 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and</li><li>R<sup>61</sup> is H, methyl, or ethyl.</li></ul>
0277In additional embodiments, "Tail" is selected from: <ul id="ul0025" list-style="none" compact="compact"><li>-N(R<sup>61</sup>)-(CH<sub>2</sub>)<sub>m1</sub>-O(CH<sub>2</sub>)<sub>n2</sub>-O(CH<sub>2</sub>)<sub>o1</sub>-O(CH<sub>2</sub>)<sub>p1</sub>-O(CH<sub>2</sub>)<sub>q1</sub>-O(CH<sub>2</sub>)<sub>r1</sub>-OCH<sub>2</sub>-X<sup>22</sup>,</li><li>-O-(CH2)<sub>m1</sub>-O(CH<sub>2</sub>)<sub>n2</sub>-O(CH<sub>2</sub>)<sub>o1</sub>-O(CH<sub>2</sub>)<sub>p1</sub>-O(CH<sub>2</sub>)<sub>q1</sub>-O(CH<sub>2</sub>)<sub>r1</sub>-OCH<sub>2</sub>-X<sup>22</sup>,</li><li>-O-(CH<sub>2</sub>)<sub>m1</sub>-O(CH<sub>2</sub>)<sub>n2</sub>-O(CH<sub>2</sub>)<sub>o1</sub>-O(CH<sub>2</sub>)<sub>p1</sub>-O(CH<sub>2</sub>)<sub>q1</sub>-O(CH<sub>2</sub>)<sub>r1</sub>-OH;</li><li>-N(R<sup>61</sup>)-(CH<sub>2</sub>)<sub>m1</sub>-O(CH<sub>2</sub>)<sub>n2</sub>-O(CH<sub>2</sub>)<sub>o1</sub>-O(CH<sub>2</sub>)<sub>p1</sub>-O(CH<sub>2</sub>)<sub>q1</sub>-O(CH<sub>2</sub>)<sub>r1</sub>-OH;</li><li>-(CH<sub>2</sub>)<sub>m1</sub>-O(CH<sub>2</sub>)<sub>n2</sub>-O(CH<sub>2</sub>)<sub>o1</sub>-O(CH<sub>2</sub>)<sub>p1</sub>-O(CH<sub>2</sub>)<sub>q1</sub>-O(CH<sub>2</sub>)<sub>r1</sub>-OH;</li><li>-(CH<sub>2</sub>)<sub>m1</sub>-O(CH<sub>2</sub>)<sub>n2</sub>-O(CH<sub>2</sub>)<sub>o1</sub>-O(CH<sub>2</sub>)<sub>p1</sub>-O(CH<sub>2</sub>)<sub>q1</sub>-O(CH<sub>2</sub>)<sub>r1</sub>-OCH<sub>2</sub>-X<sup>22</sup>;</li><li>-O(CH<sub>2</sub>)<sub>m1</sub>O(CH<sub>2</sub>)<sub>n2</sub>O(CH<sub>2</sub>)<sub>p1</sub>O(CH<sub>2</sub>)<sub>q1</sub>OCH<sub>2</sub>-X<sup>22</sup>;</li><li>-O(CH<sub>2</sub>)<sub>m1</sub>O(CH<sub>2</sub>)<sub>n2</sub>O(CH<sub>2</sub>)<sub>p1</sub>O(CH<sub>2</sub>)<sub>q1</sub>OCH<sub>2</sub>-X<sup>22</sup>; wherein</li></ul><ul id="ul0026" list-style="none" compact="compact"><li>m1, n2, o1, p1, q1, and r1 are independently 1, 2, 3, 4, or 5; and</li><li>R<sup>61</sup> is H, methyl, or ethyl.</li></ul>
0278In additional embodiments, "Tail" is selected from: <chemistry id="chem0596" num="0596"><img file="EP4470618A2_D0596.tif" /></chemistry><chemistry id="chem0597" num="0597"><img file="EP4470618A2_D0597.tif" /></chemistry><chemistry id="chem0598" num="0598"><img file="EP4470618A2_D0598.tif" /></chemistry><chemistry id="chem0599" num="0599"><img file="EP4470618A2_D0599.tif" /></chemistry><chemistry id="chem0600" num="0600"><img file="EP4470618A2_D0600.tif" /></chemistry><chemistry id="chem0601" num="0601"><img file="EP4470618A2_D0601.tif" /></chemistry><chemistry id="chem0602" num="0602"><img file="EP4470618A2_D0602.tif" /></chemistry><chemistry id="chem0603" num="0603"><img file="EP4470618A2_D0603.tif" /></chemistry> m1, n2, o1, p1, q2, and r1 are independently 1, 2, 3, 4, or 5.
0279In additional embodiments, "Tail" is selected from: <chemistry id="chem0604" num="0604"><img file="EP4470618A2_D0604.tif" /></chemistry><chemistry id="chem0605" num="0605"><img file="EP4470618A2_D0605.tif" /></chemistry><chemistry id="chem0606" num="0606"><img file="EP4470618A2_D0606.tif" /></chemistry><chemistry id="chem0607" num="0607"><img file="EP4470618A2_D0607.tif" /></chemistry><chemistry id="chem0608" num="0608"><img file="EP4470618A2_D0608.tif" /></chemistry><chemistry id="chem0609" num="0609"><img file="EP4470618A2_D0609.tif" /></chemistry><chemistry id="chem0610" num="0610"><img file="EP4470618A2_D0610.tif" /></chemistry><chemistry id="chem0611" num="0611"><img file="EP4470618A2_D0611.tif" /></chemistry><chemistry id="chem0612" num="0612"><img file="EP4470618A2_D0612.tif" /></chemistry><chemistry id="chem0613" num="0613"><img file="EP4470618A2_D0613.tif" /></chemistry><chemistry id="chem0614" num="0614"><img file="EP4470618A2_D0614.tif" /></chemistry><chemistry id="chem0615" num="0615"><img file="EP4470618A2_D0615.tif" /></chemistry><chemistry id="chem0616" num="0616"><img file="EP4470618A2_D0616.tif" /></chemistry><chemistry id="chem0617" num="0617"><img file="EP4470618A2_D0617.tif" /></chemistry><chemistry id="chem0618" num="0618"><img file="EP4470618A2_D0618.tif" /></chemistry><chemistry id="chem0619" num="0619"><img file="EP4470618A2_D0619.tif" /></chemistry>
0280In additional embodiments, "Tail" is selected from: <chemistry id="chem0620" num="0620"><img file="EP4470618A2_D0620.tif" /></chemistry><chemistry id="chem0621" num="0621"><img file="EP4470618A2_D0621.tif" /></chemistry><chemistry id="chem0622" num="0622"><img file="EP4470618A2_D0622.tif" /></chemistry><chemistry id="chem0623" num="0623"><img file="EP4470618A2_D0623.tif" /></chemistry><chemistry id="chem0624" num="0624"><img file="EP4470618A2_D0624.tif" /></chemistry>
0281In additional embodiments, "Tail" is selected from: <chemistry id="chem0625" num="0625"><img file="EP4470618A2_D0625.tif" /></chemistry><chemistry id="chem0626" num="0626"><img file="EP4470618A2_D0626.tif" /></chemistry><chemistry id="chem0627" num="0627"><img file="EP4470618A2_D0627.tif" /></chemistry><chemistry id="chem0628" num="0628"><img file="EP4470618A2_D0628.tif" /></chemistry><chemistry id="chem0629" num="0629"><img file="EP4470618A2_D0629.tif" /></chemistry><chemistry id="chem0630" num="0630"><img file="EP4470618A2_D0630.tif" /></chemistry><chemistry id="chem0631" num="0631"><img file="EP4470618A2_D0631.tif" /></chemistry><chemistry id="chem0632" num="0632"><img file="EP4470618A2_D0632.tif" /></chemistry><chemistry id="chem0633" num="0633"><img file="EP4470618A2_D0633.tif" /></chemistry><chemistry id="chem0634" num="0634"><img file="EP4470618A2_D0634.tif" /></chemistry><chemistry id="chem0635" num="0635"><img file="EP4470618A2_D0635.tif" /></chemistry><chemistry id="chem0636" num="0636"><img file="EP4470618A2_D0636.tif" /></chemistry><chemistry id="chem0637" num="0637"><img file="EP4470618A2_D0637.tif" /></chemistry><chemistry id="chem0638" num="0638"><img file="EP4470618A2_D0638.tif" /></chemistry><chemistry id="chem0639" num="0639"><img file="EP4470618A2_D0639.tif" /></chemistry><chemistry id="chem0640" num="0640"><img file="EP4470618A2_D0640.tif" /></chemistry><chemistry id="chem0641" num="0641"><img file="EP4470618A2_D0641.tif" /></chemistry><chemistry id="chem0642" num="0642"><img file="EP4470618A2_D0642.tif" /></chemistry><chemistry id="chem0643" num="0643"><img file="EP4470618A2_D0643.tif" /></chemistry><chemistry id="chem0644" num="0644"><img file="EP4470618A2_D0644.tif" /></chemistry><chemistry id="chem0645" num="0645"><img file="EP4470618A2_D0645.tif" /></chemistry><chemistry id="chem0646" num="0646"><img file="EP4470618A2_D0646.tif" /></chemistry><chemistry id="chem0647" num="0647"><img file="EP4470618A2_D0647.tif" /></chemistry><chemistry id="chem0648" num="0648"><img file="EP4470618A2_D0648.tif" /></chemistry><chemistry id="chem0649" num="0649"><img file="EP4470618A2_D0649.tif" /></chemistry><chemistry id="chem0650" num="0650"><img file="EP4470618A2_D0650.tif" /></chemistry><chemistry id="chem0651" num="0651"><img file="EP4470618A2_D0651.tif" /></chemistry><chemistry id="chem0652" num="0652"><img file="EP4470618A2_D0652.tif" /></chemistry><chemistry id="chem0653" num="0653"><img file="EP4470618A2_D0653.tif" /></chemistry><chemistry id="chem0654" num="0654"><img file="EP4470618A2_D0654.tif" /></chemistry><chemistry id="chem0655" num="0655"><img file="EP4470618A2_D0655.tif" /></chemistry><chemistry id="chem0656" num="0656"><img file="EP4470618A2_D0656.tif" /></chemistry><chemistry id="chem0657" num="0657"><img file="EP4470618A2_D0657.tif" /></chemistry><chemistry id="chem0658" num="0658"><img file="EP4470618A2_D0658.tif" /></chemistry><chemistry id="chem0659" num="0659"><img file="EP4470618A2_D0659.tif" /></chemistry><chemistry id="chem0660" num="0660"><img file="EP4470618A2_D0660.tif" /></chemistry><chemistry id="chem0661" num="0661"><img file="EP4470618A2_D0661.tif" /></chemistry><chemistry id="chem0662" num="0662"><img file="EP4470618A2_D0662.tif" /></chemistry><chemistry id="chem0663" num="0663"><img file="EP4470618A2_D0663.tif" /></chemistry><chemistry id="chem0664" num="0664"><img file="EP4470618A2_D0664.tif" /></chemistry><chemistry id="chem0665" num="0665"><img file="EP4470618A2_D0665.tif" /></chemistry><chemistry id="chem0666" num="0666"><img file="EP4470618A2_D0666.tif" /></chemistry><chemistry id="chem0667" num="0667"><img file="EP4470618A2_D0667.tif" /></chemistry><chemistry id="chem0668" num="0668"><img file="EP4470618A2_D0668.tif" /></chemistry><chemistry id="chem0669" num="0669"><img file="EP4470618A2_D0669.tif" /></chemistry><chemistry id="chem0670" num="0670"><img file="EP4470618A2_D0670.tif" /></chemistry><chemistry id="chem0671" num="0671"><img file="EP4470618A2_D0671.tif" /></chemistry><chemistry id="chem0672" num="0672"><img file="EP4470618A2_D0672.tif" /></chemistry><chemistry id="chem0673" num="0673"><img file="EP4470618A2_D0673.tif" /></chemistry><chemistry id="chem0674" num="0674"><img file="EP4470618A2_D0674.tif" /></chemistry><chemistry id="chem0675" num="0675"><img file="EP4470618A2_D0675.tif" /></chemistry><chemistry id="chem0676" num="0676"><img file="EP4470618A2_D0676.tif" /></chemistry> wherein R<sup>71</sup> is -O-, -NH, Nalkyl, heteroaliphatic, aliphatic, or -NMe.
0282In additional embodiments, "Tail" is selected from: <chemistry id="chem0677" num="0677"><img file="EP4470618A2_D0677.tif" /></chemistry><chemistry id="chem0678" num="0678"><img file="EP4470618A2_D0678.tif" /></chemistry><chemistry id="chem0679" num="0679"><img file="EP4470618A2_D0679.tif" /></chemistry><chemistry id="chem0680" num="0680"><img file="EP4470618A2_D0680.tif" /></chemistry><chemistry id="chem0681" num="0681"><img file="EP4470618A2_D0681.tif" /></chemistry><chemistry id="chem0682" num="0682"><img file="EP4470618A2_D0682.tif" /></chemistry><chemistry id="chem0683" num="0683"><img file="EP4470618A2_D0683.tif" /></chemistry><chemistry id="chem0684" num="0684"><img file="EP4470618A2_D0684.tif" /></chemistry><chemistry id="chem0685" num="0685"><img file="EP4470618A2_D0685.tif" /></chemistry><chemistry id="chem0686" num="0686"><img file="EP4470618A2_D0686.tif" /></chemistry><chemistry id="chem0687" num="0687"><img file="EP4470618A2_D0687.tif" /></chemistry><chemistry id="chem0688" num="0688"><img file="EP4470618A2_D0688.tif" /></chemistry><chemistry id="chem0689" num="0689"><img file="EP4470618A2_D0689.tif" /></chemistry><chemistry id="chem0690" num="0690"><img file="EP4470618A2_D0690.tif" /></chemistry><chemistry id="chem0691" num="0691"><img file="EP4470618A2_D0691.tif" /></chemistry>
0283In additional embodiments, "Tail" is selected from: <chemistry id="chem0692" num="0692"><img file="EP4470618A2_D0692.tif" /></chemistry><chemistry id="chem0693" num="0693"><img file="EP4470618A2_D0693.tif" /></chemistry><chemistry id="chem0694" num="0694"><img file="EP4470618A2_D0694.tif" /></chemistry><chemistry id="chem0695" num="0695"><img file="EP4470618A2_D0695.tif" /></chemistry><chemistry id="chem0696" num="0696"><img file="EP4470618A2_D0696.tif" /></chemistry><chemistry id="chem0697" num="0697"><img file="EP4470618A2_D0697.tif" /></chemistry><chemistry id="chem0698" num="0698"><img file="EP4470618A2_D0698.tif" /></chemistry>
0284In additional embodiments, "Tail" is selected from: <chemistry id="chem0699" num="0699"><img file="EP4470618A2_D0699.tif" /></chemistry><chemistry id="chem0700" num="0700"><img file="EP4470618A2_D0700.tif" /></chemistry><chemistry id="chem0701" num="0701"><img file="EP4470618A2_D0701.tif" /></chemistry><chemistry id="chem0702" num="0702"><img file="EP4470618A2_D0702.tif" /></chemistry>
0285In additional embodiments, "Tail" is selected from: <chemistry id="chem0703" num="0703"><img file="EP4470618A2_D0703.tif" /></chemistry><chemistry id="chem0704" num="0704"><img file="EP4470618A2_D0704.tif" /></chemistry><chemistry id="chem0705" num="0705"><img file="EP4470618A2_D0705.tif" /></chemistry><chemistry id="chem0706" num="0706"><img file="EP4470618A2_D0706.tif" /></chemistry><chemistry id="chem0707" num="0707"><img file="EP4470618A2_D0707.tif" /></chemistry><chemistry id="chem0708" num="0708"><img file="EP4470618A2_D0708.tif" /></chemistry><chemistry id="chem0709" num="0709"><img file="EP4470618A2_D0709.tif" /></chemistry><chemistry id="chem0710" num="0710"><img file="EP4470618A2_D0710.tif" /></chemistry><chemistry id="chem0711" num="0711"><img file="EP4470618A2_D0711.tif" /></chemistry>
0286In additional embodiments, "Tail" is selected from: <chemistry id="chem0712" num="0712"><img file="EP4470618A2_D0712.tif" /></chemistry><chemistry id="chem0713" num="0713"><img file="EP4470618A2_D0713.tif" /></chemistry>
0287In the above embodiments X<sup>22</sup> is selected such that a compound sufficiently stable or the intended use results.
0288In additional embodiments, "Tail" is selected from: <chemistry id="chem0714" num="0714"><img file="EP4470618A2_D0714.tif" /></chemistry>
0289In certain embodiments, "Tail" is selected from: <chemistry id="chem0715" num="0715"><img file="EP4470618A2_D0715.tif" /></chemistry><chemistry id="chem0716" num="0716"><img file="EP4470618A2_D0716.tif" /></chemistry><chemistry id="chem0717" num="0717"><img file="EP4470618A2_D0717.tif" /></chemistry><chemistry id="chem0718" num="0718"><img file="EP4470618A2_D0718.tif" /></chemistry>
0290In certain embodiments "Tail" is selected from: <chemistry id="chem0719" num="0719"><img file="EP4470618A2_D0719.tif" /></chemistry><chemistry id="chem0720" num="0720"><img file="EP4470618A2_D0720.tif" /></chemistry><chemistry id="chem0721" num="0721"><img file="EP4470618A2_D0721.tif" /></chemistry><chemistry id="chem0722" num="0722"><img file="EP4470618A2_D0722.tif" /></chemistry><chemistry id="chem0723" num="0723"><img file="EP4470618A2_D0723.tif" /></chemistry><chemistry id="chem0724" num="0724"><img file="EP4470618A2_D0724.tif" /></chemistry><chemistry id="chem0725" num="0725"><img file="EP4470618A2_D0725.tif" /></chemistry><chemistry id="chem0726" num="0726"><img file="EP4470618A2_D0726.tif" /></chemistry><chemistry id="chem0727" num="0727"><img file="EP4470618A2_D0727.tif" /></chemistry><chemistry id="chem0728" num="0728"><img file="EP4470618A2_D0728.tif" /></chemistry>
0291In the above structures <chemistry id="chem0729" num="0729"><img file="EP4470618A2_D0729.tif" /></chemistry> represents <chemistry id="chem0730" num="0730"><img file="EP4470618A2_D0730.tif" /></chemistry>
0292In certain embodiments, "Tail" can be a 4-24 carbon atom linear chains, wherein one or more the carbon atoms in the linear chain can be replaced or substituted with oxygen, nitrogen, amide, fluorinated carbon, etc., such as the following: <chemistry id="chem0731" num="0731"><img file="EP4470618A2_D0731.tif" /></chemistry><chemistry id="chem0732" num="0732"><img file="EP4470618A2_D0732.tif" /></chemistry><chemistry id="chem0733" num="0733"><img file="EP4470618A2_D0733.tif" /></chemistry><chemistry id="chem0734" num="0734"><img file="EP4470618A2_D0734.tif" /></chemistry><chemistry id="chem0735" num="0735"><img file="EP4470618A2_D0735.tif" /></chemistry><chemistry id="chem0736" num="0736"><img file="EP4470618A2_D0736.tif" /></chemistry><chemistry id="chem0737" num="0737"><img file="EP4470618A2_D0737.tif" /></chemistry><chemistry id="chem0738" num="0738"><img file="EP4470618A2_D0738.tif" /></chemistry><chemistry id="chem0739" num="0739"><img file="EP4470618A2_D0739.tif" /></chemistry><chemistry id="chem0740" num="0740"><img file="EP4470618A2_D0740.tif" /></chemistry><chemistry id="chem0741" num="0741"><img file="EP4470618A2_D0741.tif" /></chemistry><chemistry id="chem0742" num="0742"><img file="EP4470618A2_D0742.tif" /></chemistry><chemistry id="chem0743" num="0743"><img file="EP4470618A2_D0743.tif" /></chemistry><chemistry id="chem0744" num="0744"><img file="EP4470618A2_D0744.tif" /></chemistry><chemistry id="chem0745" num="0745"><img file="EP4470618A2_D0745.tif" /></chemistry><chemistry id="chem0746" num="0746"><img file="EP4470618A2_D0746.tif" /></chemistry><chemistry id="chem0747" num="0747"><img file="EP4470618A2_D0747.tif" /></chemistry><chemistry id="chem0748" num="0748"><img file="EP4470618A2_D0748.tif" /></chemistry><chemistry id="chem0749" num="0749"><img file="EP4470618A2_D0749.tif" /></chemistry><chemistry id="chem0750" num="0750"><img file="EP4470618A2_D0750.tif" /></chemistry><chemistry id="chem0751" num="0751"><img file="EP4470618A2_D0751.tif" /></chemistry><chemistry id="chem0752" num="0752"><img file="EP4470618A2_D0752.tif" /></chemistry> and <chemistry id="chem0753" num="0753"><img file="EP4470618A2_D0753.tif" /></chemistry>
0293In certain embodiments, "Tail" can be a nonlinear chain, and can be, or include, aliphatic or aromatic or heteroaromatic cyclic moieties.
0294In certain embodiments, "Tail" may include contiguous, partially contiguous or non-contiguous ethylene glycol unit groups ranging in size from about 1 to about 12 ethylene glycol units, between 1 and about 10 ethylene glycol units, about 2 about 6 ethylene glycol units, between about 2 and 5 ethylene glycol units, between about 2 and 4 ethylene glycol units, for example, 1, 2, 3, 4, 6, 6, 7, 8, 9, 10, 11 or 12 ethylene glycol units.
0295In certain embodiments, "Tail" may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 fluorine substituents. In another embodiment "Tail" is perfluorinated. In yet another embodiment "Tail" is a partially or fully fluorinated poly ether. Nonlimiting examples of fluorinated "Tail" moieties include: <chemistry id="chem0754" num="0754"><img file="EP4470618A2_D0754.tif" /></chemistry><chemistry id="chem0755" num="0755"><img file="EP4470618A2_D0755.tif" /></chemistry><chemistry id="chem0756" num="0756"><img file="EP4470618A2_D0756.tif" /></chemistry><chemistry id="chem0757" num="0757"><img file="EP4470618A2_D0757.tif" /></chemistry><chemistry id="chem0758" num="0758"><img file="EP4470618A2_D0758.tif" /></chemistry>
0296Representative examples of X<sup>22</sup> include: <chemistry id="chem0759" num="0759"><img file="EP4470618A2_D0759.tif" /></chemistry><chemistry id="chem0760" num="0760"><img file="EP4470618A2_D0760.tif" /></chemistry><chemistry id="chem0761" num="0761"><img file="EP4470618A2_D0761.tif" /></chemistry>
0297In certain embodiments, the length can be adjusted as desired or as found necessary for the desired application.
IV.
Methods of Treatment
0298The compounds of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) can be used in an effective amount to treat a host, including a human, in need thereof, optionally in a pharmaceutically acceptable carrier to treat any of the disorders described herein.
0299The terms "treat", "treating", and "treatment", etc., as used herein, refer to any action providing a benefit to a patient for which the present compounds may be administered, including the treatment of any disease state or condition which is modulated through the protein to which the present compounds bind. Illustrative non-limiting disease states or conditions, including cancer, which may be treated using compounds according to the present invention are set forth hereinabove.
0300The term "disease state or condition" when used in connection with a Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) compound for example, refers to any therapeutic indication which can be treated by decreasing the activity of cereblon or a cereblon-containing E3 Ligase, including but not limited to uses known for the cereblon binders thalidomide, pomalidomide or lenalidomide. Nonlimiting examples of uses for cereblon binders are multiple myeloma, a hematological disorder such as myelodysplastic syndrome, cancer, tumor, abnormal cellular proliferation, HIV/AIDS, HBV, HCV, hepatitis, Crohn's disease, sarcoidosis, graft-versus-host disease, rheumatoid arthritis, Behcet's disease, tuberculosis, and myelofibrosis. Other indications include a myelo- or lymphoproliferative disorder such as B- or T-cell lymphomas, Waldenstrom's macroglobulinemia, Wiskott-Aldrich syndrome, or a post-transplant lymphoproliferative disorder; an immune disorder, including autoimmune disorders such as Addison disease, Celiac disease, dermatomyositis, Graves disease, thyroiditis, multiple sclerosis, pernicious anemia, arthritis, and in particular rheumatoid arthritis, lupus, or type I diabetes; a disease of cardiologic malfunction, including hypercholesterolemia; an infectious disease, including viral and/or bacterial infection, as described generally herein; an inflammatory condition, including asthma, chronic peptic ulcers, tuberculosis, rheumatoid arthritis, periodontitis and ulcerative colitis.
0301In certain embodiments, the present invention provides for administering a compound of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) to a patient, for example, a human, having an infectious disease, wherein the therapy targets a protein of the infectious agent, optionally in combination with another bioactive agent. The disease state or condition may be a disease caused by a microbial agent or other exogenous agent such as a virus (as non-limiting examples, HIV, HBV, HCV, HSV, HPV, RSV, CMV, Ebola, Flavivirus, Pestivirus, Rotavirus, Influenza, Coronavirus, EBV, viral pneumonia, drug-resistant viruses, Bird flu, RNA virus, DNA virus, adenovirus, poxvirus, Picornavirus, Togavirus, Orthomyxovirus, Retrovirus or Hepadnovirus), bacteria (Gram-negative, Gram-positive, , fungus, protozoa, helminth, worms, prion, parasite, or other microbe or may be a disease state, which is caused by overexpression of a protein, which leads to a disease state and/or condition.
0302In certain embodiments, the condition treated with a compound of the present invention is a disorder related to abnormal cellular proliferation. Abnormal cellular proliferation, notably hyperproliferation, can occur as a result of a wide variety of factors, including genetic mutation, infection, exposure to toxins, autoimmune disorders, and benign or malignant tumor induction.
0303There are a number of skin disorders associated with cellular hyperproliferation. Psoriasis, for example, is a benign disease of human skin generally characterized by plaques covered by thickened scales. The disease is caused by increased proliferation of epidermal cells of unknown cause. Chronic eczema is also associated with significant hyperproliferation of the epidermis. Other diseases caused by hyperproliferation of skin cells include atopic dermatitis, lichen planus, warts, pemphigus vulgaris, actinic keratosis, basal cell carcinoma and squamous cell carcinoma.
0304Other hyperproliferative cell disorders include blood vessel proliferation disorders, fibrotic disorders, autoimmune disorders, graft-versus-host rejection, tumors and cancers.
0305Blood vessel proliferative disorders include angiogenic and vasculogenic disorders. Proliferation of smooth muscle cells in the course of development of plaques in vascular tissue cause, for example, restenosis, retinopathies and atherosclerosis. Both cell migration and cell proliferation play a role in the formation of atherosclerotic lesions.
0306Fibrotic disorders are often due to the abnormal formation of an extracellular matrix. Examples of fibrotic disorders include hepatic cirrhosis and mesangial proliferative cell disorders. Hepatic cirrhosis is characterized by the increase in extracellular matrix constituents resulting in the formation of a hepatic scar. Hepatic cirrhosis can cause diseases such as cirrhosis of the liver. An increased extracellular matrix resulting in a hepatic scar can also be caused by viral infection such as hepatitis. Lipocytes appear to play a major role in hepatic cirrhosis.
0307Mesangial disorders are brought about by abnormal proliferation of mesangial cells. Mesangial hyperproliferative cell disorders include various human renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic micro-angiopathy syndromes, transplant rejection, and glomerulopathies.
0308Another disease with a proliferative component is rheumatoid arthritis. Rheumatoid arthritis is generally considered an autoimmune disease that is thought to be associated with activity of autoreactive T cells, and to be caused by autoantibodies produced against collagen and IgE.
0309Other disorders that can include an abnormal cellular proliferative component include Bechet's syndrome, acute respiratory distress syndrome (ARDS), ischemic heart disease, post-dialysis syndrome, leukemia, acquired immune deficiency syndrome, vasculitis, lipid histiocytosis, septic shock and inflammation in general.
0310Cutaneous contact hypersensitivity and asthma are just two examples of immune responses that can be associated with significant morbidity. Others include atopic dermatitis, eczema, Sjogren's Syndrome, including keratoconjunctivitis sicca secondary to Sjogren's Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, and drug eruptions. These conditions may result in any one or more of the following symptoms or signs: itching, swelling, redness, blisters, crusting, ulceration, pain, scaling, cracking, hair loss, scarring, or oozing of fluid involving the skin, eye, or mucosal membranes.
0311In atopic dermatitis, and eczema in general, immunologically mediated leukocyte infiltration (particularly infiltration of mononuclear cells, lymphocytes, neutrophils, and eosinophils) into the skin importantly contributes to the pathogenesis of these diseases. Chronic eczema also is associated with significant hyperproliferation of the epidermis. Immunologically mediated leukocyte infiltration also occurs at sites other than the skin, such as in the airways in asthma and in the tear producing gland of the eye in keratoconjunctivitis sicca.
0312In one non-limiting embodiment compounds of the present invention are used as topical agents in treating contact dermatitis, atopic dermatitis, eczematous dermatitis, psoriasis, Sjogren's Syndrome, including keratoconjunctivitis sicca secondary to Sjogren's Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, and drug eruptions. The novel method may also be useful in reducing the infiltration of skin by malignant leukocytes in diseases such as mycosis fungoides. These compounds can also be used to treat an aqueous-deficient dry eye state (such as immune mediated keratoconjunctivitis) in a patient suffering therefrom, by administering the compound topically to the eye.
0313Disease states of conditions which may be treated using compounds according to the present invention include, for example, asthma, autoimmune diseases such as multiple sclerosis, various cancers, ciliopathies, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive error, infertility, Angelman syndrome, Canavan disease, Coeliac disease, Charcot-Marie-Tooth disease, Cystic fibrosis, Duchenne muscular dystrophy, Haemochromatosis, Haemophilia, Klinefelter's syndrome, Neurofibromatosis, Phenylketonuria, Polycystic kidney disease 1 (PKD1) or 2 (PKD2) Prader-Willi syndrome, Sickle-cell disease, Tay-Sachs disease, Turner syndrome.
0314Further disease states or conditions which may be treated by compounds according to the present invention include Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's disease), Anorexia nervosa, Anxiety disorder, Atherosclerosis, Attention deficit hyperactivity disorder, Autism, Bipolar disorder, Chronic fatigue syndrome, Chronic obstructive pulmonary disease, Crohn's disease, Coronary heart disease, Dementia, Depression, Diabetes mellitus type 1, Diabetes mellitus type 2, Epilepsy, Guillain-Barré syndrome, Irritable bowel syndrome, Lupus, Metabolic syndrome, Multiple sclerosis, Myocardial infarction, Obesity, Obsessive-compulsive disorder, Panic disorder, Parkinson's disease, Psoriasis, Rheumatoid arthritis, Sarcoidosis, Schizophrenia, Stroke, Thromboangiitis obliterans, Tourette syndrome, Vasculitis.
0315Still additional disease states or conditions which can be treated by compounds according to the present invention include aceruloplasminemia, Achondrogenesis type II, achondroplasia, Acrocephaly, Gaucher disease type 2, acute intermittent porphyria, Canavan disease, Adenomatous Polyposis Coli, ALA dehydratase deficiency, adenylosuccinate lyase deficiency, Adrenogenital syndrome, Adrenoleukodystrophy, ALA-D porphyria, ALA dehydratase deficiency, Alkaptonuria, Alexander disease, Alkaptonuric ochronosis, alpha 1-antitrypsin deficiency, alpha-1 proteinase inhibitor, emphysema, amyotrophic lateral sclerosis Alström syndrome, Alexander disease, Amelogenesis imperfecta, ALA dehydratase deficiency, Anderson-Fabry disease, androgen insensitivity syndrome, Anemia Angiokeratoma Corporis Diffusum, Angiomatosis retinae (von Hippel-Lindau disease) Apert syndrome, Arachnodactyly (Marfan syndrome), Stickler syndrome, Arthrochalasis multiplex congenital (Ehlers-Danlos syndrome#arthrochalasia type) ataxia telangiectasia, Rett syndrome, primary pulmonary hypertension, Sandhoff disease, neurofibromatosis type II, Beare-Stevenson cutis gyrata syndrome, Mediterranean fever, familial, Benjamin syndrome, beta-thalassemia, Bilateral Acoustic Neurofibromatosis (neurofibromatosis type II), factor V Leiden thrombophilia, Bloch-Sulzberger syndrome (incontinentia pigmenti), Bloom syndrome, X-linked sideroblastic anemia, Bonnevie-Ullrich syndrome (Turner syndrome), Bourneville disease (tuberous sclerosis), prion disease, Birt-Hogg-Dubé syndrome, Brittle bone disease (osteogenesis imperfecta), Broad Thumb-Hallux syndrome (Rubinstein-Taybi syndrome), Bronze Diabetes/Bronzed Cirrhosis (hemochromatosis), Bulbospinal muscular atrophy (Kennedy's disease), Burger-Grutz syndrome (lipoprotein lipase deficiency), CGD Chronic granulomatous disorder, Campomelic dysplasia, biotinidase deficiency, Cardiomyopathy (Noonan syndrome), Cri du chat, CAVD (congenital absence of the vas deferens), Caylor cardiofacial syndrome (CBAVD), CEP (congenital erythropoietic porphyria), cystic fibrosis, congenital hypothyroidism, Chondrodystrophy syndrome (achondroplasia), otospondylomegaepiphyseal dysplasia, Lesch-Nyhan syndrome, galactosemia, Ehlers-Danlos syndrome, Thanatophoric dysplasia, Coffin-Lowry syndrome, Cockayne syndrome, (familial adenomatous polyposis), Congenital erythropoietic porphyria, Congenital heart disease, Methemoglobinemia/Congenital methaemoglobinaemia, achondroplasia, X-linked sideroblastic anemia, Connective tissue disease, Conotruncal anomaly face syndrome, Cooley's Anemia (beta-thalassemia), Copper storage disease (Wilson's disease), Copper transport disease (Menkes disease), hereditary coproporphyria, Cowden syndrome, Craniofacial dysarthrosis (Crouzon syndrome), Creutzfeldt-Jakob disease (prion disease), Cockayne syndrome, Cowden syndrome, Curschmann-Batten-Steinert syndrome (myotonic dystrophy), Beare-Stevenson cutis gyrata syndrome, primary hyperoxaluria, spondyloepimetaphyseal dysplasia (Strudwick type), muscular dystrophy, Duchenne and Becker types (DBMD), Usher syndrome, Degenerative nerve diseases including de Grouchy syndrome and Dejerine-Sottas syndrome, developmental disabilities, distal spinal muscular atrophy, type V, androgen insensitivity syndrome, Diffuse Globoid Body Sclerosis (Krabbe disease), Di George's syndrome, Dihydrotestosterone receptor deficiency, androgen insensitivity syndrome, Down syndrome, Dwarfism, erythropoietic protoporphyria Erythroid 5-aminolevulinate synthetase deficiency, Erythropoietic porphyria, erythropoietic protoporphyria, erythropoietic uroporphyria, Friedreich's ataxia-familial paroxysmal polyserositis, porphyria cutanea tarda, familial pressure sensitive neuropathy, primary pulmonary hypertension (PPH), Fibrocystic disease of the pancreas, fragile X syndrome, galactosemia, genetic brain disorders, Giant cell hepatitis (Neonatal hemochromatosis), Gronblad-Strandberg syndrome (pseudoxanthoma elasticum), Gunther disease (congenital erythropoietic porphyria), haemochromatosis, Hallgren syndrome, sickle cell anemia, hemophilia, hepatoerythropoietic porphyria (HEP), Hippel-Lindau disease (von Hippel-Lindau disease), Huntington's disease, Hutchinson-Gilford progeria syndrome (progeria), Hyperandrogenism, Hypochondroplasia, Hypochromic anemia, Immune system disorders, including X-linked severe combined immunodeficiency, Insley-Astley syndrome, Jackson-Weiss syndrome, Joubert syndrome, Lesch-Nyhan syndrome, Jackson-Weiss syndrome, Kidney diseases, including hyperoxaluria, Klinefelter's syndrome, Kniest dysplasia, Lacunar dementia, Langer-Saldino achondrogenesis, ataxia telangiectasia, Lynch syndrome, Lysyl-hydroxylase deficiency, Machado-Joseph disease, Metabolic disorders, including Kniest dysplasia, Marfan syndrome, Movement disorders, Mowat-Wilson syndrome, cystic fibrosis, Muenke syndrome, Multiple neurofibromatosis, Nance-Insley syndrome, Nance-Sweeney chondrodysplasia, Niemann-Pick disease, Noack syndrome (Pfeiffer syndrome), Osler-Weber-Rendu disease, Peutz-Jeghers syndrome, Polycystic kidney disease, polyostotic fibrous dysplasia (McCune-Albright syndrome), Peutz-Jeghers syndrome, Prader-Labhart-Willi syndrome, hemochromatosis, primary hyperuricemia syndrome (Lesch-Nyhan syndrome), primary pulmonary hypertension, primary senile degenerative dementia, prion disease, progeria (Hutchinson Gilford Progeria Syndrome), progressive chorea, chronic hereditary (Huntington) (Huntington's disease), progressive muscular atrophy, spinal muscular atrophy, propionic acidemia, protoporphyria, proximal myotonic dystrophy, pulmonary arterial hypertension, PXE (pseudoxanthoma elasticum), Rb (retinoblastoma), Recklinghausen disease (neurofibromatosis type I), Recurrent polyserositis, Retinal disorders, Retinoblastoma, Rett syndrome, RFALS type 3, Ricker syndrome, Riley-Day syndrome, Roussy-Levy syndrome, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Li-Fraumeni syndrome, sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome, sclerosis tuberose (tuberous sclerosis), SDAT, SED congenital (spondyloepiphyseal dysplasia congenita), SED Strudwick (spondyloepimetaphyseal dysplasia, Strudwick type), SEDc (spondyloepiphyseal dysplasia congenita) SEMD, Strudwick type (spondyloepimetaphyseal dysplasia, Strudwick type), Shprintzen syndrome, Skin pigmentation disorders, Smith-Lemli-Opitz syndrome, South-African genetic porphyria (variegate porphyria), infantile-onset ascending hereditary spastic paralysis, Speech and communication disorders, sphingolipidosis, Tay-Sachs disease, spinocerebellar ataxia, Stickler syndrome, stroke, androgen insensitivity syndrome, tetrahydrobiopterin deficiency, beta-thalassemia, Thyroid disease, Tomaculous neuropathy (hereditary neuropathy with liability to pressure palsies), Treacher Collins syndrome, Triplo X syndrome (triple X syndrome), Trisomy 21 (Down syndrome), Trisomy X, VHL syndrome (von Hippel-Lindau disease), Vision impairment and blindness (Alström syndrome), Vrolik disease, Waardenburg syndrome, Warburg Sjo Fledelius Syndrome, Weissenbacher-Zweymüller syndrome, Wolf-Hirschhorn syndrome, Wolff Periodic disease, Weissenbacher-Zweymüller syndrome and Xeroderma pigmentosum, among others.
0316The term "neoplasia" or "cancer" is used throughout the specification to refer to the pathological process that results in the formation and growth of a cancerous or malignant neoplasm, i.e., abnormal tissue that grows by cellular proliferation, often more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease. Malignant neoplasms show partial or complete lack of structural organization and functional coordination with the normal tissue and most invade surrounding tissues, metastasize to several sites, and are likely to recur after attempted removal and to cause the death of the patient unless adequately treated. As used herein, the term neoplasia is used to describe all cancerous disease states and embraces or encompasses the pathological process associated with malignant hematogenous, ascitic and solid tumors. Exemplary cancers which may be treated by the present compounds either alone or in combination with at least one additional anti-cancer agent include squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor and teratocarcinomas. Additional cancers which may be treated using compounds according to the present invention include, for example, T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre-B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML.
0317Additional cancers which may be treated using the disclosed compounds according to the present invention include, for example, acute granulocytic leukemia, acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), adenocarcinoma, adenosarcoma, adrenal cancer, adrenocortical carcinoma, anal cancer, anaplastic astrocytoma, angiosarcoma, appendix cancer, astrocytoma, Basal cell carcinoma, B-Cell lymphoma, bile duct cancer, bladder cancer, bone cancer, bone marrow cancer, bowel cancer, brain cancer, brain stem glioma, breast cancer, triple (estrogen, progesterone and HER-2) negative breast cancer, double negative breast cancer (two of estrogen, progesterone and HER-2 are negative), single negative (one of estrogen, progesterone and HER-2 is negative), estrogen-receptor positive, HER2-negative breast cancer, estrogen receptor-negative breast cancer, estrogen receptor positive breast cancer, metastatic breast cancer, luminal A breast cancer, luminal B breast cancer, Her2-negative breast cancer, HER2-positive or negative breast cancer, progesterone receptor-negative breast cancer, progesterone receptor-positive breast cancer, recurrent breast cancer, carcinoid tumors, cervical cancer, cholangiocarcinoma, chondrosarcoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), colon cancer, colorectal cancer, craniopharyngioma, cutaneous lymphoma, cutaneous melanoma, diffuse astrocytoma, ductal carcinoma in situ (DCIS), endometrial cancer, ependymoma, epithelioid sarcoma, esophageal cancer, ewing sarcoma, extrahepatic bile duct cancer, eye cancer, fallopian tube cancer, fibrosarcoma, gallbladder cancer, gastric cancer, gastrointestinal cancer, gastrointestinal carcinoid cancer, gastrointestinal stromal tumors (GIST), germ cell tumor glioblastoma multiforme (GBM), glioma, hairy cell leukemia, head and neck cancer, hemangioendothelioma, Hodgkin lymphoma, hypopharyngeal cancer, infiltrating ductal carcinoma (IDC), infiltrating lobular carcinoma (ILC), inflammatory breast cancer (IBC), intestinal Cancer, intrahepatic bile duct cancer, invasive/infiltrating breast cancer, Islet cell cancer, jaw cancer, Kaposi sarcoma, kidney cancer, laryngeal cancer, leiomyosarcoma, leptomeningeal metastases, leukemia, lip cancer, liposarcoma, liver cancer, lobular carcinoma in situ, low-grade astrocytoma, lung cancer, lymph node cancer, lymphoma, male breast cancer, medullary carcinoma, medulloblastoma, melanoma, meningioma, Merkel cell carcinoma, mesenchymal chondrosarcoma, mesenchymous, mesothelioma metastatic breast cancer, metastatic melanoma metastatic squamous neck cancer, mixed gliomas, monodermal teratoma, mouth cancer mucinous carcinoma, mucosal melanoma, multiple myeloma, Mycosis Fungoides, myelodysplastic syndrome, nasal cavity cancer, nasopharyngeal cancer, neck cancer, neuroblastoma, neuroendocrine tumors (NETs), non-Hodgkin's lymphoma, non-small cell lung cancer (NSCLC), oat cell cancer, ocular cancer, ocular melanoma, oligodendroglioma, oral cancer, oral cavity cancer, oropharyngeal cancer, osteogenic sarcoma, osteosarcoma, ovarian cancer, ovarian epithelial cancer ovarian germ cell tumor, ovarian primary peritoneal carcinoma, ovarian sex cord stromal tumor, Paget's disease, pancreatic cancer, papillary carcinoma, paranasal sinus cancer, parathyroid cancer, pelvic cancer, penile cancer, peripheral nerve cancer, peritoneal cancer, pharyngeal cancer, pheochromocytoma, pilocytic astrocytoma, pineal region tumor, pineoblastoma, pituitary gland cancer, primary central nervous system (CNS) lymphoma, prostate cancer, rectal cancer, renal cell carcinoma, renal pelvis cancer, rhabdomyosarcoma, salivary gland cancer, soft tissue sarcoma, bone sarcoma, sarcoma, sinus cancer, skin cancer, small cell lung cancer (SCLC), small intestine cancer, spinal cancer, spinal column cancer, spinal cord cancer, squamous cell carcinoma, stomach cancer, synovial sarcoma, T-cell lymphoma, testicular cancer, throat cancer, thymoma/thymic carcinoma, thyroid cancer, tongue cancer, tonsil cancer, transitional cell cancer, tubal cancer, tubular carcinoma, undiagnosed cancer, ureteral cancer, urethral cancer, uterine adenocarcinoma, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, T-cell lineage acute lymphoblastic leukemia (T-ALL), T-cell lineage lymphoblastic lymphoma (T-LL), peripheral T-cell lymphoma, Adult T-cell leukemia, Pre-B ALL, Pre-B lymphomas, large B-cell lymphoma, Burkitts lymphoma, B-cell ALL, Philadelphia chromosome positive ALL, Philadelphia chromosome positive CML, juvenile myelomonocytic leukemia (JMML), acute promyelocytic leukemia (a subtype of AML), large granular lymphocytic leukemia, Adult T-cell chronic leukemia, diffuse large B cell lymphoma, follicular lymphoma; Mucosa-Associated Lymphatic Tissue lymphoma (MALT), small cell lymphocytic lymphoma, mediastinal large B cell lymphoma, nodal marginal zone B cell lymphoma (NMZL); splenic marginal zone lymphoma (SMZL); intravascular large B-cell lymphoma; primary effusion lymphoma; or lymphomatoid granulomatosis;; B-cell prolymphocytic leukemia; splenic lymphoma/leukemia, unclassifiable, splenic diffuse red pulp small B-cell lymphoma; lymphoplasmacytic lymphoma; heavy chain diseases, for example, Alpha heavy chain disease, Gamma heavy chain disease, Mu heavy chain disease, plasma cell myeloma, solitary plasmacytoma of bone; extraosseous plasmacytoma; primary cutaneous follicle center lymphoma, T cell/histocyte rich large B-cell lymphoma, DLBCL associated with chronic inflammation; Epstein-Barr virus (EBV)+ DLBCL of the elderly; primary mediastinal (thymic) large B-cell lymphoma, primary cutaneous DLBCL, leg type, ALK+ large B-cell lymphoma, plasmablastic lymphoma; large B-cell lymphoma arising in HHV8-associated multicentric, Castleman disease; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma, or B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.
0318In one embodiment the cancer is NUT midline cardinioma.
0319In one embodiment the cancer is adenoid cystic carcinoma.
0320The term "bioactive agent" is used to describe an agent, other than a compound according to the present invention, which is used in combination with the present compounds as an agent with biological activity to assist in effecting an intended therapy, inhibition and/or prevention/prophylaxis for which the present compounds are used. Preferred bioactive agents for use herein include those agents which have pharmacological activity similar to that for which the present compounds are used or administered and include for example, anti-cancer agents, antiviral agents, especially including anti-HIV agents and anti-HCV agents, antimicrobial agents, antifungal agents, etc.
V. Combination Therapy
0321The compounds of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) can be used in an effective amount alone or in combination to treat a host such as a human with a disorder as described herein.
0322The disclosed compounds described herein can be used in an effective amount alone or in combination with another compound of the present invention or another bioactive agent to treat a host such as a human with a disorder as described herein.
0323The term "bioactive agent" is used to describe an agent, other than the selected compound according to the present invention, which can be used in combination or alternation with a compound of the present invention to achieve a desired result of therapy. In one embodiment, the compound of the present invention and the bioactive agent are administered in a manner that they are active in vivo during overlapping time periods, for example, have time-period overlapping Cmax, Tmax, AUC or other pharmacokinetic parameter. In another embodiment, the compound of the present invention and the bioactive agent are administered to a host in need thereof that do not have overlapping pharmacokinetic parameter, however, one has a therapeutic impact on the therapeutic efficacy of the other.
0324In one aspect of this embodiment, the bioactive agent is an immune modulator, including but not limited to a checkpoint inhibitor, including as non-limiting examples, a PD-1 inhibitor, PD-L1 inhibitor, PD-L2 inhibitor, CTLA-4 inhibitor, LAG-3 inhibitor, TIM-3 inhibitor, V-domain Ig suppressor of T-cell activation (VISTA) inhibitors, small molecule, peptide, nucleotide, or other inhibitor. In certain aspects, the immune modulator is an antibody, such as a monoclonal antibody.
VI. Pharmaceutical Compositions
0325The compounds of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) as disclosed herein can be administered as the neat chemical, but are more typically administered as a pharmaceutical composition, that includes an effective amount for a host, typically a human, in need of such treatment for any of the disorders described herein. Accordingly, the disclosure provides pharmaceutical compositions comprising an effective amount of compound or pharmaceutically acceptable salt together with at least one pharmaceutically acceptable carrier for any of the uses described herein. The pharmaceutical composition may contain a compound or salt as the only active agent, or, in an alternative embodiment, the compound and at least one additional active agent.
0326In certain embodiments the pharmaceutical composition is in a dosage form that contains from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of the active compound and optionally from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of an additional active agent in a unit dosage form. Examples are dosage forms with at least 0.1, 1, 5, 10, 25, 50, 100, 200, 250, 300, 400, 500, 600, 700, or 750 mg of active compound, or its salt. The pharmaceutical composition may also include a molar ratio of the active compound and an additional active agent. For example the pharmaceutical composition may contain a molar ratio of about 0.5:1, about 1:1, about 2:1, about 3:1 or from about 1.5:1 to about 4:1 of an anti-inflammatory or immunosuppressing agent. Compounds disclosed herein may be administered orally, topically, parenterally, by inhalation or spray, sublingually, via implant, including ocular implant, transdermally, via buccal administration, rectally, as an ophthalmic solution, injection, including ocular injection, intraveneous, intra-aortal, intracranial, subdermal, intraperitioneal, subcutaneous, transnasal, sublingual, or rectal or by other means, in dosage unit formulations containing conventional pharmaceutically acceptable carriers. For ocular delivery, the compound can be administered, as desired, for example, via intravitreal, intrastromal, intracameral, sub-tenon, sub-retinal, retro-bulbar, peribulbar, suprachorodial, conjunctival, subconjunctival, episcleral, periocular, transscleral, retrobulbar, posterior juxtascleral, circumcorneal, or tear duct injections, or through a mucus, mucin, or a mucosal barrier, in an immediate or controlled release fashion or via an ocular device.
0327The pharmaceutical composition may be formulated as any pharmaceutically useful form, e.g., as an aerosol, a cream, a gel, a pill, an injection or infusion solution, a capsule, a tablet, a syrup, a transdermal patch, a subcutaneous patch, a dry powder, an inhalation formulation, in a medical device, suppository, buccal, or sublingual formulation, parenteral formulation, or an ophthalmic solution. Some dosage forms, such as tablets and capsules, are subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.
0328Carriers include excipients and diluents and must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated. The carrier can be inert or it can possess pharmaceutical benefits of its own. The amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.
0329Classes of carriers include, but are not limited to binders, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, flavorants, glidents, lubricants, preservatives, stabilizers, surfactants, tableting agents, and wetting agents. Some carriers may be listed in more than one class, for example vegetable oil may be used as a lubricant in some formulations and a diluent in others. Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin; talc, and vegetable oils. Optional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of the present invention.
0330The pharmaceutical compositions/combinations can be formulated for oral administration. These compositions can contain any amount of active compound that achieves the desired result, for example between 0.1 and 99 weight % (wt.%) of the compound and usually at least about 5 wt.% of the compound. Some embodiments contain from about 25 wt.% to about 50 wt. % or from about 5 wt.% to about 75 wt.% of the compound.
0331Formulations suitable for rectal administration are typically presented as unit dose suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
0332Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.
0333Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Formulations suitable for transdermal administration may also be delivered by iontophoresis (<i>see</i>, for example, <nplcit id="ncit0010" npl-type="s"><text>Pharmaceutical Research 3 (6):318 (1986</text></nplcit>)) and typically take the form of an optionally buffered aqueous solution of the active compound. In one embodiment, microneedle patches or devices are provided for delivery of drugs across or into biological tissue, particularly the skin. The microneedle patches or devices permit drug delivery at clinically relevant rates across or into skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue.
0334Formulations suitable for administration to the lungs can be delivered by a wide range of passive breath driven and active power driven single/-multiple dose dry powder inhalers (DPI). The devices most commonly used for respiratory delivery include nebulizers, metered-dose inhalers, and dry powder inhalers. Several types of nebulizers are available, including jet nebulizers, ultrasonic nebulizers, and vibrating mesh nebulizers. Selection of a suitable lung delivery device depends on parameters, such as nature of the drug and its formulation, the site of action, and pathophysiology of the lung.
0335The compounds described herein and the pharmaceutically acceptable salts can be used as therapeutically active substances, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
0336The compounds described herein and the pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatin capsules. Suitable carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatin capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
0337The pharmaceutical preparations can, moreover, contain pharmaceutically acceptable auxiliary substances such as preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
0338Medicaments containing a compound of the present invention or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also provided by the present invention, as is a process for their production, which comprises bringing one or more compounds of Formula I and/or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.
0339The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general Formula XIV or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.
0340The following examples illustrate the present invention without limiting it, but serve merely as representative thereof. The pharmaceutical preparations conveniently contain about 1-500 mg, particularly 1-100 mg, of a compound of Formula XIV. Examples of compositions according to the invention are:
Example
A
0341Tablets of the following composition are manufactured in the usual manner: <tables id="tabl0001" num="0001"><table frame="all"><title><b><i>Table 1: possible tablet composition</i></b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="42mm" /><colspec colnum="2" colname="col2" colwidth="11mm" /><colspec colnum="3" colname="col3" colwidth="11mm" /><colspec colnum="4" colname="col4" colwidth="11mm" /><colspec colnum="5" colname="col5" colwidth="11mm" /><thead valign="top"><row><entry morerows="1">ingredient</entry><entry namest="col2" nameend="col5" align="left">mg/tablet</entry></row><row><entry>5</entry><entry>25</entry><entry>100</entry><entry>500</entry></row></thead><tbody><row><entry>Compound of Formula XIV</entry><entry>5</entry><entry>25</entry><entry>100</entry><entry>500</entry></row><row><entry>Lactose Anhydrous DTG</entry><entry>125</entry><entry>105</entry><entry>30</entry><entry>150</entry></row><row><entry>Sta-Rx 1500</entry><entry>6</entry><entry>6</entry><entry>6</entry><entry>60</entry></row><row><entry>Microcrystalline Cellulose</entry><entry>30</entry><entry>30</entry><entry>30</entry><entry>450</entry></row><row><entry>Magnesium Stearate</entry><entry>1</entry><entry>1</entry><entry>1</entry><entry>1</entry></row><row><entry>Total</entry><entry>167</entry><entry>167</entry><entry>167</entry><entry>831</entry></row></tbody></tgroup></table></tables>
Manufacturing Procedure
0342<ol id="ol0011" compact="compact"><li>1. Mix ingredients 1, 2, 3 and 4 and granulate with purified water.</li><li>2. Dry the granules at 50 °C.</li><li>3. Pass the granules through suitable milling equipment.</li><li>4. Add ingredient 5 and mix for three minutes; compress on a suitable press.</li></ol>
Example B-1
0343Capsules of the following composition are manufactured: <tables id="tabl0002" num="0002"><table frame="all"><title><b><i>Table 2: possible capsule ingredient composition</i></b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="43mm" /><colspec colnum="2" colname="col2" colwidth="14mm" /><colspec colnum="3" colname="col3" colwidth="14mm" /><colspec colnum="4" colname="col4" colwidth="14mm" /><colspec colnum="5" colname="col5" colwidth="14mm" /><thead valign="top"><row><entry morerows="1">ingredient</entry><entry namest="col2" nameend="col5" align="left">mg/capsule</entry></row><row><entry>5</entry><entry>25</entry><entry>100</entry><entry>500</entry></row></thead><tbody><row><entry>Compound of Formula XIV</entry><entry>5</entry><entry>25</entry><entry>100</entry><entry>500</entry></row><row><entry>Hydrous Lactose</entry><entry>159</entry><entry>123</entry><entry>148</entry><entry>-</entry></row><row><entry>Corn Starch</entry><entry>25</entry><entry>35</entry><entry>40</entry><entry>70</entry></row><row><entry>Talk</entry><entry>10</entry><entry>15</entry><entry>10</entry><entry>25</entry></row><row><entry>Magnesium Stearate</entry><entry>1</entry><entry>2</entry><entry>2</entry><entry>5</entry></row><row><entry>Total</entry><entry>200</entry><entry>200</entry><entry>300</entry><entry>600</entry></row></tbody></tgroup></table></tables>
Manufacturing Procedure
0344<ol id="ol0012" compact="compact"><li>1. Mix ingredients 1, 2 and 3 in a suitable mixer for 30 minutes.</li><li>2. Add ingredients 4 and 5 and mix for 3 minutes.</li><li>3. Fill into a suitable capsule.</li></ol>
0345The compound of Formula XIV, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine. The mixture is returned to the mixer; the talc is added thereto and mixed thoroughly. The mixture is filled by machine into suitable capsules, e.g. hard gelatin capsules.
Example B-2
0346Soft Gelatin Capsules of the following composition are manufactured: <tables id="tabl0003" num="0003"><table frame="all"><title><b><i>Table 3: possible soft gelatin capsule ingredient composition</i></b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="50mm" /><colspec colnum="2" colname="col2" colwidth="45mm" /><thead valign="top"><row><entry>ingredient</entry><entry>mg/capsule</entry></row></thead><tbody><row><entry>Compound of Formula XIV</entry><entry>5</entry></row><row><entry>Yellow wax</entry><entry>8</entry></row><row><entry>Hydrogenated Soya bean oil</entry><entry>8</entry></row><row><entry>Partially hydrogenated plant oils</entry><entry>34</entry></row><row><entry>Soya bean oil</entry><entry>110</entry></row><row><entry>Total</entry><entry>165</entry></row></tbody></tgroup></table></tables><tables id="tabl0004" num="0004"><table frame="all"><title><b><i>Table 4: possible soft gelatin capsule composition</i></b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="39mm" /><colspec colnum="2" colname="col2" colwidth="39mm" /><thead valign="top"><row><entry>ingredient</entry><entry>mg/capsule</entry></row></thead><tbody><row><entry>Gelatin</entry><entry>75</entry></row><row><entry>Glycerol 85 %</entry><entry>32</entry></row><row><entry>Karion 83</entry><entry>8 (dry matter)</entry></row><row><entry>Titan dioxide</entry><entry>0.4</entry></row><row><entry>Iron oxide yellow</entry><entry>1.1</entry></row><row><entry>Total</entry><entry>116.5</entry></row></tbody></tgroup></table></tables>
Manufacturing Procedure
0347The compound of Formula XIV is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures.
Example C
0348Suppositories of the following composition are manufactured: <tables id="tabl0005" num="0005"><table frame="all"><title><b><i>Table 5: possible suppository composition</i></b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="42mm" /><colspec colnum="2" colname="col2" colwidth="31mm" /><thead valign="top"><row><entry>ingredient</entry><entry>mg/supp.</entry></row></thead><tbody><row><entry>Compound of Formula XIV</entry><entry>15</entry></row><row><entry>Suppository mass</entry><entry>1285</entry></row><row><entry>Total</entry><entry>1300</entry></row></tbody></tgroup></table></tables>
Manufacturing Procedure
0349The suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45 °C. Thereupon, the finely powdered compound of Formula XIV is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository molds of suitable size, left to cool; the suppositories are then removed from the molds and packed individually in wax paper or metal foil.
Example D
0350Injection solutions of the following composition are manufactured: <tables id="tabl0006" num="0006"><table frame="all"><title><b><i>Table 6: possible injection solution composition</i></b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="42mm" /><colspec colnum="2" colname="col2" colwidth="36mm" /><thead valign="top"><row><entry>ingredient</entry><entry>mg/injection solution.</entry></row></thead><tbody><row><entry>Compound of Formula XIV</entry><entry>3</entry></row><row><entry>Polyethylene Glycol 400</entry><entry>150</entry></row><row><entry>acetic acid</entry><entry>q.s. ad pH 5.0</entry></row><row><entry>water for injection solutions</entry><entry>ad 1.0 ml</entry></row></tbody></tgroup></table></tables>
Manufacturing Procedure
0351The compound of Formula XIV is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part). The pH is adjusted to 5.0 by acetic acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.
Example
E
0352Sachets of the following composition are manufactured: <tables id="tabl0007" num="0007"><table frame="all"><title><b><i>Table 7: possible sachet composition</i></b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="66mm" /><colspec colnum="2" colname="col2" colwidth="22mm" /><thead valign="top"><row><entry>ingredient</entry><entry>mg/sachet</entry></row></thead><tbody><row><entry>Compound of Formula XIV</entry><entry>50</entry></row><row><entry>Lactose, fine powder</entry><entry>1015</entry></row><row><entry>Microcrystalline cellulose (AVICEL PH 102)</entry><entry>1400</entry></row><row><entry>Sodium carboxymethyl cellulose</entry><entry>14</entry></row><row><entry>Polyvinylpyrrolidon K 30</entry><entry>10</entry></row><row><entry>Magnesium stearate</entry><entry>10</entry></row><row><entry>Flavoring additives</entry><entry>1</entry></row><row><entry>Total</entry><entry>2500</entry></row></tbody></tgroup></table></tables>
Manufacturing Procedure
0353The compound of Formula XIV is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water. The granulate is mixed with magnesium stearate and the flavoring additives and filled into sachets.
VII. Use of Compounds
0354The compounds of of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) of the present invention bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The present compounds are thus useful for the treatment or prophylaxis of various cancers.
0355In one aspect, the present invention provides compounds of of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) as described herein for use as therapeutically active substance.
0356In a further aspect, the present invention provides compounds of of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) as defined herein, for use in the treatment or prophylaxis of cancer.
0357In a further aspect, the present invention provides the use of a compound of of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) as defined herein for the treatment or prophylaxis of cancer.
0358In a further aspect, the present invention provides a method of treating or preventing cancer, comprising administering a thereapeutically effective amount of a compound of of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) as defined herein to a subject.
0359In a further aspect, the present invention provides the use of a compound of of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) as defined herein for the manufacture of a medicament for the treatment or prophylaxis of cancer.
0360The compounds of of Formula I, Formulas II-a to II-k, Formula III, Formulas IV-a to IV-j, Formula V, Formula VI, Formulas VII-a to VII-e, Formulas VIII-a to VIII-i, Formulas IX-a to IX-j, Formulas X-a to X-i, Formulas XI-a to XI-i, Formula XII, Formulas XIII-a to XIII-i, Formula XIV, Formula I(1), Formulas II(1)-a to II(1)-k, Formula III(1), Formulas IV(1)-a to IV(1)-j, Formula V(1), Formula VI(1), Formulas VII(1)-a to VII(1)-e, Formulas VIII(1)-a to VIII(1)-i, Formulas IX(1)-a to IX(1)-j, Formulas X(1)-a to X(1)-i, Formulas XI(1)-a to XI(1)-i, Formula XII(1), Formulas XIII(1)-a to XIII(1)-i, or Formula XIV(1) may also be used to prepare bifunctional degrader compounds by linking them to a protein-targeting moiety that binds to a target protein or to a target polypeptide, in analogy to the bifunctional compounds which have been described e.g. in <patcit id="pcit0067" dnum="WO2013020557A"><text>WO2013020557</text></patcit>, <patcit id="pcit0068" dnum="WO2013063560A"><text>WO2013063560</text></patcit>, <patcit id="pcit0069" dnum="WO2013106643A"><text>WO 2013106643</text></patcit>, <patcit id="pcit0070" dnum="WO2015160845A"><text>WO2015160845</text></patcit>, <patcit id="pcit0071" dnum="WO2016011906A"><text>WO2016011906</text></patcit>, <patcit id="pcit0072" dnum="WO2016105518A"><text>WO2016105518</text></patcit>, <patcit id="pcit0073" dnum="WO2017007612A"><text>WO2017007612</text></patcit>, <patcit id="pcit0074" dnum="WO2017024318A"><text>WO2017024318</text></patcit>, and <patcit id="pcit0075" dnum="WO2017117473A"><text>WO2017117473</text></patcit>.
VIII. General Synthesis and Processes of Manufacture
0361The compounds described herein can be prepared by methods known by those skilled in the art. In one non-limiting example the disclosed compounds can be made by the schemes provided below.
0362The preparation of compounds of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the compounds of the invention are shown in the following schemes 1-3 and in the description of 27 specific examples. The skills required for carrying out the reaction and purification of the resulting products are known to those skilled in the art. The substituents and indices used in the following description of the processes have the significance given herein before unless indicated to the contrary.
0363In more detail, the compounds described herein can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. The reaction sequence is not limited to the one displayed in schemes 1-3, however, depending on the starting materials and their respective reactivity the sequence of reaction steps can be freely altered. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in references cited in the description or in the examples, or by methods known in the art. <chemistry id="chem0762" num="0762"><img file="EP4470618A2_D0762.tif" /></chemistry>
0364<b><i>Step A:</i></b> Nitro-amino-arene compound <b>3</b> can be obtained by an aromatic nucleophilic substitution (S<sub>N</sub>Ar) reaction between a 1,2-fluoro-nitro-arene <b>1</b> and an aromatic amine compound <b>2.</b>
0365Examples of suitable 1,2-fluoro-nitro-arenes <b>1</b> include, but are not limited to, 1-fluoro-2-nitrobenzene (<nplcit id="ncit0011" npl-type="c"><text>CAS 1493-27-2</text></nplcit>), 4-fluoro-<i>N</i>-methyl-3-nitrobenzamide (<nplcit id="ncit0012" npl-type="c"><text>CAS 475216-25-2</text></nplcit>) and methyl 4-fluoro-3-nitro-benzoate (<nplcit id="ncit0013" npl-type="c"><text>CAS 185629-31-6</text></nplcit>).
0366Examples of suitable aromatic amine compounds <b>2</b> include, but are not limited to, 6-amino-3<i>H</i>-1,3-benzoxazol-2-one (<nplcit id="ncit0014" npl-type="c"><text>CAS 22876-17-1</text></nplcit>), 6-amino-3<i>H</i>-1,3-benzothiazol-2-one (<nplcit id="ncit0015" npl-type="c"><text>CAS 56354-98-4</text></nplcit>), 5-aminoindolin-2-one (<nplcit id="ncit0016" npl-type="c"><text>CAS 20876-36-2</text></nplcit>), 5-amino-3,3-difluoro-indolin-2-one (<nplcit id="ncit0017" npl-type="c"><text>CAS 813424-17-8</text></nplcit>), 6-aminoindolin-2-one (<nplcit id="ncit0018" npl-type="c"><text>CAS 150544-04-0</text></nplcit>) and 5-amino-1,3-dihydropyrrolo[2,3-b]pyridin-2-one (<nplcit id="ncit0019" npl-type="c"><text>CAS 869371-00-6</text></nplcit>).
0367The S<sub>N</sub>Ar reaction is carried out in the presence of an organic base such as <i>N,N-</i>diisopropylethylamine, triethylamine or N-methylmorpholine in a polar aprotic organic solvent such as N-methyl-2-pyrrolidinone or N,N-dimethylformamide at elevated temperatures. Preferred conditions are <i>N</i>,<i>N-</i>diisopropylethylamine in N-methyl-2-pyrrolidinone at 120 °C for 3 hours.
0368<b><i>Step B:</i></b> Reduction of nitro-amino-arene compound <b>3</b> to diamino-arene <b>4</b> can be effected by hydrogenation with hydrogen under normal or elevated pressure in the presence of a catalyst such as PtO<sub>2</sub>, Pd-C or Raney nickel in polar solvents such as MeOH, EtOH, dioxane, THF, or mixtures thereof.
0369Preferred conditions are 1 atm of hydrogen in the presence of 10% palladium on charcoal in a mixture of methanol and THF at room temperature for 12 hours.
0370<b><i>Step</i> C:</b> Benzimidazole <b>7</b> can be obtained by cyclisation of diamino-arene <b>4</b> with an aldehyde <b>5</b> in the presence of sodium metabisulfite. The cyclisation reaction is carried out in a polar aprotic organic solvent such as N-methyl-2-pyrrolidinone or N,N-dimethylformamide at elevated temperatures. Preferred conditions are <i>N</i>,<i>N-</i>dimethylformamide at 120 °C for 1 hour.
0371Benzimidazole <b>7</b> can also be obtained by cyclisation of diamino-arene <b>4</b> with a carboxylic acid <b>6</b> in the presence of another acid. The cyclisation reaction is carried out in an aqueous solution of a strong acid such as HCl or H<sub>2</sub>SO<sub>4</sub>. Preferred conditions are 6 M aq. HCl at 120 °C for 12 hours. <chemistry id="chem0763" num="0763"><img file="EP4470618A2_D0763.tif" /></chemistry><ul id="ul0027" list-style="none" compact="compact"><li>R,R' = H, aryl, heterocycloalkyl, heteroaryl or form together with the nitrogen they are attached to a heterocycloalkyl or a heteroaryl, as defined herein</li><li>W, A<sup>1</sup>, A<sup>2</sup> = as decribed herein</li></ul>
0372<b><i>Step A:</i></b> Amide bond formation can be accomplished by a coupling reaction between a suitable carboxylic acid <b>8</b> and a primary or secondary amine <b>9</b> in the presence of a coupling reagent such as DCC, EDC, TBTU or HATU in the presence of an organic base such as triethylamine, <i>N,N</i>-diisopropylethylamine or <i>N</i>-methylmorpholine in halogenated solvents such as dichloromethane or 1,2-dichloroethane or ethereal solvents such as diethyl ether, dioxane, THF, DME or TBME or polar non-protic organic solvent such as <i>N,N-</i>dimethylformamide at room temperature or at elevated temperatures for 2-18 hours.
0373Examples of suitable carboxylic acids <b>8</b> include, but are not limited to, 2-oxo-3<i>H</i>-1,3-benzoxazole-6-carboxylic acid (<nplcit id="ncit0020" npl-type="c"><text>CAS 54903-16-1</text></nplcit>), 2-oxo-3<i>H</i>-1,3-benzothiazole-6-carboxylic acid (<nplcit id="ncit0021" npl-type="c"><text>CAS 99615-68-6</text></nplcit>), 2-oxoindoline-5-carboxylic acid (<nplcit id="ncit0022" npl-type="c"><text>CAS 102359-00-2</text></nplcit>), 2-oxo-3<i>H</i>-oxazolo[4,5-b]pyridine-6-carboxylic acid (<nplcit id="ncit0023" npl-type="c"><text>CAS 1555998-02-1</text></nplcit>) and 2-oxo-1,3-dihydropyrrolo[2,3-b]pyridine-5-carboxylic acid (<nplcit id="ncit0024" npl-type="c"><text>CAS 1260665-66-4</text></nplcit>).
0374Preferred conditions are HATU with <i>N</i>,<i>N</i>-diisopropylethylamine in <i>N,N-</i>dimethylformamide at room temperature for 4 hours. <chemistry id="chem0764" num="0764"><img file="EP4470618A2_D0764.tif" /></chemistry><ul id="ul0028" list-style="none" compact="compact"><li>R = as defined herein</li><li>W, A<sup>1</sup>, A<sup>2</sup> = as decribed herein</li></ul>
0375<b><i>Step A:</i></b> Amide bond formation can be accomplished by a coupling reaction between a suitable amine <b>2</b> and a carboxylic acid <b>11</b> in the presence of a coupling reagent such as DCC, EDC, TBTU or HATU in the presence of an organic base such as triethylamine, <i>N,N-</i>diisopropylethylamine or <i>N</i>-methylmorpholine in halogenated solvents such as dichloromethane or 1,2-dichloroethane or ethereal solvents such as diethyl ether, dioxane, THF, DME or TBME or polar non-protic organic solvent such as <i>N</i>,<i>N</i>-dimethylformamide at room temperature or at elevated temperatures for 2-18 hours.
0376Alternatively, amide bond formation can be accomplished by a coupling reaction between a suitable amine <b>2</b> and a carboxylic acid <b>11</b> in the presence of a coupling reagent such as DMTMM in alcoholic solvents such as methanol, ethanol, n-propanol or isopropanol at room temperature for 1-4 hours.
0377Examples of suitable aromatic amine compounds <b>2</b> include, but are not limited to, 6-amino-3<i>H</i>-1,3-benzoxazol-2-one (<nplcit id="ncit0025" npl-type="c"><text>CAS 22876-17-1</text></nplcit>), 6-amino-3<i>H</i>-1,3-benzothiazol-2-one (<nplcit id="ncit0026" npl-type="c"><text>CAS 56354-98-4</text></nplcit>), 5-aminoindolin-2-one (<nplcit id="ncit0027" npl-type="c"><text>CAS 20876-36-2</text></nplcit>), 5-amino-3,3-difluoro-indolin-2-one (<nplcit id="ncit0028" npl-type="c"><text>CAS 813424-17-8</text></nplcit>), 6-aminoindolin-2-one (<nplcit id="ncit0029" npl-type="c"><text>CAS 150544-04-0</text></nplcit>) and 5-amino-1,3-dihydropyrrolo[2,3-b]pyridin-2-one (<nplcit id="ncit0030" npl-type="c"><text>CAS 869371-00-6</text></nplcit>).
0378Preferred conditions are DMTMM in methanol at room temperature for 4 hours. <chemistry id="chem0765" num="0765"><img file="EP4470618A2_D0765.tif" /></chemistry>
0379A compound of Formula XIV(1) may be synthesized as shown in Scheme 4 by coupling an intermediate 14 (wherein X<sup>1</sup> is NR<sup>34</sup>, O, or S) with an intermediate 13 wherein LG<sup>1</sup> is an appropriate leaving group as would be understood by one of skill in the art, for example a halogen (e.g., Cl, Br, or I) or a sulfonate (for example -O(SO<sub>2</sub>)CH<sub>3</sub>, -O(SO<sub>2</sub>)CF<sub>3</sub>, or -O(SO<sub>2</sub>)(4-methylphenyl)) in the presence of an appropriate base (for example, an inorganic base such as sodium carbonate or sodium hydride or an organic base such as triethylamine, DIPEA, or DBU) in an organic solvent (for example dichloromethane, dimethylformamide, or dimethylsulfoxide) at room temperature for 1-24 hours. <chemistry id="chem0766" num="0766"><img file="EP4470618A2_D0766.tif" /></chemistry>
0380A compound of Formula XIV(1) may be synthesized as shown in Scheme 5 by coupling an intermediate 16 with a CG<sup>1</sup> group with an intermediate 17 with a CG<sup>2</sup> group in the presence of a palladium catalyst (for example Pd(PPh<sub>3</sub>)<sub>4</sub>, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, or similar catalyst as would be appropriately selected by a person of skill in the art) in an organic solvent at elevated temperature (for example, reflux of the organic solvent) for 1-48 hours. In some embodiments wherein X<sup>1</sup> is NR<sup>34</sup>, O, or S, CG<sup>1</sup> is H and CG<sup>2</sup> can be selected from -B(OH)<sub>2</sub>, -Zn(halogen), or Sn(alkyl)<sub>3</sub>. In some embodiments, wherein X<sup>1</sup> is CH<sub>2</sub>, CHR<sup>34</sup>, or C(R<sup>34</sup>)<sub>2</sub>, CG<sup>1</sup> is selected from a halogen or sulfonate and CG<sup>2</sup> can be selected from -B(OH)<sub>2</sub>, -Zn(halogen), or Sn(alkyl)<sub>3</sub>. In other embodiments, wherein X<sup>1</sup> is CH<sub>2</sub>, CHR<sup>34</sup>, or C(R<sup>34</sup>)<sub>2</sub>, CG<sup>1</sup> can be selected from -B(OH)<sub>2</sub>, - Zn(halogen), or Sn(alkyl)<sub>3</sub> and CG<sup>2</sup> can be selected from halogen or sulfonate. <chemistry id="chem0767" num="0767"><img file="EP4470618A2_D0767.tif" /></chemistry>
0381A compound 21 of Formula XIV(1) may be synthesized as shown in Scheme 6 by a sequential Heck reaction followed by a hydrogenation or other appropriate reduction. In Step A, heterocycloalkene 18 containing a CG<sup>1</sup> group is reacted with bromide 19 in the presence of a palladium catalyst (for example, Pd(dppf)Cl<sub>2</sub> or similar catalyst as would be appropriately selected by a person of skill in the art) and base (for example, sodium carbonate) in an organic solvent (for example, 1,4-dioxane) at elevated temperature (for example, 80 °C) for 1-24 hours. In one embodiment of Step A, the CG<sup>1</sup> group is a pinacolatoboron group. In Step B, heterocycloalkene 20 is reacted under a hydrogen atmosphere with palladium on carbon catalyst in organic solvent (for example, ethanol) for 1-48 hours. The heterocycloalkene group of 18 can be substituted by any cycloalkene or heterocycloalkene group as would be understood to be appropriate by a person having ordinary skill in the art. <chemistry id="chem0768" num="0768"><img file="EP4470618A2_D0768.tif" /></chemistry>
0382A compound 24 of Formula XIV(1) may be synthesized as shown in Scheme 7 by a Heck reaction followed by a hydrogenation or other appropriate reduction. In Step A, alkene 22 is reacted with bromide 19 in the presence of a palladium catalyst (for example, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> or similar catalyst as would be appropriately selected by a person of skill in the art) and base (for example, triethylamine) in an organic solvent (for example, DMF) at elevated temperature (for example, 90 °C) for 1-24 hours. In Step B, alkene 23 is reacted under a hydrogen atmosphere with palladium on carbon catalyst in organic solvent (for example, ethanol) for 1-48 hours. <chemistry id="chem0769" num="0769"><img file="EP4470618A2_D0769.tif" /></chemistry>
0383A compound 28 of Formula XIV(1) may be synthesized as shown in Scheme 8 by an azide-alkyne Huisgen cycloaddition sequence. In Step A, alcohol 25 is reacted with propargyl bromide in the presence of base (for example, cesium carbonate) in organic solvent (for example, DMF) at room temperature for 1-24 hours. In Step B, alkyne 27 is reacted with azide 27 in the presence of copper sulfate and sodium ascorbate in organic solvent (for example, DMSO). <chemistry id="chem0770" num="0770"><img file="EP4470618A2_D0770.tif" /></chemistry>
0384A compound 30 of Formula XIV(1) may be synthesized as shown in Scheme 9 by reacting a carboxylic acid 29 and an alcohol 25 in the presence of a coupling agent (for example, a mixture of 2,4,6-trichlorobenzoyl chloride and 4-dimethylaminopyridine) and a base (for example, triethylamine) in organic solvent (for example, THF) at room temperature for 1-24 hours. In some embodiment, the alcohol group of 25 may be substituted by an amino or thio group as would be readily understood by a person of skill in the art. <chemistry id="chem0771" num="0771"><img file="EP4470618A2_D0771.tif" /></chemistry>
0385A compound 32 of Formula XIV(1) may be synthesized as shown in Scheme 10 by a Mitsunobu reaction by reacting an alcohol 31 with a second alcohol 25 in the presence of a phosphine (for example, triphenylphosphine) and an azodicarboxylate compound (for example, DEAD or DIAD) in organic solvent (for example, THF) at elevated temperature (for example, reflux) for 1-24 hours. <chemistry id="chem0772" num="0772"><img file="EP4470618A2_D0772.tif" /></chemistry>
0386A compound 35 of Formula XIV(1) may be synthesized as shown in Scheme 11 by reductive amination by reacting a piperidine 33 with an aldehyde 34 in the presence of sodium triacetoxyborohydride and acetic acid optionally in an organic solvent (for example THF) at room temperature for 1-24 hours. In one embodiment, the piperidine group of compound 33 can be substituted with a heterocyclic amine group of different size or substitution as would be readily apparent to a person of ordinary skill in the art. <chemistry id="chem0773" num="0773"><img file="EP4470618A2_D0773.tif" /></chemistry>
0387A compound 38 of Formula XIV(1) may be synthesized as shown in Scheme 12 by reacting a carboxylic acid 36 with a piperidine 37 in the presence of a coupling agent (for example, COMU) and a base (for example, diisopropylethylamine) in organic solvent (for example, DMF) at room temperature for 1-24 hours. In one embodiment, the piperidine group of compound 37 can be substituted by a heterocyclic amine group of different size or substitution as would be readily apparent to a person of ordinary skill in the art. <chemistry id="chem0774" num="0774"><img file="EP4470618A2_D0774.tif" /></chemistry>
0388A compound 41 of Formula XIV(1) may be synthesized as shown in Scheme 13 by reacting an amine 39 with compound 40 substituted with a leaving group (LG), for example a bromide, iodide, or sulfonate group, in the presence of a base (for example, diisopropylethylamine) in organic solvent (for example, DMF) at elevated temperature (for example, 60 °C) for 1-24 hours. In some embodiments, the amino group of 39 can be substituted by an alcohol or thio group as would be readily understood by a person of skill in the art. <chemistry id="chem0775" num="0775"><img file="EP4470618A2_D0775.tif" /></chemistry>
0389A compound 44 of Formula XIV(1) may be synthesized as shown in Scheme 14 by a Sonagashira reaction by reacting a terminal alkyne 41 with a bromide 43 in the presence of a copper(I) catalyst (for example, CuI) and a palladium catalyst (for example, Pd(PPh<sub>3</sub>)<sub>4</sub>) in the presence of a base (for example, triethylamine) in organic solvent (for example, DMF) at elevated temperature (for example, 80 °C) for 1-24 hours.
Isolation and purification of the Compounds
0390Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the preparations and examples herein below. However, other equivalent separation or isolation procedures could, of course, also be used. Racemic mixtures of chiral compounds of Formula XIV can be separated using chiral HPLC. Racemic mixtures of chiral synthetic intermediates may also be separated using chiral HPLC.
0391In cases where the compounds of Formula XIV are basic they may be converted to a corresponding acid addition salt. The conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Typically, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent. The temperature is maintained between 0 °C and 50 °C. The resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.
0392Insofar as their preparation is not described in the examples, the compounds of Formula XIV as well as all intermediate products can be prepared according to analogous methods or according to the methods set forth herein. Starting materials are commercially available, known in the art or can be prepared by methods known in the art or in analogy thereto.
0393It will be appreciated that the compounds of general Formula XIV in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound <i>in vivo.</i>
Stereochemistry
0394Compounds of the present invention with stereocenters may be drawn without stereochemistry for convenience. One skilled in the art will recognize that pure enantiomers and diastereomers can be prepared by methods known in the art. Examples of methods to obtain optically active materials include at least the following. <ol id="ol0013" compact="compact"><li>i) physical separation of crystals-a technique whereby macroscopic crystals of the individual enantiomers are manually separated. This technique can be used if crystals of the separate enantiomers exist, i.e., the material is a conglomerate, and the crystals are visually distinct;</li><li>ii) simultaneous crystallization-a technique whereby the individual enantiomers are separately crystallized from a solution of the racemate, possible only if the latter is a conglomerate in the solid state;</li><li>iii) enzymatic resolutions-a technique whereby partial or complete separation of a racemate by virtue of differing rates of reaction for the enantiomers with an enzyme;</li><li>iv) enzymatic asymmetric synthesis-a synthetic technique whereby at least one step of the synthesis uses an enzymatic reaction to obtain an enantiomerically pure or enriched synthetic precursor of the desired enantiomer;</li><li>v) chemical asymmetric synthesis-a synthetic technique whereby the desired enantiomer is synthesized from an achiral precursor under conditions that produce asymmetry (i.e., chirality) in the product, which may be achieved using chiral catalysts or chiral auxiliaries;</li><li>vi) diastereomer separations-a technique whereby a racemic compound is reacted with an enantiomerically pure reagent (the chiral auxiliary) that converts the individual enantiomers to diastereomers. The resulting diastereomers are then separated by chromatography or crystallization by virtue of their now more distinct structural differences and the chiral auxiliary later removed to obtain the desired enantiomer;</li><li>vii) first- and second-order asymmetric transformations-a technique whereby diastereomers from the racemate equilibrate to yield a preponderance in solution of the diastereomer from the desired enantiomer or where preferential crystallization of the diastereomer from the desired enantiomer perturbs the equilibrium such that eventually in principle all the material is converted to the crystalline diastereomer from the desired enantiomer. The desired enantiomer is then released from the diastereomer;</li><li>viii) kinetic resolutions-this technique refers to the achievement of partial or complete resolution of a racemate (or of a further resolution of a partially resolved compound) by virtue of unequal reaction rates of the enantiomers with a chiral, non-racemic reagent or catalyst under kinetic conditions;</li><li>ix) enantiospecific synthesis from non-racemic precursors-a synthetic technique whereby the desired enantiomer is obtained from non-chiral starting materials and where the stereochemical integrity is not or is only minimally compromised over the course of the synthesis;</li><li>x) chiral liquid chromatography-a technique whereby the enantiomers of a racemate are separated in a liquid mobile phase by virtue of their differing interactions with a stationary phase (including via chiral HPLC). The stationary phase can be made of chiral material or the mobile phase can contain an additional chiral material to provoke the differing interactions;</li><li>xi) chiral gas chromatography-a technique whereby the racemate is volatilized and enantiomers are separated by virtue of their differing interactions in the gaseous mobile phase with a column containing a fixed non-racemic chiral adsorbent phase;</li><li>xii) extraction with chiral solvents-a technique whereby the enantiomers are separated by virtue of preferential dissolution of one enantiomer into a particular chiral solvent;</li><li>xiii) transport across chiral membranes-a technique whereby a racemate is placed in contact with a thin membrane barrier. The barrier typically separates two miscible fluids, one containing the racemate, and a driving force such as concentration or pressure differential causes preferential transport across the membrane barrier. Separation occurs as a result of the non-racemic chiral nature of the membrane that allows only one enantiomer of the racemate to pass through.</li><li>xiv) simulated moving bed chromatography, is used in one embodiment. A wide variety of chiral stationary phases are commercially available.</li></ol>
REPRESENTATIVE EXAMPLES OF THE PRESENT INVENTION
0395The invention will be more fully understood by reference to the following examples. The claims should not, however, be construed as limited to the scope of the examples.
0396In case the preparative examples are obtained as a mixture of enantiomers, the pure enantiomers can be separated by methods described herein or by methods known to the man skilled in the art, such as e.g., chiral chromatography (e.g., chiral SFC or chiral HPLC) or crystallization.
0397All reaction examples and intermediates were prepared under a nitrogen atmosphere if not specified otherwise.
<b>Example</b> 1
<i>N</i>-(2-Oxo-3<i>H</i>-1,3-benzoxazol-6-yl)benzamide
0398<chemistry id="chem0776" num="0776"><img file="EP4470618A2_D0776.tif" /></chemistry>
0399The title compound (<nplcit id="ncit0031" npl-type="c"><text>CAS 932474-64-1</text></nplcit>) can be purchased from commercial vendors as listed, for instance, in chemical databases such as SciFinder<sup>®</sup> (American Chemical Society).
<i>Example 2</i>
N (2-Oxoindolin-5-yl)furan-2-carboxamide
0400<chemistry id="chem0777" num="0777"><img file="EP4470618A2_D0777.tif" /></chemistry>
0401The title compound (<nplcit id="ncit0032" npl-type="c"><text>CAS 921814-32-6</text></nplcit>) can be purchased from commercial vendors as listed, for instance, in chemical databases such as SciFinder<sup>®</sup> (American Chemical Society).
<b>Example</b> 3
2-(2-Methylphenoxy)-N (2-oxo-3H 1,3-benzothiazol-6-yl)acetamide
0402<chemistry id="chem0778" num="0778"><img file="EP4470618A2_D0778.tif" /></chemistry>
0403The title compound (<nplcit id="ncit0033" npl-type="c"><text>CAS 931736-40-2</text></nplcit>) can be purchased from commercial vendors as listed, for instance, in chemical databases such as SciFinder<sup>®</sup> (American Chemical Society).
<i>Example 4</i>
2-Isopropyl-N methyl-1-(2-oxoindolin-6-yl)benzimidazole-5-carboxamide
0404<chemistry id="chem0779" num="0779"><img file="EP4470618A2_D0779.tif" /></chemistry>
a) <i>N</i>-
Methyl-3-nitro-4-[(2-oxoindolin-6-yl)amino]benzamide
0405A stirred solution of 4-fluoro-N-methyl-3-nitrobenzamide (1264 mg, <nplcit id="ncit0034" npl-type="c"><text>CAS 475216-25-2</text></nplcit>), 6-aminoindolin-2-one (151 mg, <nplcit id="ncit0035" npl-type="c"><text>CAS 150544-04-0</text></nplcit>) and N,N-diisopropylethylamine (1.59 ml) in N-methyl-2-pyrrolidinone (20 ml) was heated at 120 °C for three hours. The reaction mixture was then cooled to room temperature and poured into water and extracted three times with ethyl acetate. The combined organic layers were dried with sodium sulfate, filtered, and dried <i>in vacuo</i> to afford N-methyl-3-nitro-4-[(2-oxoindolin-6-yl)amino]benzamide (1800 mg, 36%) as a black oil which was used in the next step without further purification. MS (ISP): 327.2 ([M+H]<sup>+</sup>).
b) 3-Amino-<i>N</i>-methyl-4-[(2-oxoindolin-6-yl)amino]benzamide
0406To a stirred suspension of N-methyl-3-nitro-4-[(2-oxoindolin-6-yl)amino]benzamide (1800 mg) in methanol (20 ml) and THF (20 ml) was added 10% palladium on charcoal (200 mg). The reaction mixture was stirred at room temperature for 12 hours under an atmosphere of hydrogen. The catalyst was collected by filtration, washing with methanol. The filtrate was then concentrated <i>in vacuo.</i> The crude material was purified by flash chromatography (silica gel, eluent: 0 to 10% of methanol in dichloromethane) to afford 3-amino-N-methyl-4-[(2-oxoindolin-6-yl)amino]benzamide (800 mg, 49%) as a brown solid. MS (ISP): 297.2 ([M+H]<sup>+</sup>).
c) 2-Isopropyl-<i>N</i>-methyl-1-(2-oxoindolin-6-yl)benzimidazole-5-carboxamide
0407To a stirred solution of 3-amino-N-methyl-4-[(2-oxoindolin-6-yl)amino]benzamide (199 mg) and isobutyraldehyde (48.5 mg, <nplcit id="ncit0036" npl-type="c"><text>CAS 78-84-2</text></nplcit>) in <i>N</i>,<i>N</i>-dimethylformamide (10 ml) was added sodium metabisulfite (153.4 mg) at room temperature. The reaction mixture was then heated at 120 °C for 1 hour. Subsequent TLC and LC-MS analysis showed the reaction was complete. The reaction mixture was poured into water and extracted three times with ethyl acetate. The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo.</i> The crude material was purified by preparative reversed phase HPLC to afford 2-isopropyl-N-methyl-1-(2-oxoindolin-6-yl)benzimidazole-5-carboxamide (90 mg, 35%) as a brown solid. MS (ISP): 349.1 ([M+H]<sup>+</sup>).
<i>Example 5</i>
2-Isopropyl-N methyl-1-(2-oxoindolin-5-yl)benzimidazole-5-carboxamide
0408<chemistry id="chem0780" num="0780"><img file="EP4470618A2_D0780.tif" /></chemistry>
0409The title compound was obtained in analogy to example 4 using 5-aminoindolin-2-one (<nplcit id="ncit0037" npl-type="c"><text>CAS 20876-36-2</text></nplcit>) in place of 6-aminoindolin-2-one for step a. White solid. MS (ISP): 349.1 ([M+H]<sup>+</sup>).
<i>Example 6</i>
6-(2-Aminoanilino)-3<i>H</i>-1,3-benzothiazol-2-one
0410<chemistry id="chem0781" num="0781"><img file="EP4470618A2_D0781.tif" /></chemistry>
0411The title compound was obtained in analogy to example 4 steps a and b using 1-fluoro-2-nitrobenzene (<nplcit id="ncit0038" npl-type="c"><text>CAS 1493-27-2</text></nplcit>) in place of 4-fluoro-N-methyl-3-nitrobenzamide and 6-aminobenzo[d]thiazol-2(3<i>H</i>)-one (<nplcit id="ncit0039" npl-type="c"><text>CAS 56354-98-4</text></nplcit>) in place of 6-aminoindolin-2-one in step a. Brown solid. MS (ISP): 258.3 ([M+H]<sup>+</sup>).
<i>Example 7</i>
6-(2-Isopropylbenzimidazol-1-yl)-3<i>H</i>-1,3-benzothiazol-2-one
0412<chemistry id="chem0782" num="0782"><img file="EP4470618A2_D0782.tif" /></chemistry>
0413The title compound was obtained in analogy to example 4 step c using 6-(2-Aminoanilino)-3H-1,3-benzothiazol-2-one in place of 3-amino-N-methyl-4-[(2-oxoindolin-6-yl)amino]benzamide. White solid. MS (ISP): 310.2 ([M+H]<sup>+</sup>).
<i>Example 8</i>
6-(2-Aminoanilino)-3<i>H-</i>1,3-benzoxazol-2-one
0414<chemistry id="chem0783" num="0783"><img file="EP4470618A2_D0783.tif" /></chemistry>
0415The title compound was obtained in analogy to example 4 steps a and b using 1-fluoro-2-nitrobenzene (<nplcit id="ncit0040" npl-type="c"><text>CAS 1493-27-2</text></nplcit>) in place of 4-fluoro-N-methyl-3-nitrobenzamide and 6-aminobenzo[d]oxazol-2(3<i>H</i>)-one (<nplcit id="ncit0041" npl-type="c"><text>CAS 22876-17-1</text></nplcit>) in place of 6-aminoindolin-2-one in step a. Brown solid. MS (ISP): 242.2 ([M+H]+).
<i>Example 9</i>
6-(2-Isopropylbenzimidazol-1-yl)-3H 1,3-benzoxazol-2-one
0416<chemistry id="chem0784" num="0784"><img file="EP4470618A2_D0784.tif" /></chemistry>
0417The title compound was obtained in analogy to example 4 step c using 6-(2-aminoanilino)-3H-1,3-benzoxazol-2-one in place of 3-amino-<i>N</i>-methyl-4-[(2-oxoindolin-6-yl)amino]benzamide. White solid. MS (ISP): 294.3 ([M+H]<sup>+</sup>).
<i>Example 10</i>
2-Oxo-N-phenylindoline-5-carboxamide
0418<chemistry id="chem0785" num="0785"><img file="EP4470618A2_D0785.tif" /></chemistry>
0419The title compound (<nplcit id="ncit0042" npl-type="c"><text>CAS 1168720-81-7</text></nplcit>) can be purchased from commercial vendors as listed, for instance, in chemical databases such as SciFinder<sup>®</sup> (American Chemical Society).
<i>Example 11</i>
2-Oxo-<i>N-</i>phenyl-3<i>H-</i>1,3-benzoxazole-6-carboxamide
0420<chemistry id="chem0786" num="0786"><img file="EP4470618A2_D0786.tif" /></chemistry>
0421The title compound (<nplcit id="ncit0043" npl-type="c"><text>CAS 1791206-26-2</text></nplcit>) can be purchased from commercial vendors as listed, for instance, in chemical databases such as SciFinder<sup>®</sup> (American Chemical Society).
<i>Example 12</i>
<i>N</i>-(1-Acetyl-4-piperidyl)-2-oxo-3<i>H-</i>1,3-benzoxazole-6-carboxamide
0422<chemistry id="chem0787" num="0787"><img file="EP4470618A2_D0787.tif" /></chemistry>
0423To a mixture of 1-(4-aminopiperidin-1-yl)ethan-1-one (50 mg, <nplcit id="ncit0044" npl-type="c"><text>CAS 160357-94-8</text></nplcit>) and 2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxylic acid (69.3 mg, <nplcit id="ncit0045" npl-type="c"><text>CAS 54903-16-1</text></nplcit>) was added dropwise <i>N</i>,<i>N</i>-diisopropylethylamine (181 µl) followed by a solution of HATU in <i>N,N-</i>dimethylformamide (245 mg, 1.8 ml, 0.358 M solution). The reaction mixture was shaken at 25 °C for 4 hours. The reaction mixture was directly purified by preparative HPLC followed by lyophilisation to afford N-(1-acetyl-4-piperidyl)-2-oxo-3H-1,3-benzoxazole-6-carboxamide (45.5 mg, 43%) as a white solid. MS (ISP): 304.2 ([M+H]<sup>+</sup>).
<i>Example 13</i>
6-(Indoline-1-carbonyl)-3<i>H-</i>1,3-benzoxazol-2-one
0424<chemistry id="chem0788" num="0788"><img file="EP4470618A2_D0788.tif" /></chemistry>
0425The title compound (<nplcit id="ncit0046" npl-type="c"><text>CAS 1787518-86-8</text></nplcit>) can be purchased from commercial vendors as listed, for instance, in chemical databases such as SciFinder<sup>®</sup> (American Chemical Society).
<i>Example 14</i>
6-(2,3-Dihydropyrrolo[2,3-b]pyridine-1-carbonyl)-3<i>H</i>-1,3-benzoxazol-2-one
0426<chemistry id="chem0789" num="0789"><img file="EP4470618A2_D0789.tif" /></chemistry>
0427The title compound was obtained in analogy to example 12 using 2,3-dihydro-1<i>H-</i>pyrrolo[2,3-b]pyridine (<nplcit id="ncit0047" npl-type="c"><text>CAS 10592-27-5</text></nplcit>) in place of 1-(4-aminopiperidin-1-yl)ethan-1-one. White solid. MS (ISP): 282.1 ([M+H]<sup>+</sup>).
<i>Example 15</i>
2-Oxo-<i>N</i>-phenyl-3<i>H</i>-1,3-benzothiazole-6-carboxamide
0428<chemistry id="chem0790" num="0790"><img file="EP4470618A2_D0790.tif" /></chemistry>
0429The title compound (<nplcit id="ncit0048" npl-type="c"><text>CAS 503443-01-4</text></nplcit>) can be purchased from commercial vendors as listed, for instance, in chemical databases such as SciFinder<sup>®</sup> (American Chemical Society).
<i>Example 16</i>
6-(Indoline-1-carbonyl)-3<i>H-</i>1,3-benzothiazol-2-one
0430<chemistry id="chem0791" num="0791"><img file="EP4470618A2_D0791.tif" /></chemistry>
0431The title compound was obtained in analogy to example 12 using indoline (<nplcit id="ncit0049" npl-type="c"><text>CAS 496-15-1</text></nplcit>) in place of 1-(4-aminopiperidin-1-yl)ethan-1-one and 2-oxo-2,3-dihydrobenzo[d]thiazole-6-carboxylic acid (<nplcit id="ncit0050" npl-type="c"><text>CAS 99615-68-6</text></nplcit>) in place of 2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxylic acid. White solid. MS (ISP): 297.2 ([M+H]<sup>+</sup>).
<i>Example 17</i>
5-(Indoline-1-carbonyl)indolin-2-one
0432<chemistry id="chem0792" num="0792"><img file="EP4470618A2_D0792.tif" /></chemistry>
0433The title compound was obtained in analogy to example 12 using indoline (<nplcit id="ncit0051" npl-type="c"><text>CAS 496-15-1</text></nplcit>) in place of 1-(4-aminopiperidin-1-yl)ethan-1-one and 2-oxoindoline-5-carboxylic acid (<nplcit id="ncit0052" npl-type="c"><text>CAS 102359-00-2</text></nplcit>) instead of 2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxylic acid. White solid. MS (ISP): 279.3 ([M+H]<sup>+</sup>).
<i>Example 18</i>
2-Oxo-<i>N</i>-phenyl-3<i>H</i>-oxazolo[4,5-b]pyridine-6-carboxamide
0434<chemistry id="chem0793" num="0793"><img file="EP4470618A2_D0793.tif" /></chemistry>
0435The title compound was obtained in analogy to example 12 using aniline in place of 1-(4-aminopiperidin-1-yl)ethan-1-one and 2-oxo-2,3-dihydrooxazolo[4,5-b]pyridine-6-carboxylic acid (<nplcit id="ncit0053" npl-type="c"><text>CAS 1555998-02-1</text></nplcit>) instead of 2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxylic acid. White solid. MS (ISP): 256.3 ([M+H]<sup>+</sup>).
<i>Example 19</i>
N (1-Acetyl-4-piperidyl)-2-oxo-3H oxazolo[4,5-b]pyridine-6-carboxamide
0436<chemistry id="chem0794" num="0794"><img file="EP4470618A2_D0794.tif" /></chemistry>
0437The title compound was obtained in analogy to example 12 using 2-oxo-2,3-dihydrooxazolo[4,5-b]pyridine-6-carboxylic acid (<nplcit id="ncit0054" npl-type="c"><text>CAS 1555998-02-1</text></nplcit>) instead of 2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxylic acid. White solid. MS (ISP): 305.3 ([M+H]<sup>+</sup>).
<i>Example 20</i>
5-(Indoline-1-carbonyl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one
0438<chemistry id="chem0795" num="0795"><img file="EP4470618A2_D0795.tif" /></chemistry>
0439The title compound was obtained in analogy to example 12 using indoline (<nplcit id="ncit0055" npl-type="c"><text>CAS 496-15-1</text></nplcit>) in place of 1-(4-aminopiperidin-1-yl)ethan-1-one and 2-oxo-2,3-dihydro-1<i>H</i>-pyrrolo[2,3-b]pyridine-5-carboxylic acid (<nplcit id="ncit0056" npl-type="c"><text>CAS 1260665-66-4</text></nplcit>) instead of 2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxylic acid. White solid. MS (ISP): 280.2 ([M+H]<sup>+</sup>).
<i>Example 21</i>
3,3-Difluoro-5-(2-isopropylbenzimidazol-1-yl)indolin-2-one
0440<chemistry id="chem0796" num="0796"><img file="EP4470618A2_D0796.tif" /></chemistry>
0441The title compound was obtained in analogy to example 4 using using 1-fluoro-2-nitrobenzene (<nplcit id="ncit0057" npl-type="c"><text>CAS 1493-27-2</text></nplcit>) in place of 4-fluoro-N-methyl-3-nitrobenzamide and 5-amino-3,3-difluoroindolin-2-one (<nplcit id="ncit0058" npl-type="c"><text>CAS 813424-17-8</text></nplcit>) in place of 6-aminoindolin-2-one in step a. White solid. MS (ISP): 328.1 ([M+H]<sup>+</sup>).
<i>Example 22</i>
6-(4-Hydroxyisoindoline-2-carbonyl)-3H-1,3-benzoxazol-2-one
0442<chemistry id="chem0797" num="0797"><img file="EP4470618A2_D0797.tif" /></chemistry>
0443The title compound was obtained in analogy to example 12 using isoindolin-4-ol hydrochloride (<nplcit id="ncit0059" npl-type="c"><text>CAS 72695-20-6</text></nplcit>) in place of 1-(4-aminopiperidin-1-yl)ethan-1-one. White solid. MS (ISP): 295.2 ([M-H]<sup>-</sup>).
<i>Example 23</i>
6-(4-Nitroisoindoline-2-carbonyl)-3H 1,3-benzoxazol-2-one
0444<chemistry id="chem0798" num="0798"><img file="EP4470618A2_D0798.tif" /></chemistry>
0445The title compound was obtained in analogy to example 12 using 4-nitroisoindoline hydrochloride (<nplcit id="ncit0060" npl-type="c"><text>CAS 1159826-78-4</text></nplcit>) in place of 1-(4-aminopiperidin-1-yl)ethan-1-one. White solid. MS (ISP): 326.5 ([M+H]<sup>+</sup>).
<i>Example 24</i>
N (3,3-difluoro-2-oxo-indolin-5-yl)tetralin-1-carboxamide
0446<chemistry id="chem0799" num="0799"><img file="EP4470618A2_D0799.tif" /></chemistry>
0447To a stirred solution of 1,2,3,4-tetrahydronaphthalene-1-carboxylic acid (47.8 mg, <nplcit id="ncit0061" npl-type="c"><text>CAS 1914-65-4</text></nplcit>) and 5-amino-3,3-difluoroindolin-2-one (50 mg, <nplcit id="ncit0062" npl-type="c"><text>CAS 813424-17-8</text></nplcit>) in methanol (1.67 ml) at room temperature was added DMTMM (90.2 mg, <nplcit id="ncit0063" npl-type="c"><text>CAS 3945-69-5</text></nplcit>). The reaction mixture was stirred at room temperature for 4 h. The reaction mixture was then poured into 20 ml brine and extracted twice with EtOAc/THF (1:1). The organic layers were dried over sodium sulfate and concentrated <i>in vacuo.</i> The crude material was purified by preparative HPLC (Gemini NX, 12 nm, 5 µm, 100 x 30 mm, flow rate: 40 ml/min, eluant: CH<sub>3</sub>CN/H<sub>2</sub>O+Et<sub>3</sub>N). The product was lyophilised to afford N-(3,3-difluoro-2-oxo-indolin-5-yl)tetralin-1-carboxamide (16 mg, 17%) as a light orange solid. MS (ISP): 343.1 ([M+H]<sup>+</sup>).
<i>Example 25</i>
N (3,3-Difluoro-2-oxo-indolin-5-yl)benzofuran-3-carboxamide
0448<chemistry id="chem0800" num="0800"><img file="EP4470618A2_D0800.tif" /></chemistry>
0449The title compound was obtained in analogy to example 24 using benzofuran-3-carboxylic acid (<nplcit id="ncit0064" npl-type="c"><text>CAS 26537-68-8</text></nplcit>) in place of 1,2,3,4-tetrahydronaphthalene-1-carboxylic acid. White solid. MS (ISP): 327.1 ([M-H]<sup>-</sup>).
<i>Example 26</i>
2-Isopropyl-N methyl-1-(2-oxo-1,3-dihydropyrrolo[2,3-b]pyridin-5-yl)benzimidazole-5-carboxamide
0450<chemistry id="chem0801" num="0801"><img file="EP4470618A2_D0801.tif" /></chemistry>
a) <i>N</i>-Methyl-3-nitro-4-(1<i>H</i>-pyrrolo[2,3-b]pyridin-5-ylamino)benzamide
0451The title compound was obtained in analogy to example 4 step a using 1<i>H</i>-pyrrolo[2,3-b]pyridin-5-amine (<nplcit id="ncit0065" npl-type="c"><text>CAS 100960-07-4</text></nplcit>) in place of 6-aminoindolin-2-one for step a. Red solid. MS (ISP): 312.0([M+H]<sup>+</sup>).
b) 4-[(3,3-Dibromo-2-oxo-1<i>H</i>-pyrrolo[2,3-b]pyridin-5-yl)amino]-<i>N</i>-methyl-3-nitro-benzamide
0452To a stirred solution of <i>N-</i>methyl-3-nitro-4-(1<i>H</i>-pyrrolo[2,3-b]pyridin-5-ylamino)benzamide (3.0 g) in tert-butanol (100 ml) was added in small portions pyridinium tribromide (8.32 g) over 7 min. The reaction was stirred at 25 °C for 12 hours. According to TLC the reaction was finished. The solvent was removed by concentration <i>in vacuo</i> and the resulting residue was dissolved in a 1:1 mixture of ethyl acetate/water (400 ml). The organic layer was separated and the aqueous layer was further extracted with ethyl acetate (2 x 100 ml). The combined organic extracts were washed sequentially with water and with saturated brine, then dried over magnesium sulfate and concentrated <i>in vacuo</i> to afford 4-[(3,3-dibromo-2-oxo-1<i>H-</i>pyrrolo[2,3-b]pyridin-5-yl)amino]-N-methyl-3-nitro-benzamide (2.2 g, 18%). Brown solid. MS (ISP): 485.9 ([M+H]<sup>+</sup>).
c) 3-Amino-<i>N</i>-methyl-4-[(2-oxo-1,3-dihydropyrrolo[2,3-b]pyndin-5-yl)amino]benzamide
0453To a stirred solution of 4-[(3,3-dibromo-2-oxo-1<i>H</i>-pyrrolo[2,3-b]pyridin-5-yl)amino]-<i>N-</i>methyl-3-nitro-benzamide (1g) in a 1:1 mixture of methanol/THF (20 ml) at room temperature was added 10% palladium on charcoal (120 mg). The reaction mixture was hydrogenated at room temperature under an atmosphere of hydrogen. After stirring vigorously for 3 hours, the catalyst was collected by filtration, washing with methanol. The filtrate was then concentrated <i>in vacuo.</i> The crude material was purified by column chromatography (SiO<sub>2</sub>, petrol ether/ethylacetate 1: 1) to afford 3-amino-N-methyl-4-[(2-oxo-1,3-dihydropyrrolo[2,3-b]pyridin-5-yl)amino]benzamide (500 mg, 89%) as a brown solid. MS (ISP): 298.8 ([M+H]<sup>+</sup>).
d) 2- Isopropyl-<i>N</i>-methyl-1-(2-oxo-1,3-dihydropyrrolo[2,3-b]pyridin-5-yl)benzimidazole-5-carboxamide
0454The title compound was obtained in analogy to example 4 step c using 3-amino-N-methyl-4-[(2-oxo-1,3-dihydropyrrolo[2,3-b]pyridin-5-yl)amino]benzamide in place of 3-amino-N-methyl-4-[(2-oxoindolin-6-yl)amino]benzamide. Brown oil. MS (ISP): 350.3 ([M+H]<sup>+</sup>).
<i>Example 27</i>
5-(2-Isopropylbenzimidazol-1-yl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one
0455<chemistry id="chem0802" num="0802"><img file="EP4470618A2_D0802.tif" /></chemistry>
0456The title compound was obtained in analogy to example 26 using 1-fluoro-2-nitrobenzene (<nplcit id="ncit0066" npl-type="c"><text>CAS 1493-27-2</text></nplcit>) in place of 4-fluoro-N-methyl-3-nitrobenzamide for step a. Green solid. MS (ISP): 293.3 ([M+H]<sup>+</sup>).
<i>Example 28</i>
5-(5-(Piperidin-4-yl)indoline-1-carbonyl)-1,3-dihydro-2<i>H</i>-pyrrolo[2,3-b]pyridin-2-one
0457<chemistry id="chem0803" num="0803"><img file="EP4470618A2_D0803.tif" /></chemistry>
Step 1: 5-(5-Bromoindoline-1-carbonyl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one
0458The title compound is obtained in analogy to example 12 using 5-bromoindoline (<nplcit id="ncit0067" npl-type="c"><text>CAS 22190-33-6</text></nplcit>) in place of 1-(4-aminopiperidin-1-yl)ethan-1-one and 2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (<nplcit id="ncit0068" npl-type="c"><text>CAS 1260665-66-4</text></nplcit>) instead of 2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxylic acid.
Step 2: <i>tert</i>-Butyl 4-(1-(2-Oxo-2,3-dihydro-1<i>H-</i>pyrrolo[2,3-<i>b</i>]pyridine-5-carbonyl)indolin-5-yl)-3,6-dihydropyridine-1(2<i>H</i>)-carboxylate
04595-(5-bromoindoline-1-carbonyl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one is dissolved in a dioxane:water mixture (3:1) (0.1M), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (<nplcit id="ncit0069" npl-type="c"><text>CAS 286961-14-6</text></nplcit>, 1.3 equiv.) is added followed by sodium carbonate (2.5 equiv.) and 1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.1 equiv.). The solution is degassed with nitrogen and heated at 80 °C for 2 hours. The organic supernatant is separated, evaporated under reduced pressure, and the residue is purified by silica gel column chromatography to afford the title compound.
Step 3: tert-butyl 4-(1-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbonyl)indolin-5-yl)piperidine-1-carboxylate
0460tert-Butyl 4-(1-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbonyl)indolin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate is dissolved in ethanol (0.1 M), and palladium on charcoal 10% is added to the reaction mixture. The container is sealed and placed under an atmosphere of hydrogen for 24 hours. The reaction mixture is filtered on celite, and the filtrate is evaporated under reduced pressure to afford the title compound.
Step 4: 5-(5-(piperidin-4-yl)indoline-1-carbonyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one
0461tert-butyl 4-(1-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbonyl)indolin-5-yl)piperidine-1-carboxylate is dissolved in 1,4-dioxane:methanol (1:1), and hydrogen chloride (4 M in 1,4-dioxane) is added. The reaction mixture is stirred for 2 hours at 40 °C and the reaction mixture is evaporated under reduced pressure to afford the title compound.
<i>Example 29</i>
3-(1-(2-Oxo-2,3-dihydro-1<i>H</i>-pyrrolo[2,3-b]pyridine-5-carbonyl)indolin-6-yl)propanoic acid
0462<chemistry id="chem0804" num="0804"><img file="EP4470618A2_D0804.tif" /></chemistry>
Step 1: 5-(6-bromoindoline-1-carbonyl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one
0463The title compound is obtained in analogy to example 12 using 6-bromoindoline (<nplcit id="ncit0070" npl-type="c"><text>CAS 63839-24-7</text></nplcit>) in place of 1-(4-aminopiperidin-1-yl)ethan-1-one and 2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (<nplcit id="ncit0071" npl-type="c"><text>CAS 1260665-66-4</text></nplcit>) instead of 2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxylic acid.
Step 2: tert-butyl (E)-3-(1-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbonyl)indolin-6-yl)acrylate
04645-(6-bromoindoline-1-carbonyl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one is dissolved in N,N-dimethylformamide. Tert-butyl acrylate (1.3 equiv), triethylamine (2.5 equiv.) and bis(triphenylphosphine)palladium(II) dichloride (0.1 equiv.) is added, and the reaction mixture is degassed with nitrogen for 10 minutes. The reaction mixture is heated at 90 °C for 4 hours. The reaction mixture is diluted in ethyl acetate, washed twice with brine, and the organic layer is evaporated under reduced pressure. The crude residue is purified by silica gel column chromatography to afford tert-butyl (E)-3-(1-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbonyl)indolin-6-yl)acrylate.
Step 3: tert-butyl 3-(1-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbonyl)indolin-6-yl)propanoate
0465tert-Butyl (E)-3-(1-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbonyl)indolin-6-yl)acrylate is dissolved in ethanol (0.1 M), and palladium on charcoal 10% is added to the reaction mixture. The container is sealed and placed under an atmosphere of hydrogen for 24 hours. The reaction mixture is filtered on celite, and the filtrate is evaporated under reduced pressure to afford the title compound.
Step 4: 3-(1-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbonyl)indolin-6-yl)propanoic acid
0466tert-Butyl 3-(1-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbonyl)indolin-6-yl)propanoate is dissolved in dichloromethane (0.1 M), and trifluoracetic acid is added. The reaction mixture is stirred at 35 degrees for 24 hours. The volatiles are evaporated under reduced pressure to afford the title compound.
<i>Example 30</i>
5-(4-((1-(2-hydroxyethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methoxy)indoline-1-carbonyl)-1,3-dihydro-2<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-one
0467<chemistry id="chem0805" num="0805"><img file="EP4470618A2_D0805.tif" /></chemistry>
Step 1: 5-(4-hydroxyindoline-1-carbonyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one
0468The title compound is obtained in analogy to example 12 using indolin-4-ol (<nplcit id="ncit0072" npl-type="c"><text>CAS 85926-99-4</text></nplcit>) in place of 1-(4-aminopiperidin-1-yl)ethan-1-one and 2-oxo-2,3-dihydro-1<i>H</i>-pyrrolo[2,3-b]pyridine-5-carboxylic acid (<nplcit id="ncit0073" npl-type="c"><text>CAS 1260665-66-4</text></nplcit>) instead of 2-oxo-2,3-dihydrobenzo[d]oxazole-6-carboxylic acid.
Step 2: 5-(4-(prop-2-yn-1-yloxy)indoline-1-carbonyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one
04695-(4-Hydroxyindoline-1-carbonyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one is dissolved in N,N-dimethylformamide, and cesium carbonate (1.1 equiv.) and propargyl bromide are added. The reaction mixture is stirred at 25 °C for 2 hours. The reaction mixture is partitioned between ethyl acetate and sodium bicarbonate, and the organic layer is evaporated under reduced pressure. The crude residue is purified by silica gel chromatography to afford 5-(4-(prop-2-yn-1-yloxy)indoline-1-carbonyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one.
Step 3: 5-(4-((1-(2-hydroxyethyl)-1H-1,2,3-triazol-4-yl)methoxy)indoline-1-carbonyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one
04705-(4-(prop-2-yn-1-yloxy)indoline-1-carbonyl)-1,3 -dihydro-2H-pyrrolo[2,3 -b]pyridin-2-one is dissolved in DMSO (0.1 M), 2-azidoethanol (2.0 equiv., <nplcit id="ncit0074" npl-type="c"><text>CAS 1517-05-1</text></nplcit>) is added, the reaction mixture is degassed with nitrogen. Aqueous copper sulfate (1M, 1.0 equiv.) and aqueous sodium ascorbate (2M, 2.0 equiv.) are added dropwise, in sequence, to the reaction mixture. The compound is purified by column chromatography to afford the title compound.
<i>Example 31</i>
2-(2-Oxo-2,3-dihydrobenzo[<i>d</i>]oxazole-6-carbonyl)isoindolin-4-yl Piperidine-4-carboxylate
0471<chemistry id="chem0806" num="0806"><img file="EP4470618A2_D0806.tif" /></chemistry><chemistry id="chem0807" num="0807"><img file="EP4470618A2_D0807.tif" /></chemistry>
Step 1: 1-(tert-Butyl) 4-(2-(2-Oxo-2,3-dihydrobenzo[<i>d</i>]oxazole-6-carbonyl)isoindolin-4-yl) Piperidine-1,4-dicarboxylate
04721-(tert-Butoxycarbonyl)piperidine-4-carboxylic acid (<nplcit id="ncit0075" npl-type="c"><text>CAS 84358-13-4</text></nplcit>, 1 equiv.), 2,4,6-trichlorobenzoyl chloride (<nplcit id="ncit0076" npl-type="c"><text>CAS 4136-95-2</text></nplcit>, 1 equiv.), and 6-(4-hydroxyisoindoline-2-carbonyl)benzo[<i>d</i>]oxazol-2(3<i>H</i>)-one (1 equiv.) are dissolved in dry THF (0.1 M). Triethylamine (2 equiv.) is added slowly, followed by DMAP (25 mol %). The reaction mixture is stirred at rt until the reaction is complete and then quenched with 10 % hydrochloric acid solution. The solution is extracted twice with ethyl acetate. The combined organic phase is washed twice with saturated sodium bicarbonate solution, dried and purified by flash column chromatography on silica gel to afford the title compound.
Step 2: 2-(2-Oxo-2,3-dihydrobenzo[<i>d</i>]oxazole-6-carbonyl)isoindolin-4-yl Piperidine-4-carboxylate
04731-(tert-Butyl) 4-(2-(2-oxo-2,3-dihydrobenzo[<i>d</i>]oxazole-6-carbonyl)isoindolin-4-yl) piperidine-1,4-dicarboxylate (1 equiv.) is dissolved in DCM (0.2 M) and a solution of 4 M HCl in dioxane (0.2 M) is added at rt. The reaction iss stirred at rt to completion. The mixture is concentrated and lyophilized to afford the title compound.
<i>Example 32</i>
3-((2-(2-Oxo-2,3-dihydrobenzo[<i>d</i>]oxazole-6-carbonyl)isoindolin-4-yl)oxy)propanoic Acid
0474<chemistry id="chem0808" num="0808"><img file="EP4470618A2_D0808.tif" /></chemistry>
Step
1:
tert-Butyl 3-((2-(2-Oxo-2,3-dihydrobenzo[<i>d</i>]oxazole-6-carbonyl)isoindolin-4-yl)oxy)propanoate
0475A solution of diisopropyl azodicarboxylate (1.3 equiv.) in toluene is added drop-wise to a 0 °C solution of 6-(4-hydroxyisoindoline-2-carbonyl)benzo[<i>d</i>]oxazol-2(3<i>H</i>)-one (1 equiv.), tert-butyl 3-hydroxypropanoate (<nplcit id="ncit0077" npl-type="c"><text>CAS 59854-11-4</text></nplcit>, 1 equiv.) and Ph<sub>3</sub>P (1.3 equiv.) in THF (0.2 M). The reaction mixture is heated at reflux until completion. The reaction mixture is cooled and concentrated, and purified by silica gel flash chromatography to afford the title compound.
Step 2: 3-((2-(2-Oxo-2,3-dihydrobenzo[<i>d</i>]oxazole-6-carbonyl)isoindolin-4-yl)oxy)propanoic Acid
0476tert-Butyl 3-((2-(2-oxo-2,3-dihydrobenzo[<i>d</i>]oxazole-6-carbonyl)isoindolin-4-yl)oxy)propanoate (1 equiv.) is dissolved in DCM (0.2 M), and TFA (0.2 M) is added at rt. The reaction is stirred at rt to completion. The mixture is concentrated and lyophilized to afford the title compound.
<i>Example 33</i>
6-(4-Hydroxy-5-((4-(hydroxymethyl)piperidin-1-yl)methyl)isoindoline-2-carbonyl)benzo[<i>d</i>]oxazol-2(3<i>H</i>)-one
0477<chemistry id="chem0809" num="0809"><img file="EP4470618A2_D0809.tif" /></chemistry><chemistry id="chem0810" num="0810"><img file="EP4470618A2_D0810.tif" /></chemistry>
Step 1: 4-Hydroxy-2-(2-oxo-2,3-dihydrobenzo[<i>d</i>]oxazole-6-carbonyl)isoindoline-5-carbaldehyde
04786-(4-Hydroxyisoindoline-2-carbonyl)benzo[<i>d</i>]oxazol-2(3<i>H</i>)-one (1 equiv.) and hexamethylenetetramine (<nplcit id="ncit0078" npl-type="c"><text>CAS 100-97-0</text></nplcit>, 4 equiv.) is dissolved in TFA (0.5 M). The reaction mixture is refluxed using a dean stark system until reaction completion. The mixture is thereafter cooled to room temperature. Water is added, and the reaction is heated to 80 ° C for 2 h. After cooling to room temperature, the mixture is filtered, and the precipitate is purified by silica gel flash chromatography to afford the title compound.
Step 2: 6-(4-Hydroxy-5-((4-(hydroxymethyl)piperidin-1-yl)methyl)isoindoline-2-carbonyl)benzo[<i>d</i>]oxazol-2(3<i>H</i>)-one
04794-Hydroxy-2-(2-oxo-2,3-dihydrobenzo[d]oxazole-6-carbonyl)isoindoline-5-carbaldehyde (1 equiv.) and 4-Piperidinemethanol (<nplcit id="ncit0079" npl-type="c"><text>CAS 6457-49-4</text></nplcit>, 1.1 equiv.) are dissolved in THF (0.4 M). Acetic acid (drops) is added, followed by sodium triacetoxyborohydride (1.3 equiv.). The reaction mixture is stirred at rt until reaction completion. The reaction mixture is partitioned between ethyl acetate and saturated ammonia chloride, and the organic layer is evaporated under reduced pressure. The crude residue is purified by silica gel chromatography to afford the title compound.
<i>Example 34</i>
5-(5-(1-(5-hydroxypentanoyl)piperidin-4-yl)-2-isopropyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)-1,3-dihydro-2<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-one
0480<chemistry id="chem0811" num="0811"><img file="EP4470618A2_D0811.tif" /></chemistry>
Step
1:
tert-Butyl 4-(4-Fluoro-3-nitrophenyl)piperidine-1-carboxylate
04814-(4-Fluorophenyl)piperidine hydrochloride (1 equiv.) is dissolved in concentrated sulfuric acid (0.5 M reaction concentration). The mixture is cooled to 0 °C, and concentrated nitric acid (1.5 equiv.) is added slowly drop-wise. The solution is slowly warmed to room temperature and then heated to 50 °C. The solution is allowed to stir for 24 hours. The mixture is then cooled to room temperature, poured into ice water, and treated with 1M NaOH until basic. The product is then extracted from the solution with ethyl ether (3x). The combined organic layers are washed with brine and dried over sodium sulfate. The solvent is removed under reduced pressure.
0482The crude material is then dissolved in THF (0.1 M reaction concentration). DMAP (0.1 equiv.) is added followed by Boc anhydride (1 equiv.). The mixture is allowed to stir for two hours. It is then diluted with ethyl acetate and washed with water. The organic layer wis then washed with brine and dried over sodium sulfate before concentrating under reduced pressure. Column chromatography using a gradient of ethyl acetate in hexanes affords tert-butyl 4-(4-fluoro-3-nitrophenyl)piperidine-1-carboxylate.
Step 2: <i>tert-Butyl</i> 4-(3-Nitro-4-((2-oxo-2,3-dihydro-1<i>H-</i>pyrrolo[2,3-<i>b</i>]pyridin-5-yl)amino)phenyl)piperidine-1-carboxylate
0483The title compound is synthesized in analogy to Example 4 using <i>tert</i>-butyl 4-(4-fluoro-3-nitrophenyl)piperidine-1-carboxylate in place of 4-fluoro-<i>N</i>-methyl-3-nitrobenzamide.
Step 3: tert-Butyl 4-(3-Amino-4-((2-oxo-2,3-dihydro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)amino)phenyl)piperidine-1-carboxylate
0484The title compound is synthesized in analogy to Example 4 using <i>tert</i>-butyl 4-(3-nitro-4-((2-oxo-2,3-dihydro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)amino)phenyl)piperidine-1-carboxylate in place of <i>N-</i>methyl-3-nitro-4-[(2-oxoindolin-6-yl)amino]benzamide.
Step 4: tert-Butyl 4-(2-Isopropyl-1-(2-oxo-2,3-dihydro-1<i>H-</i>pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H-</i>benzo[<i>d</i>]imidazol-5-yl)piperidine-1-carboxylate
0485The title compound is synthesized in analogy to Example 4 using <i>tert</i>-butyl 4-(3-amino-4-((2-oxo-2,3-dihydro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)amino)phenyl)piperidine-1-carboxylate in place of 3-amino-<i>N</i>-methyl-4-[(2-oxoindolin-6-yl)amino]benzamide.
Step 5: 5-(2-Isopropyl-5-(piperidin-4-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)-1,3-dihydro-2<i>H-</i>pyrrolo [2,3-b] pyridin-2-one Trifluoroacetate
0486<i>tert</i>-Butyl 4-(2-isopropyl-1-(2-oxo-2,3-dihydro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H-</i>benzo[<i>d</i>]imidazol-5-yl)piperidine-1-carboxylate (1 equiv.) is dissolved in dichloromethane (0.2 M reaction concentration). Trifluoroacetate acid (10 equiv.) is then added, and the mixture is allowed to stir at room temperature for 24 hours. The mixture is then concentrated under reduced pressure to afford the title compound.
Step 6: 5-(5-(1-(5-Hydroxypentanoyl)piperidin-4-yl)-2-isopropyl-1<i>H-</i>benzo[<i>d</i>]imidazol-1-yl)-1,3-dihydro-2<i>H-</i>pyrrolo[2,3-<i>b</i>]pyridin-2-one
04875-(2-Isopropyl-5-(piperidin-4-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)-1,3-dihydro-2<i>H-</i>pyrrolo[2,3-<i>b</i>]pyridin-2-one trifluoroacetate (1 equiv.) and 5-hydroxypentanoic acid (1 equiv.) are dissolved in DMF (0.1 M reaction concentration). Hunig's base (3 equiv.) is added followed by COMU (1.1 equiv.). The mixture is allowed to stir at room temperature for 2 hr. The mixture is then diluted with ethyl acetate and water. The organic layer is separated, and the product is extracted from the aqueous layer with ethyl acetate (3 x). The combined organic layers are washed with brine and dried over sodium sulfate before concentrating. The crude material is then purified on silica using a gradient of ethyl acetate in hexanes to afford the desired compound.
<i>Example 35</i>
6-(((2-Isopropyl-1-(2-oxo-2,3-dihydro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H-</i>benzo[<i>d</i>]imidazol-4-yl)methyl)amino)hexanoic Acid
0488<chemistry id="chem0812" num="0812"><img file="EP4470618A2_D0812.tif" /></chemistry><chemistry id="chem0813" num="0813"><img file="EP4470618A2_D0813.tif" /></chemistry>
Step 1: tert-Butyl((3-Fluoro-2-nitrobenzyl)oxy)dimethylsilane
0489(3-Fluoro-2-nitrophenyl)methanol (1 equiv.) is dissolved in THF (0.1 M reaction concentration). Imidazole (1.2 equiv.) is added followed by TBSCl (1.1 equiv.). The mixture is allowed to stir for 24 hrs. It is then diluted with ethyl acetate and water. The organic layer is separated, and the product is extracted from the aqueous layer using ethyl acetate (3x). The combined organic layers are washed with brine and dried over sodium sulfate before concentrating. The crude material is then purified on silica using a gradient of ethyl acetate in hexanes to afford the desired compound.
Step 2: 5-((3-(((tert-Butyldimethylsilyl)oxy)methyl)-2-nitrophenyl)amino)-1,3-dihydro-2H-pyrrolo [2,3-b] pyridin-2-one
0490The title compound is synthesized in analogy to Example 4 using <i>tert</i>-butyl((3-fluoro-2-nitrobenzyl)oxy)dimethylsilane in place of 4-fluoro-<i>N</i>-methyl-3-nitrobenzamide.
Step 3: 5-((2-Amino-3-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)phenyl)amino)-1,3-dihydro-2<i>H-</i>pyrrolo [2,3-b] pyridin-2-one
0491The title compound is synthesized in analogy to Example 4 using 5-((3-(((<i>tert</i>butyldimethylsilyl)oxy)methyl)-2-nitrophenyl)amino)-1,3-dihydro-2<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-one in place of<i>N</i>-methyl-3-nitro-4-[(2-oxoindolin-6-yl)amino]benzamide.
Step 4: 5-(4-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-2-isopropyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)-1,3-dihydro-2<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-one
0492The title compound is synthesized in analogy to Example 4 using 5-((2-amino-3-(((<i>tert</i>butyldimethylsilyl)oxy)methyl)phenyl)amino)-1,3-dihydro-2<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-one in place of 3-amino-<i>N</i>-methyl-4-[(2-oxoindolin-6-yl)amino]benzamide.
Step
5:
5-(4-(Hydroxymethyl)-2-isopropyl-1<i>H-</i>benzo[<i>d</i>]imidazol-1-yl)-1,3-dihydro-2<i>H-</i>pyrrolo [2,3-b] pyridin-2-one
04935-(4-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-2-isopropyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)-1,3-dihydro-2<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-one (1 equiv.) is dissolved in THF (0.1 M reaction concentration) and cooled to 0 °C. TBAF (1 equiv.) is added, and the mixture is allowed to stir for 2 hours. The mixture is then diluted with water. The product is extracted with ethyl acetate (x3). The combined organic layers are then washed with brine and dried over sodium sulfate. The crude material is then purified on silica using a gradient of ethyl acetate in hexanes.
Step 6: (2-Isopropyl-1-(2-oxo-2,3-dihydro-1<i>H-</i>pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H-</i>benzo[<i>d</i>]imidazol-4-yl)methyl 4-methylbenzenesulfonate
04945-(4-(Hydroxymethyl)-2-isopropyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)-1,3-dihydro-2<i>H-</i>pyrrolo[2,3-<i>b</i>]pyridin-2-one (1 equiv.) is dissolved in THF (0.1 M reaction concentration). Hunig's base (2 equiv.) is added followed by tosyl chloride. The mixture is allowed to stir for 8 hours. It is then diluted with water. The product is extracted with ethyl acetate (x3). The combined organic layers are then washed with brine and dried over sodium sulfate. The crude material is then purified on silica using a gradient of ethyl acetate in hexanes to afford the desired compound.
Step 7: tert-Butyl 6-(((2-Isopropyl-1-(2-oxo-2,3-dihydro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H-</i>benzo[<i>d</i>]imidazol-4-yl)methyl)amino)hexanoate
0495(2-Isopropyl-1-(2-oxo-2,3-dihydro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-4-yl)methyl 4-methylbenzenesulfonate (1 equiv.) is dissolved in DMF (0.2 M reaction concentration). Hunig's base (3 equiv.) is added followed by tert-butyl 6 aminohexanoate (1 equiv.). The mixture is heated to 60 °C for 8 hours. The mixture is then cooled to room temperature and diluted with ethyl acetate and 1.0 M HCl aqueous solution. The organic layer is separated, and the product is extracted from the aqueous layer using ethyl acetate (3x). The combined organic layers are then washed with brine and dried over sodium sulfate. The crude material is then purified on silica using a gradient of methanol in dichloromethane to afford the desired compound.
Step 8: 6-(((2-isopropyl-1-(2-oxo-2,3-dihydro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H-</i>benzo[<i>d</i>]imidazol-4-yl)methyl)amino)hexanoic acid
0496<i>tert</i>-Butyl 6-(((2-isopropyl-1-(2-oxo-2,3-dihydro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H-</i>benzo[<i>d</i>]imidazol-4-yl)methyl)amino)hexanoate (1 equiv.) is dissolved in dichloromethane (0.5 M reaction concentration). Trifluoroacetic acid (10 equiv.) is then added, and the mixture is allowed to stir at room temperature for 24 hours. The solvent is then removed under reduced pressure, and the crude material is purified on silica using a gradient of methanol in dichloromethane to obtain the desired product.
<i>Example 36</i>
<i>tert</i>-Butyl 3-(2-Isopropyl-1-(2-oxo-2,3-dihydro-1<i>H-</i>pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H-</i>benzo[<i>d</i>]imidazol-5-yl)propiolate
0497<chemistry id="chem0814" num="0814"><img file="EP4470618A2_D0814.tif" /></chemistry>
Step 1: 5-((4-Bromo-2-nitrophenyl)amino)-1,3-dihydro-2<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-one
0498The title compound is synthesized in analogy to Example 4 using 4-bromo-1-fluoro-2-nitrobenzene in place of 4-fluoro-N-methyl-3-nitrobenzamide.
Step 2: 5-((2-amino-4-bromophenyl)amino)-1,3-dihydro-2<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-one
0499The title compound is synthesized in analogy to Example 4 using 5-((4-bromo-2-nitrophenyl)amino)-1,3-dihydro-2<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-onein place of <i>N</i>-methyl-3-nitro-4-[(2-oxoindolin-6-yl)amino]benzamide.
Step 3: 5-(5-bromo-2-isopropyl-1<i>H-</i>benzo[<i>d</i>]imidazol-1-yl)-1,3-dihydro-2<i>H-</i>pyrrolo[2,3-b]pyridin-2-one
0500The title compound is synthesized in analogy to Example 4 using 5-((2-amino-4-bromophenyl)amino)-1,3-dihydro-2<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-one in place of 3-amino-N-methyl-4-[(2-oxoindolin-6-yl)amino]benzamide.
Step 4: tert-butyl 3-(2-isopropyl-1-(2-oxo-2,3-dihydro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-1<i>H-</i>benzo[<i>d</i>]imidazol-5-yl)propiolate
05015-(5-bromo-2-isopropyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)-1,3-dihydro-2<i>H</i>-pyrrolo[2,3-b]pyridin-2-one (1 equiv.) and tert-butyl propiolate (1.5 equiv.) are dissolved in DMF (0.2 M reaction concentration). Triethylamine (5 equiv.) is added, and the mixture is degassed for 20 minutes. CuI (0.05 equiv.) is then added followed by Pd(PPh<sub>3</sub>)<sub>4</sub> (0.1 equiv.). The mixture is degassed a further 10 minutes and then heated to 80 °C. The mixture is allowed to stir for 12 hours. It is then cooled to room temperature and diluted with ethyl acetate and water. The organic layer is separated, and the product is extracted from the aqueous layer using ethyl acetate (3x). The combined organic layers are then washed with brine and dried over sodium sulfate. The crude material is then purified on silica using a gradient of methanol in dichloromethane to afford the desired compound.
Pharmacological Tests
0502The compounds described herein and their pharmaceutically acceptable salts possess valuable pharmacological properties. The compounds were investigated in accordance with the test given hereinafter.
Fluorescence Direct Binding Protocol
Principle
0503Determination of the affinities of compounds to protein containing one or more tryptophan is measurable by monitoring the fluorescence emission in direct mode. The measurements depending on the protein available amounts are performed either manually in a cuvette on ISS-PC1 photon counting spectrofluorometer or automatically in well plates on a fluorescence plate reader device. Fluorescence titrations are performed at 20 °C in the chosen binding assay buffer by using a defined constant protein concentration against ligand concentration variations. Small aliquots of known ligand concentration solubilized in DMSO were added and the fluorescence, excited at 280 nm, was recorded at 340 nm. The fluorescence intensity was corrected for protein dilution and for the filter effect (Birdsall et al.). The corrected fluorescence intensity was plotted against the ligand concentration and fitted using a four-parameter sigmoidal function, from which the equilibrium dissociation constant Kd was computed using the law of mass action assuming a 1:1 protein-ligand complex (Eftink, 1997).
Process
0504<ol id="ol0014" compact="compact"><li>1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content</li><li>2) Titration measurements of the protein against ligand by at least 12 titration steps to obtain a good s-curve fit</li><li>3) Repeat the same titration measurements with the ligand alone to enable correction</li><li>4) Check the stability of the protein once by titration against DMSO alone</li><li>5) Determination of the molar extinction coefficients of the ligand at 280 and 340 nm with help of an UV- spectrophotometer</li><li>6) Use Excel template for the correction of the measured raw data</li></ol>
0505Use GraphPad Prism software for the quadratic binding fit and the K<sub>D</sub> evaluation. <tables id="tabl0008" num="0008"><table frame="all"><title><b><i>Table 8: Protein</i> - <i>buffers, Reference compound: thalidomide, Contergan, Softenon</i></b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="63mm" /><colspec colnum="2" colname="col2" colwidth="68mm" /><thead valign="top"><row><entry><b>Protein Batch #</b></entry><entry><b>Cereblon_17_13</b></entry></row></thead><tbody><row><entry>Construct name</entry><entry>hCereblon(M1-L442)_hDDB1(M1-H1140)</entry></row><row><entry>Concentration</entry><entry>2.54 mg/ml</entry></row><row><entry>MW</entry><entry>180180 Da</entry></row><row><entry>Molar extinction coefficient</entry><entry>□<sub>280</sub> = 165045 M<sup>-1</sup>.cm<sup>-1</sup></entry></row><row><entry>Storage buffer</entry><entry>20 mM MES pH 6.5 200 mM NaCl 1 mM TCEP</entry></row><row><entry>Assay buffer</entry><entry>50 mM Hepes 7.4 200mM NaCl</entry></row></tbody></tgroup></table></tables><tables id="tabl0009" num="0009"><table frame="all"><title><b><i>Table 9: Settings</i></b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="43mm" /><colspec colnum="2" colname="col2" colwidth="28mm" /><tbody><row><entry>Device</entry><entry>ISS-PC1</entry></row><row><entry>Excitation wavelength [nm]</entry><entry>280</entry></row><row><entry>Emission wavelength [nm]</entry><entry>340</entry></row><row><entry>Cuvette</entry><entry>Hellma 115F-QS</entry></row><row><entry>Volume [µL]</entry><entry>500</entry></row></tbody></tgroup></table></tables>
Protein preparation:
0506<tables id="tabl0010" num="0010"><table frame="all"><title><b><i>Table 10: Protein preparation</i></b></title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="32mm" /><colspec colnum="2" colname="col2" colwidth="31mm" /><colspec colnum="3" colname="col3" colwidth="41mm" /><thead valign="top"><row><entry>Volume Protein [µL]</entry><entry>Volume buffer [µL]</entry><entry>Protein concentration [M]</entry></row></thead><tbody><row><entry>1.8 @ 2.54 mg/ml</entry><entry>498.2</entry><entry>5.0 E-8</entry></row></tbody></tgroup></table></tables><tables id="tabl0011" num="0011"><table frame="all"><title><b><i>Table 11: Titration steps</i></b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="24mm" /><colspec colnum="2" colname="col2" colwidth="26mm" /><colspec colnum="3" colname="col3" colwidth="27mm" /><colspec colnum="4" colname="col4" colwidth="22mm" /><colspec colnum="5" colname="col5" colwidth="28mm" /><thead valign="top"><row><entry><b>C Lig [ M ]</b></entry><entry><b>C Aliquot [ M ]</b></entry><entry><b>V Aliquot [ µL ]</b></entry><entry><b>C Prot[ M ]</b></entry><entry><b>Dilution factor;</b></entry></row></thead><tbody><row><entry>1E-10</entry><entry>1.0E-07</entry><entry>0.5</entry><entry>4.995E-08</entry><entry>1.001</entry></row><row><entry>1.1E-09</entry><entry>1.0E-06</entry><entry>0.5</entry><entry>4.990E-08</entry><entry>1.002</entry></row><row><entry>3.1E-09</entry><entry>1.0E-06</entry><entry>1</entry><entry>4.980E-08</entry><entry>1.004</entry></row><row><entry>5.1E-09</entry><entry>1.0E-06</entry><entry>1</entry><entry>4.970E-08</entry><entry>1.006</entry></row><row><entry>1.51E-08</entry><entry>1.0E-05</entry><entry>0.5</entry><entry>4.965E-08</entry><entry>1.007</entry></row><row><entry>2.51E-08</entry><entry>1.0E-05</entry><entry>0.5</entry><entry>4.960E-08</entry><entry>1.008</entry></row><row><entry>4.51E-08</entry><entry>1.0E-05</entry><entry>1</entry><entry>4.95011-08</entry><entry>1.01</entry></row><row><entry>6.51E-08</entry><entry>1.0E-05</entry><entry>1</entry><entry>4.941E-08</entry><entry>1.012</entry></row><row><entry>1.651E-07</entry><entry>1.0E-04</entry><entry>0.5</entry><entry>4.936E-08</entry><entry>1.013</entry></row><row><entry>3.651E-07</entry><entry>1.0E-04</entry><entry>1</entry><entry>4.926E-08</entry><entry>1.015</entry></row><row><entry>5.651E-07</entry><entry>1.0E-04</entry><entry>1</entry><entry>4.916E-08</entry><entry>1.017</entry></row><row><entry>7.651E-07</entry><entry>1.0E-04</entry><entry>1</entry><entry>4.907E-08</entry><entry>1.019</entry></row><row><entry>9.651E-07</entry><entry>1.0E-04</entry><entry>1</entry><entry>4.897E-08</entry><entry>1.021</entry></row><row><entry>1.9651E-06</entry><entry>1.0E-03</entry><entry>0.5</entry><entry>4.892E-08</entry><entry>1.022</entry></row><row><entry>2.9651E-06</entry><entry>1.0E-03</entry><entry>0.5</entry><entry>4.888E-08</entry><entry>1.023</entry></row><row><entry>1.29651E-05</entry><entry>1.0E-02</entry><entry>0.5</entry><entry>4.883E-08</entry><entry>1.024</entry></row><row><entry>2.29651E-05</entry><entry>1.0E-02</entry><entry>0.5</entry><entry>4.878E-08</entry><entry>1.025</entry></row><row><entry>4.29651E-05</entry><entry>1.0E-02</entry><entry>1</entry><entry>4.869E-08</entry><entry>1.027</entry></row><row><entry>6.29651E-05</entry><entry>1.0E-02</entry><entry>1</entry><entry>4.859E-08</entry><entry>1.029</entry></row><row><entry>8.29651E-05</entry><entry>1.0E-02</entry><entry>1</entry><entry>4.850E-08</entry><entry>1.031</entry></row></tbody></tgroup></table></tables><tables id="tabl0012" num="0012"><table frame="all"><title><b><i>Table 12: affinities of examples to CRBN protein</i></b></title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="13mm" /><colspec colnum="2" colname="col2" colwidth="94mm" /><colspec colnum="3" colname="col3" colwidth="60mm" /><thead valign="middle"><row><entry><b>Ex.</b></entry><entry><b>Name</b></entry><entry><b>Fluorescence h-Cereblon_DDB1 Mean K<sub>d</sub>_EQ (µM)</b></entry></row></thead><tbody valign="middle"><row><entry>1</entry><entry><i>N</i>-(2-oxo-3<i>H</i>-1,3-benzoxazol-6-yl)benzamide</entry><entry>0.004</entry></row><row><entry>2</entry><entry><i>N</i>-(2-oxoindolin-5-yl)furan-2-carboxamide</entry><entry>0.007</entry></row><row><entry>3</entry><entry>2-(2-methylphenoxy)-<i>N</i>-(2-oxo-3H-1,3-benzothiazol-6-yl)acetamide</entry><entry>0.014</entry></row><row><entry>4</entry><entry>2-isopropyl-<i>N</i>-methyl-1-(2-oxoindolin-6-yl)benzimidazole-5-carboxamide</entry><entry>0.002</entry></row><row><entry>5</entry><entry>2-isopropyl-<i>N-</i>methyl-1-(2-oxoindolin-5-yl)benzimidazole-5-carboxamide</entry><entry>0.003</entry></row><row><entry>6</entry><entry>6-(2-aminoanilino)-3<i>H</i>-1,3-benzothiazol-2-one</entry><entry>< 0.001</entry></row><row><entry>7</entry><entry>6-(2-isopropylbenzimidazol-1-yl)-3<i>H</i>-1,3-benzothiazol-2-one</entry><entry>0.019</entry></row><row><entry>8</entry><entry>6-(2-aminoanilino)-3<i>H</i>-1,3-benzoxazol-2-one</entry><entry>0.008</entry></row><row><entry>9</entry><entry>6-(2-isopropylbenzimidazol-1-yl)-3<i>H</i>-1,3-benzoxazol-2-one</entry><entry>0.108</entry></row><row><entry>10</entry><entry>2-oxo-<i>N</i>-phenylindoline-5-carboxamide</entry><entry>0.091</entry></row><row><entry>11</entry><entry>2-oxo-<i>N</i>-phenyl-3<i>H</i>-1,3-benzoxazole-6-carboxamide</entry><entry>0.054</entry></row><row><entry>12</entry><entry><i>N-</i>(1-acetyl-4-piperidyl)-2-oxo-3<i>H</i>-1,3-benzoxazole-6-carboxamide</entry><entry>0.006</entry></row><row><entry>13</entry><entry>6-(indoline-1-carbonyl)-3<i>H</i>-1,3-benzoxazol-2-one</entry><entry>0.004</entry></row><row><entry>14</entry><entry>6-(2,3-dihydropyrrolo[2,3-b]pyridine-1-carbonyl)-3<i>H-</i>1,3-benzoxazol-2-one</entry><entry>0.024</entry></row><row><entry>15</entry><entry>2-oxo-<i>N</i>-phenyl-3<i>H</i>-1,3-benzothiazole-6-carboxamide</entry><entry>0.079</entry></row><row><entry>16</entry><entry>6-(indoline-1-carbonyl)-3<i>H</i>-1,3-benzothiazol-2-one</entry><entry>0.028</entry></row><row><entry>17</entry><entry>5-(indoline-1-carbonyl)indolin-2-one</entry><entry>0.015</entry></row><row><entry>18</entry><entry>2-oxo-<i>N</i>-phenyl-3<i>H</i>-oxazolo[4,5-b]pyridine-6-carboxamide</entry><entry>0.024</entry></row><row><entry>19</entry><entry><i>N</i>-(1-acetyl-4-piperidyl)-2-oxo-3<i>H</i>-oxazolo[4,5-b]pyridine-6-carboxamide</entry><entry>0.007</entry></row><row><entry>20</entry><entry>5-(indoline-1-carbonyl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one</entry><entry>0.013</entry></row><row><entry>21</entry><entry>3,3-difluoro-5-(2-isopropylbenzimidazol-1-yl)indolin-2-one</entry><entry>< 0.001</entry></row><row><entry>22</entry><entry>6-(4-hydroxyisoindoline-2-carbonyl)-3<i>H</i>-1,3-benzoxazol-2-one</entry><entry>0.002</entry></row><row><entry>23</entry><entry>6-(4-nitroisoindoline-2-carbonyl)-3<i>H</i>-1,3-benzoxazol-2-one</entry><entry>0.014</entry></row><row><entry>24</entry><entry><i>N</i>-(3,3-difluoro-2-oxo-indolin-5-yl)tetralin-1-carboxamide</entry><entry>0.028</entry></row><row><entry>25</entry><entry><i>N</i>-(3,3-difluoro-2-oxo-indolin-5-yl)benzofuran-3-carboxamide</entry><entry>0.052</entry></row><row><entry>26</entry><entry>2-isopropyl-<i>N</i>-methyl-1-(2-oxo-1,3-dihydropyrrolo[2,3-b]pyridin-5-yl)benzimidazole-5-carboxamide</entry><entry>0.007</entry></row><row><entry>27</entry><entry>5-(2-isopropylbenzimidazol-1-yl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one</entry><entry>< 0.001</entry></row></tbody></tgroup></table></tables>
0507All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.
0508Although the foregoing invention has been described in some detail by way of illustration and example for the purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teaching of this invention that certain changes and modification may be made thereto without departing from the spirit or scope of the invention as defined in the claims.
0509Aspects and features of the present disclosure are set out in the following numbered clauses which contain the subject matter of the claims of the parent application as filed. <ol id="ol0015"><li>1. A compound of Formula I: <chemistry id="chem0815" num="0815"><img file="EP4470618A2_D0815.tif" /></chemistry> or a pharmaceutically acceptable salt thereof; wherein: <ul id="ul0029" list-style="none" compact="compact"><li>A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, -CF<sub>2</sub>- and -NH-, and A<sup>2</sup> is -CH<sub>2</sub>-; or</li><li>A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, and -CF<sub>2</sub>-, and A<sup>2</sup> is-NH-;</li><li>W is CH or N;</li><li>R<sup>3</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl substituted by R<sup>9</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl; -(CH<sub>2</sub>)<sub>0-1</sub>-heterocycloalkyl; -C(=O)C<sub>1-6</sub>alkyl; -(CH<sub>2</sub>)<sub>0-2</sub>-C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -OH; -NO<sub>2</sub>; -C<sub>1-6</sub>alkyl-N(R<sup>11</sup>)-C(=O)-R<sup>12</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl-aryl; -N(R<sup>5</sup>,R<sup>6</sup>); -NH-C(=O)C<sub>1-6</sub>alkyl; -NH-C(=O)OC<sub>1-6</sub>alkyl; and =O as allowed by valence;</li><li>m is 0, 1, or 2;</li><li>R<sup>5</sup> and R<sup>6</sup> are independently selected at each occurrence from H, C<sub>1-6</sub>alkyl and phenyl;</li><li>or R<sup>5</sup> and R<sup>6</sup>, taken together with the nitrogen to which they are attached, form a heterocycloalkyl ring;</li><li>R<sup>7</sup> and R<sup>8</sup> are independently selected at each occurrence from H and C<sub>1-6</sub>alkyl;</li><li>or R<sup>7</sup> and R<sup>8</sup>, taken together with the nitrogen to which they are attached, form a heterocycloalkyl ring;</li><li>R<sup>9</sup> is independently selected at each occurrence from C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkyl, halogen, halogen-C<sub>1-6</sub>alkyl, heteroaryl, and heteroaryl substituted by C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkoxy;</li><li>R<sup>10</sup> is independently selected at each occurrence from C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl-C<sub>1-6</sub>alkoxy, halogen, and halogen-C<sub>1-6</sub>alkyl;</li><li>R<sup>11</sup> is independently selected at each occurrence from H and C<sub>1-6</sub>alkyl; and</li><li>R<sup>12</sup> is independently selected at each occurrence from H, C<sub>1-6</sub>alkyl and C<sub>3-7</sub>cycloalkyl.</li></ul></li><li>2. A compound selected from one of the following formulas: <chemistry id="chem0816" num="0816"><img file="EP4470618A2_D0816.tif" /></chemistry><chemistry id="chem0817" num="0817"><img file="EP4470618A2_D0817.tif" /></chemistry><chemistry id="chem0818" num="0818"><img file="EP4470618A2_D0818.tif" /></chemistry><chemistry id="chem0819" num="0819"><img file="EP4470618A2_D0819.tif" /></chemistry><chemistry id="chem0820" num="0820"><img file="EP4470618A2_D0820.tif" /></chemistry><chemistry id="chem0821" num="0821"><img file="EP4470618A2_D0821.tif" /></chemistry> or a pharmaceutically acceptable salt thereof; wherein: <ul id="ul0030" list-style="none" compact="compact"><li>R<sup>4</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl substituted by R<sup>9</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl; =O as allowed by valence; -C(=O)C<sub>1-6</sub>alkyl; -C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -N(R<sup>5</sup>,R<sup>6</sup>); and -NH-C(=O)C<sub>1-6</sub>alkyl;</li><li>n is 1 or 2; and</li><li>all other variables are as defined in clause 1.</li></ul></li><li>3. A compound of Formula III: <chemistry id="chem0822" num="0822"><img file="EP4470618A2_D0822.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 1 and clause 2.</li><li>4. A compound selected from one of the following formulas: <chemistry id="chem0823" num="0823"><img file="EP4470618A2_D0823.tif" /></chemistry><chemistry id="chem0824" num="0824"><img file="EP4470618A2_D0824.tif" /></chemistry><chemistry id="chem0825" num="0825"><img file="EP4470618A2_D0825.tif" /></chemistry><chemistry id="chem0826" num="0826"><img file="EP4470618A2_D0826.tif" /></chemistry><chemistry id="chem0827" num="0827"><img file="EP4470618A2_D0827.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 1 and clause 2.</li><li>5. A compound of Formula V: <chemistry id="chem0828" num="0828"><img file="EP4470618A2_D0828.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 1 and clause 2.</li><li>6. A compound of Formula VI: <chemistry id="chem0829" num="0829"><img file="EP4470618A2_D0829.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 1 and clause 2.</li><li>7. A compound selected from one of the following formulas: <chemistry id="chem0830" num="0830"><img file="EP4470618A2_D0830.tif" /></chemistry><chemistry id="chem0831" num="0831"><img file="EP4470618A2_D0831.tif" /></chemistry> and <chemistry id="chem0832" num="0832"><img file="EP4470618A2_D0832.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 1 and clause 2.</li><li>8. A compound selected from one of the following formulas: <chemistry id="chem0833" num="0833"><img file="EP4470618A2_D0833.tif" /></chemistry><chemistry id="chem0834" num="0834"><img file="EP4470618A2_D0834.tif" /></chemistry><chemistry id="chem0835" num="0835"><img file="EP4470618A2_D0835.tif" /></chemistry><chemistry id="chem0836" num="0836"><img file="EP4470618A2_D0836.tif" /></chemistry> and <chemistry id="chem0837" num="0837"><img file="EP4470618A2_D0837.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 1 and clause 2.</li><li>9. A compound selected from one of the following formulas: <chemistry id="chem0838" num="0838"><img file="EP4470618A2_D0838.tif" /></chemistry><chemistry id="chem0839" num="0839"><img file="EP4470618A2_D0839.tif" /></chemistry><chemistry id="chem0840" num="0840"><img file="EP4470618A2_D0840.tif" /></chemistry><chemistry id="chem0841" num="0841"><img file="EP4470618A2_D0841.tif" /></chemistry><chemistry id="chem0842" num="0842"><img file="EP4470618A2_D0842.tif" /></chemistry> or a pharmaceutically acceptable salt thereof; wherein: <ul id="ul0031" list-style="none" compact="compact"><li>R<sup>2</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl substituted by R<sup>9</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl; -C(=O)C<sub>1-6</sub>alkyl; -C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -N(R<sup>5</sup>,R<sup>6</sup>); -NO<sub>2</sub>; -NH-C(=O)C<sub>1-6</sub>alkyl; and -SO<sub>2</sub>-N(R<sup>5</sup>,R<sup>6</sup>); and</li><li>wherein all other variables are as defined in clause 1 and clause 2.</li></ul></li><li>10. A compound selected from one of the following formulas: <chemistry id="chem0843" num="0843"><img file="EP4470618A2_D0843.tif" /></chemistry><chemistry id="chem0844" num="0844"><img file="EP4470618A2_D0844.tif" /></chemistry><chemistry id="chem0845" num="0845"><img file="EP4470618A2_D0845.tif" /></chemistry><chemistry id="chem0846" num="0846"><img file="EP4470618A2_D0846.tif" /></chemistry> and <chemistry id="chem0847" num="0847"><img file="EP4470618A2_D0847.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 1, clause 2, and clause 9.</li><li>11. A compound selected from one of the following formulas: <chemistry id="chem0848" num="0848"><img file="EP4470618A2_D0848.tif" /></chemistry><chemistry id="chem0849" num="0849"><img file="EP4470618A2_D0849.tif" /></chemistry><chemistry id="chem0850" num="0850"><img file="EP4470618A2_D0850.tif" /></chemistry><chemistry id="chem0851" num="0851"><img file="EP4470618A2_D0851.tif" /></chemistry> and <chemistry id="chem0852" num="0852"><img file="EP4470618A2_D0852.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 1, clause 2, and clause 9.</li><li>12. A compound of Formula XII: <chemistry id="chem0853" num="0853"><img file="EP4470618A2_D0853.tif" /></chemistry> or a pharmaceutically acceptable salt thereof; wherein: <ul id="ul0032" list-style="none" compact="compact"><li>A is selected from: aryl optionally substituted with one or two R<sup>2</sup> groups; heteroaryl optionally substituted with one or two R<sup>3</sup> groups; heterocycloalkyl optionally substituted with one or two R<sup>4</sup> groups; -NH-C(=O)-C<sub>1-6</sub>alkyl; and cycloalkyl; and</li><li>wherein the remaining variables are as defined in clause 1, clause 2, and clause 9.</li></ul></li><li>13. A compound selected from one of the following formulas: <chemistry id="chem0854" num="0854"><img file="EP4470618A2_D0854.tif" /></chemistry><chemistry id="chem0855" num="0855"><img file="EP4470618A2_D0855.tif" /></chemistry><chemistry id="chem0856" num="0856"><img file="EP4470618A2_D0856.tif" /></chemistry><chemistry id="chem0857" num="0857"><img file="EP4470618A2_D0857.tif" /></chemistry> and <chemistry id="chem0858" num="0858"><img file="EP4470618A2_D0858.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 1, clause 2, and clause 9.</li><li>14. A compound of Formula I(1): <chemistry id="chem0859" num="0859"><img file="EP4470618A2_D0859.tif" /></chemistry> or a pharmaceutically acceptable salt thereof; wherein: <ul id="ul0033" list-style="none" compact="compact"><li>X<sup>1</sup> is selected from bond, NR<sup>34</sup>, CH<sub>2</sub>, CHR<sup>34</sup>, C(R<sup>34</sup>)<sub>2</sub>, O, and S;</li><li>X<sup>22</sup> is a functional group that can be used as a linking group to a protein binding moiety; or X<sup>22</sup> is a group that caps the valence and is not typically a linking group;</li><li>R<sup>34</sup> and R<sup>34'</sup> are independently selected at each occurrence from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, C<sub>3</sub>-C<sub>6</sub>heterocycle, aryl, heteroaryl, - (CO)R<sup>36</sup>, -(CS)R<sup>36</sup>, -(C=NH)R<sup>36</sup>, -(SO)R<sup>36</sup>, and -(SO<sub>2</sub>)R<sup>36</sup>;</li><li>R<sup>36</sup> is independently selected at each occurrence from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, C<sub>3</sub>-C<sub>6</sub>heterocycle, aryl, heteroaryl, hydroxyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, thio, C<sub>1</sub>-C<sub>6</sub>thioalkyl, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, C<sub>3</sub>-C<sub>7</sub>heterocycle, aryl, or heteroaryl), and -N(independently C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl, C<sub>3</sub>-C<sub>7</sub>heterocycle, aryl, or heteroaryl)<sub>2</sub>;</li><li>R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> are independently a divalent or mutltivalent linking group, including but not limited to a covalent bond, alkyl, -C(O)-, -C(O)O-, -OC(O)-, -C(O)alkyl, -C(O)Oalkyl, -C(S)-, -SO<sub>2</sub>-, -S(O)-, -C(S)-, -C(O)NH-, -NHC(O)-, -N(alkyl)C(O)-, -C(O)N(alkyl)-, -O-, -S-, -NH-, -N(alkyl)-, -CH(-O-R<sup>26</sup>)-, -CH(-NR<sup>34</sup>R<sup>34'</sup>)-, -C(-O-R<sup>26</sup>)alkyl-, -C(-NR<sup>34</sup>R<sup>34'</sup>)alkyl-, -C(R<sup>40</sup>R<sup>40</sup>)-, -alkyl(R<sup>27</sup>)-alkyl(R<sup>28</sup>)-, -C(R<sup>27</sup>R<sup>28</sup>)-, -P(O)(OR<sup>26</sup>)O-, -P(O)(OR<sup>26</sup>)-, -NR<sup>34</sup>C(O)NR<sup>34</sup> -, alkene, haloalkyl, alkoxy, alkyneheteroarylalkyl, aryl, arylalkyl, heterocycle, aliphatic, heteroaliphatic, heteroaryl, lactic acid, glycolic acid, carbocycle, -(ethylene glycol)<sub>1-6</sub>-, -(lactic-co-glycolic acid)<sub>1-6</sub>-, -(propylene glycol)<sub>1-6</sub>-, -O-(CH<sub>2</sub>)<sub>1-12</sub>-O-, -NH-(CH<sub>2</sub>)<sub>1-12</sub>-NH-, -NH-(CH<sub>2</sub>)<sub>1-12</sub>-O-, -O-(CH<sub>2</sub>)<sub>1-12</sub>-NH-, -S-(CH<sub>2</sub>)<sub>1-12</sub>-O-, -O-(CH<sub>2</sub>)<sub>1-12</sub>-S-, -S-(CH<sub>2</sub>)<sub>1-12</sub>-S-, -S-(CH<sub>2</sub>)<sub>1-12</sub>-NH-, and -NH-(CH<sub>2</sub>)<sub>1-12</sub>-S-;</li><li>each of which R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> is optionally substituted with one or more substituents selected from R<sup>101</sup>;</li><li>wherein at least one of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> is not a bond;</li><li>R<sup>101</sup> is independently selected at each occurrence from hydrogen, alkyl, alkene, alkyne, haloalkyl, alkoxy, hydroxyl, aryl, heteroaryl, heterocycle, arylalkyl, heteroarylalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, CN, -COOalkyl, COOH, NO<sub>2</sub>, F, Cl, Br, I, CF<sub>3</sub>, NH<sub>2</sub>, NHalkyl, N(alkyl)<sub>2</sub>, aliphatic, and heteroaliphatic;</li><li>R<sup>26</sup> is selected from hydrogen, alkyl, silane, arylalkyl, heteroarylalkyl, alkene, alkyne, aryl, heteroaryl, heterocyclic, aliphatic and heteroaliphatic;</li><li>R<sup>27</sup> and R<sup>28</sup> are independently selected from hydrogen, alkyl, amine, or together with the carbon atom to which they are attached, form C(O), C(S), C=CH<sub>2</sub>, a C<sub>3</sub>-C<sub>6</sub> spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O, or form a 1 or 2 carbon bridged ring; and</li><li>R<sup>40</sup> is selected at each instance from: hydrogen, alkyl, alkene, alkyne, halogen, hydroxyl, alkoxy, azide, amino, cyano, -NH(aliphatic, including alkyl), -N(aliphatic, including alkyl)<sub>2</sub>, -NHSO<sub>2</sub>(aliphatic, including alkyl), -N(aliphatic, including alkyl)SO<sub>2</sub>alkyl, -NHSO<sub>2</sub>(aryl, heteroaryl or heterocyclic), -N(alkyl)SO<sub>2</sub>(aryl, heteroaryl or heterocyclic) -NHSO<sub>2</sub>alkenyl, -N(alkyl)SO<sub>2</sub>alkenyl, -NHSO<sub>2</sub>alkynyl, -N(alkyl)SO<sub>2</sub>alkynyl, haloalkyl, aliphatic, heteroaliphatic, aryl, heteroaryl, heteroalkyl, heterocyclic, and carbocyclic; and</li><li>wherein the variables are as defined in clause 1, clause 2, and clause 9.</li></ul></li><li>15. A compound selected from one of the following formulas: <chemistry id="chem0860" num="0860"><img file="EP4470618A2_D0860.tif" /></chemistry><chemistry id="chem0861" num="0861"><img file="EP4470618A2_D0861.tif" /></chemistry><chemistry id="chem0862" num="0862"><img file="EP4470618A2_D0862.tif" /></chemistry><chemistry id="chem0863" num="0863"><img file="EP4470618A2_D0863.tif" /></chemistry><chemistry id="chem0864" num="0864"><img file="EP4470618A2_D0864.tif" /></chemistry><chemistry id="chem0865" num="0865"><img file="EP4470618A2_D0865.tif" /></chemistry><chemistry id="chem0866" num="0866"><img file="EP4470618A2_D0866.tif" /></chemistry><chemistry id="chem0867" num="0867"><img file="EP4470618A2_D0867.tif" /></chemistry><chemistry id="chem0868" num="0868"><img file="EP4470618A2_D0868.tif" /></chemistry><chemistry id="chem0869" num="0869"><img file="EP4470618A2_D0869.tif" /></chemistry> and <chemistry id="chem0870" num="0870"><img file="EP4470618A2_D0870.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 15.</li><li>16. A compound of Formula III(1): <chemistry id="chem0871" num="0871"><img file="EP4470618A2_D0871.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 15.</li><li>17. A compound selected from one of the following formulas: <chemistry id="chem0872" num="0872"><img file="EP4470618A2_D0872.tif" /></chemistry><chemistry id="chem0873" num="0873"><img file="EP4470618A2_D0873.tif" /></chemistry><chemistry id="chem0874" num="0874"><img file="EP4470618A2_D0874.tif" /></chemistry><chemistry id="chem0875" num="0875"><img file="EP4470618A2_D0875.tif" /></chemistry><chemistry id="chem0876" num="0876"><img file="EP4470618A2_D0876.tif" /></chemistry><chemistry id="chem0877" num="0877"><img file="EP4470618A2_D0877.tif" /></chemistry><chemistry id="chem0878" num="0878"><img file="EP4470618A2_D0878.tif" /></chemistry><chemistry id="chem0879" num="0879"><img file="EP4470618A2_D0879.tif" /></chemistry><chemistry id="chem0880" num="0880"><img file="EP4470618A2_D0880.tif" /></chemistry> and <chemistry id="chem0881" num="0881"><img file="EP4470618A2_D0881.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 15.</li><li>18. A compound of Formula V(1): <chemistry id="chem0882" num="0882"><img file="EP4470618A2_D0882.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 15.</li><li>19. A compound of Formula VI(1): <chemistry id="chem0883" num="0883"><img file="EP4470618A2_D0883.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 15.</li><li>20. A compound selected from one of the following formulas: <chemistry id="chem0884" num="0884"><img file="EP4470618A2_D0884.tif" /></chemistry><chemistry id="chem0885" num="0885"><img file="EP4470618A2_D0885.tif" /></chemistry><chemistry id="chem0886" num="0886"><img file="EP4470618A2_D0886.tif" /></chemistry><chemistry id="chem0887" num="0887"><img file="EP4470618A2_D0887.tif" /></chemistry> and <chemistry id="chem0888" num="0888"><img file="EP4470618A2_D0888.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 15.</li><li>21. A compound selected from one of the following formulas: <chemistry id="chem0889" num="0889"><img file="EP4470618A2_D0889.tif" /></chemistry><chemistry id="chem0890" num="0890"><img file="EP4470618A2_D0890.tif" /></chemistry><chemistry id="chem0891" num="0891"><img file="EP4470618A2_D0891.tif" /></chemistry><chemistry id="chem0892" num="0892"><img file="EP4470618A2_D0892.tif" /></chemistry><chemistry id="chem0893" num="0893"><img file="EP4470618A2_D0893.tif" /></chemistry><chemistry id="chem0894" num="0894"><img file="EP4470618A2_D0894.tif" /></chemistry><chemistry id="chem0895" num="0895"><img file="EP4470618A2_D0895.tif" /></chemistry><chemistry id="chem0896" num="0896"><img file="EP4470618A2_D0896.tif" /></chemistry> and <chemistry id="chem0897" num="0897"><img file="EP4470618A2_D0897.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 15.</li><li>22. A compound selected from one of the following formulas: <chemistry id="chem0898" num="0898"><img file="EP4470618A2_D0898.tif" /></chemistry><chemistry id="chem0899" num="0899"><img file="EP4470618A2_D0899.tif" /></chemistry><chemistry id="chem0900" num="0900"><img file="EP4470618A2_D0900.tif" /></chemistry><chemistry id="chem0901" num="0901"><img file="EP4470618A2_D0901.tif" /></chemistry><chemistry id="chem0902" num="0902"><img file="EP4470618A2_D0902.tif" /></chemistry><chemistry id="chem0903" num="0903"><img file="EP4470618A2_D0903.tif" /></chemistry><chemistry id="chem0904" num="0904"><img file="EP4470618A2_D0904.tif" /></chemistry><chemistry id="chem0905" num="0905"><img file="EP4470618A2_D0905.tif" /></chemistry><chemistry id="chem0906" num="0906"><img file="EP4470618A2_D0906.tif" /></chemistry> and <chemistry id="chem0907" num="0907"><img file="EP4470618A2_D0907.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 15.</li><li>23. A compound selected from one of the following formulas: <chemistry id="chem0908" num="0908"><img file="EP4470618A2_D0908.tif" /></chemistry><chemistry id="chem0909" num="0909"><img file="EP4470618A2_D0909.tif" /></chemistry><chemistry id="chem0910" num="0910"><img file="EP4470618A2_D0910.tif" /></chemistry><chemistry id="chem0911" num="0911"><img file="EP4470618A2_D0911.tif" /></chemistry><chemistry id="chem0912" num="0912"><img file="EP4470618A2_D0912.tif" /></chemistry><chemistry id="chem0913" num="0913"><img file="EP4470618A2_D0913.tif" /></chemistry><chemistry id="chem0914" num="0914"><img file="EP4470618A2_D0914.tif" /></chemistry><chemistry id="chem0915" num="0915"><img file="EP4470618A2_D0915.tif" /></chemistry> and <chemistry id="chem0916" num="0916"><img file="EP4470618A2_D0916.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 15.</li><li>24. A compound selected from one of the following formulas: <chemistry id="chem0917" num="0917"><img file="EP4470618A2_D0917.tif" /></chemistry><chemistry id="chem0918" num="0918"><img file="EP4470618A2_D0918.tif" /></chemistry><chemistry id="chem0919" num="0919"><img file="EP4470618A2_D0919.tif" /></chemistry><chemistry id="chem0920" num="0920"><img file="EP4470618A2_D0920.tif" /></chemistry><chemistry id="chem0921" num="0921"><img file="EP4470618A2_D0921.tif" /></chemistry><chemistry id="chem0922" num="0922"><img file="EP4470618A2_D0922.tif" /></chemistry><chemistry id="chem0923" num="0923"><img file="EP4470618A2_D0923.tif" /></chemistry><chemistry id="chem0924" num="0924"><img file="EP4470618A2_D0924.tif" /></chemistry> and <chemistry id="chem0925" num="0925"><img file="EP4470618A2_D0925.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 15.</li><li>25. A compound of Formula XII(1): <chemistry id="chem0926" num="0926"><img file="EP4470618A2_D0926.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 15.</li><li>26. A compound selected from one of the following formulas: <chemistry id="chem0927" num="0927"><img file="EP4470618A2_D0927.tif" /></chemistry><chemistry id="chem0928" num="0928"><img file="EP4470618A2_D0928.tif" /></chemistry><chemistry id="chem0929" num="0929"><img file="EP4470618A2_D0929.tif" /></chemistry><chemistry id="chem0930" num="0930"><img file="EP4470618A2_D0930.tif" /></chemistry><chemistry id="chem0931" num="0931"><img file="EP4470618A2_D0931.tif" /></chemistry><chemistry id="chem0932" num="0932"><img file="EP4470618A2_D0932.tif" /></chemistry><chemistry id="chem0933" num="0933"><img file="EP4470618A2_D0933.tif" /></chemistry><chemistry id="chem0934" num="0934"><img file="EP4470618A2_D0934.tif" /></chemistry> and <chemistry id="chem0935" num="0935"><img file="EP4470618A2_D0935.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 15.</li><li>27. The compound of any one of clauses 1-26, wherein A<sup>1</sup> is selected from the group consisting of -O- and -NH-, and A<sup>2</sup> is -CH<sub>2</sub>-.</li><li>28. The compound of any one of clauses 1-26, wherein A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, -CF<sub>2</sub>-, and A<sup>2</sup> is-NH-.</li><li>29. The compound of any one of clauses 1-28, wherein W is CH.</li><li>30. The compound of any one of clauses 1-28, wherein W is N.</li><li>31. The compound of any one of clauses 1-30, wherein R<sup>2</sup> is independently selected at each occurrence from: -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -N(R<sup>5</sup>,R<sup>6</sup>); -NO<sub>2</sub>; -NH-C(=O)C<sub>1-6</sub>alkyl; and -SO<sub>2</sub>-N(R<sup>5</sup>,R<sup>6</sup>).</li><li>32. The compound of any one of clauses 1-30, wherein R<sup>2</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; -C(=O)C<sub>1-6</sub>alkyl; - C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; and -O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl.</li><li>33. The compound of any one of clauses 1-32, wherein R<sup>3</sup> is independently selected at each occurrence from: -C(=O)C<sub>1-6</sub>alkyl; -(CH<sub>2</sub>)<sub>0-2</sub>-C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -OH; -NO<sub>2</sub>; -C<sub>1-6</sub>alkyl-N(R<sup>11</sup>)-C(=O)-R<sup>12</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl-aryl; -N(R<sup>5</sup>,R<sup>6</sup>); -NH-C(=O)C<sub>1-6</sub>alkyl; and -NH-C(=O)OC<sub>1-6</sub>alkyl.</li><li>34. The compound of any one of clauses 1-32, wherein R<sup>3</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl substituted by R<sup>9</sup>; and -(CH<sub>2</sub>)<sub>0-1</sub>-heterocycloalkyl.</li><li>35. The compound of any one of clauses 1-34, wherein R<sup>4</sup> is independently selected at each occurrence from: -C(=O)C<sub>1-6</sub>alkyl; -C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -N(R<sup>5</sup>,R<sup>6</sup>); and -NH-C(=O)C<sub>1-6</sub>alkyl.</li><li>36. The compound of any one of clauses 1-34, wherein R<sup>4</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; and -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl.</li><li>37. The compound of any one of clauses 1-36, wherein R<sup>5</sup> and R<sup>6</sup> are independently selected at each occurrence from H, C<sub>1-6</sub>alkyl and phenyl.</li><li>38. The compound of any one of clauses 1-36, wherein R<sup>5</sup> and R<sup>6</sup>, taken together with the nitrogen to which they are attached, form a heterocycloalkyl ring.</li><li>39. The compound of any one of clauses 1-38, wherein R<sup>7</sup> and R<sup>8</sup> are independently selected at each occurrence from Hand C<sub>1-6</sub>alkyl.</li><li>40. The compound of any one of clauses 1-38, wherein R<sup>7</sup> and R<sup>8</sup>, taken together with the nitrogen to which they are attached, form a heterocycloalkyl ring.</li><li>41. The compound of any one of clauses 14-40, wherein X<sup>1</sup> is selected from bond or NR<sub>3</sub><sup>4</sup>.</li><li>42. The compound of any one of clauses 14-41, wherein X<sup>22</sup> is selected from halo, -NH<sub>2</sub>, - NHR<sup>34</sup>, -N(R<sup>34</sup>)<sub>2</sub>, hydroxyl, thiol, -B(OH)<sub>2</sub>, -Sn(R<sup>36</sup>)<sub>3</sub>, -Si(R<sup>36</sup>)<sub>3</sub>, -OS(O)<sub>2</sub>alkyl, -OS(O)<sub>2</sub>haloalkyl, alkenyl, alkynyl, ethynyl, ethenyl, -C(O)H, -NR<sup>34</sup>C(O)alkene, -NR<sup>34</sup>C(O)alkyne, cyano, - SC(O)alkyl, OC(O)alkyl, heterocycle, -C(O)OH, hydrogen, alkyl, aryl, heteroaryl, aliphatic, heteroaliphatic, and carbocyclic.</li><li>43. The compound of any one of clauses 14-42, wherein R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> are independently selected from bond, alkyl, -C(O)-, -C(O)O-, -OC(O)-, -C(O)alkyl, -C(O)Oalkyl, - C(S)-, -SO<sub>2</sub>-, -S(O)-, -C(S)-, -C(O)NH-, -NHC(O)-, -N(alkyl)C(O)-, -C(O)N(alkyl)-, -O-, -S-, - NH-, -N(alkyl)-, -CH(-O-R<sup>26</sup>)-, -CH(-NR<sup>34</sup>R<sup>34'</sup>)-, -C(-O-R<sup>26</sup>)alkyl-, -C(-NR<sup>34</sup>R<sup>34'</sup>)alkyl-, - C(R<sup>40</sup>R<sup>40</sup>)-, -alkyl(R<sup>27</sup>)-alkyl(R<sup>28</sup>)-, -C(R<sup>27</sup>R<sup>28</sup>)-, -P(O)(OR<sup>26</sup>)O-, -P(O)(OR<sup>26</sup>)-, -NR<sup>34</sup>C(O)NR<sup>34'</sup>-, alkene, haloalkyl, alkoxy, alkyneheteroarylalkyl, aryl, arylalkyl, heterocycle, aliphatic, heteroaliphatic, heteroaryl, lactic acid, glycolic acid, carbocycle, -(ethylene glycol)<sub>1-6</sub>-, -(lactic-co-glycolic acid)<sub>1-6</sub>-, -(propylene glycol)<sub>1-6</sub>-, -O-(CH<sub>2</sub>)<sub>1-12</sub>-O-, -NH-(CH<sub>2</sub>)<sub>1-12</sub>-NH-, -NH-(CH<sub>2</sub>)<sub>1-12</sub>-O-, -O-(CH<sub>2</sub>)<sub>1-12</sub>-NH-, -S-(CH<sub>2</sub>)<sub>1-12</sub>-O-, -O-(CH<sub>2</sub>)<sub>1-12</sub>-S-, -S-(CH<sub>2</sub>)<sub>1-12</sub>-S-, -S-(CH<sub>2</sub>)<sub>1-12</sub>-NH-, and -NH-(CH<sub>2</sub>)<sub>1-12</sub>-S-, wherein at least one of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> is not a bond.</li><li>44. The compound of clause 43, wherein at least two of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> are not a bond.</li><li>45. The compound of clause 43, wherein at least three of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> are not a bond.</li><li>46. The compound of clause 43, wherein at least four of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> are not a bond.</li><li>47. The compound of clause 43, wherein none of R<sup>20</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup>, and R<sup>24</sup> are a bond.</li><li>48. A compound selected from: <chemistry id="chem0936" num="0936"><img file="EP4470618A2_D0936.tif" /></chemistry><chemistry id="chem0937" num="0937"><img file="EP4470618A2_D0937.tif" /></chemistry><chemistry id="chem0938" num="0938"><img file="EP4470618A2_D0938.tif" /></chemistry><chemistry id="chem0939" num="0939"><img file="EP4470618A2_D0939.tif" /></chemistry><chemistry id="chem0940" num="0940"><img file="EP4470618A2_D0940.tif" /></chemistry><chemistry id="chem0941" num="0941"><img file="EP4470618A2_D0941.tif" /></chemistry> and <chemistry id="chem0942" num="0942"><img file="EP4470618A2_D0942.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>49. A pharmaceutical composition comprising a compound of any one of clauses 1-48 in a pharmaceutically acceptable carrier.</li><li>50. A method of treating abnormal cellular proliferation in a human subject in need thereof comprising administering an effective amount of a compound of any one of clauses 1-48, or a pharmaceutically acceptable salt thereof.</li><li>51. A method for the treatment of abnormal proliferation in a human subject comprising administering a compound of Formula XIV: <chemistry id="chem0943" num="0943"><img file="EP4470618A2_D0943.tif" /></chemistry> or a pharmaceutically acceptable salt thereof; wherein: <ul id="ul0034" list-style="none" compact="compact"><li>A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, -CF<sub>2</sub>- and -NH-, and A<sup>2</sup> is -CH<sub>2</sub>-; or</li><li>A<sup>1</sup> is selected from the group consisting of -O-, -S-, -CH<sub>2</sub>-, and -CF<sub>2</sub>-, and A<sup>2</sup> is-NH-;</li><li>W is CH or N;</li><li>Z is selected from: a covalent bond; carbonyl; -(CH<sub>2</sub>)<sub>0-2</sub>-NR<sup>1</sup>-(CH<sub>2</sub>)<sub>0-2</sub>-; -(NR<sup>1</sup>)<sub>0-1</sub>-C(=O)-(NR<sup>1</sup>)<sub>0-1</sub>-; -(NR<sup>1</sup>)<sub>0-1</sub>-C(=O)-(CH<sub>2</sub>)<sub>1-3</sub>-; -O-(CH<sub>2</sub>)<sub>0-2</sub>-C(=O)-NR<sup>1</sup>-; -(CH<sub>2</sub>)<sub>1-3</sub>-; -(CH<sub>2</sub>)<sub>1-3</sub>-; -(CH<sub>2</sub>)<sub>0-2</sub>-O-(CH<sub>2</sub>)<sub>0-2</sub>; and -(NR<sup>1</sup>)<sub>0-1</sub>-SO<sub>0-2</sub>-(NR<sup>1</sup>)<sub>0-1</sub>-;</li><li>or Z is selected from alkylene, alkenylene, alkynylene, arylene, heteroarylene, heterocyclyl, or carbocyclyl;</li><li>A is selected from: aryl optionally substituted with one or two R<sup>2</sup> groups; heteroaryl optionally substituted with one or two R<sup>3</sup> groups; heterocycloalkyl optionally substituted with one or two R<sup>4</sup> groups; -NH-C(=O)-C<sub>1-6</sub>alkyl; and cycloalkyl;</li><li>R<sup>1</sup> is independently selected from H or C<sub>1-6</sub>alkyl;</li><li>R<sup>2</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl substituted by R<sup>9</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl; -C(=O)C<sub>1-6</sub>alkyl; -C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -N(R<sup>5</sup>,R<sup>6</sup>); -NO<sub>2</sub>; -NH-C(=O)C<sub>1-6</sub>alkyl; and -SO<sub>2</sub>-N(R<sup>5</sup>,R<sup>6</sup>);</li><li>R<sup>3</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl substituted by R<sup>9</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl; -(CH<sub>2</sub>)<sub>0-1</sub>-heterocycloalkyl; -C(=O)C<sub>1-6</sub>alkyl; -(CH<sub>2</sub>)<sub>0-2</sub>-C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -OH; -NO<sub>2</sub>; -C<sub>1-6</sub>alkyl-N(R<sup>11</sup>)-C(=O)-R<sup>12</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl-aryl; -N(R<sup>5</sup>,R<sup>6</sup>); -NH-C(=O)C<sub>1-6</sub>alkyl; -NH-C(=O)OC<sub>1-6</sub>alkyl; and =O as allowed by valence;</li><li>R<sup>4</sup> is independently selected at each occurrence from: -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-(C<sub>3-7</sub>cycloalkyl)-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl substituted by R<sup>10</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-C<sub>3-7</sub>cycloalkyl; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl substituted by R<sup>9</sup>; -(CH<sub>2</sub>)<sub>0-1</sub>-heteroaryl; =O as allowed by valence; -C(=O)C<sub>1-6</sub>alkyl; -C(=O)-N(R<sup>7</sup>,R<sup>8</sup>); -C(=O)OC<sub>1-6</sub>alkyl; -C<sub>1-6</sub>alkoxy; -C<sub>1-6</sub>alkyl; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl substituted by R<sup>10</sup>; -CH<sub>2</sub>-O-(CH<sub>2</sub>)<sub>0-1</sub>-aryl; -halogen; -halogen-C<sub>1-6</sub>alkyl; -hydroxy-C<sub>1-6</sub>alkyl; -N(R<sup>5</sup>,R<sup>6</sup>); and -NH-C(=O)C<sub>1-6</sub>alkyl;</li><li>R<sup>5</sup> and R<sup>6</sup> are independently selected at each occurrence from H, C<sub>1-6</sub>alkyl and phenyl;</li><li>or R<sup>5</sup> and R<sup>6</sup>, taken together with the nitrogen to which they are attached, form a heterocycloalkyl ring;</li><li>R<sup>7</sup> and R<sup>8</sup> are independently selected at each occurrence from Hand C<sub>1-6</sub>alkyl;</li><li>or R<sup>7</sup> and R<sup>8</sup>, taken together with the nitrogen to which they are attached, form a heterocycloalkyl ring;</li><li>R<sup>9</sup> is independently selected at each occurrence from C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkyl, halogen, halogen-C<sub>1-6</sub>alkyl, heteroaryl, and heteroaryl substituted by C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkoxy;</li><li>R<sup>10</sup> is independently selected at each occurrence from C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl-C<sub>1-6</sub>alkoxy, halogen, and halogen-C<sub>1-6</sub>alkyl;</li><li>R<sup>11</sup> is independently selected at each occurrence from Hand C<sub>1-6</sub>alkyl; and</li><li>R<sup>12</sup> is independently selected at each occurrence from H, C<sub>1-6</sub>alkyl and C<sub>3-7</sub>cycloalkyl.</li></ul></li><li>52. A method of treating abnormal cell proliferation in a human subject comprising administering a compound of one of the following formulas: <chemistry id="chem0944" num="0944"><img file="EP4470618A2_D0944.tif" /></chemistry><chemistry id="chem0945" num="0945"><img file="EP4470618A2_D0945.tif" /></chemistry><chemistry id="chem0946" num="0946"><img file="EP4470618A2_D0946.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>53. A method of treatment of abnormal cellular proliferation in a human subject comprising administering a compound of Formula XIV(1): <chemistry id="chem0947" num="0947"><img file="EP4470618A2_D0947.tif" /></chemistry> or a pharmaceutically acceptable salt thereof; wherein: <ul id="ul0035" list-style="none" compact="compact"><li>A<sup>B</sup> is selected from arylene optionally substituted with one or two R<sup>2</sup> groups, heteroarylene optionally substituted with one or two R<sup>3</sup> groups; heterocycloalkylene optionally substituted with one or two R<sup>4</sup> groups, -NH-C(=O)-C<sub>1-6</sub>alkylene-, and cycloalkylene;</li><li>"Tail" is <chemistry id="chem0948" num="0948"><img file="EP4470618A2_D0948.tif" /></chemistry> and</li><li>wherein the remaining variables are as defined in clause 15.</li></ul></li><li>54. The method of any one of clauses 50-53, wherein the abnormal cellular proliferation is a cancer.</li><li>55. The method of any one of clauses 50-53, wherein the abnormal cellular proliferation is a tumor.</li><li>56. A compound of any one of clauses 1-48 or a pharmaceutical composition of clause 49 for use in the treatment of abnormal cellular proliferation in a human subject.</li><li>57. A compound for use in the treatment of abnormal cellular proliferation in a human subject, wherein the compound is selected from: <chemistry id="chem0949" num="0949"><img file="EP4470618A2_D0949.tif" /></chemistry><chemistry id="chem0950" num="0950"><img file="EP4470618A2_D0950.tif" /></chemistry><chemistry id="chem0951" num="0951"><img file="EP4470618A2_D0951.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>58. A compound for use in the treatment of abnormal cellular proliferation in a human subject, wherein the compound is selected from Formula XIV and Formula XIV(1): <chemistry id="chem0952" num="0952"><img file="EP4470618A2_D0952.tif" /></chemistry> and <chemistry id="chem0953" num="0953"><img file="EP4470618A2_D0953.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 53.</li><li>59. The compound or pharmaceutical composition for use of any one of clauses 56-58, wherein the abnormal cellular proliferation is a cancer.</li><li>60. The compound or pharmaceutical composition for use of any one of clauses 56-58, wherein the abnormal cellular proliferation is a tumor.</li><li>61. Use of a compound of any one of clauses 1-48 in the manufacture of a medicament for the treatment of abnormal cellular proliferation in a human subject.</li><li>62. Use of a compound in the manufacture of a medicament for the treatment of abnormal cellular proliferation in a human subject, wherein the compound is selected from: <chemistry id="chem0954" num="0954"><img file="EP4470618A2_D0954.tif" /></chemistry><chemistry id="chem0955" num="0955"><img file="EP4470618A2_D0955.tif" /></chemistry><chemistry id="chem0956" num="0956"><img file="EP4470618A2_D0956.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>63. Use of a compound of any one of clauses 1-48 in the manufacture of a medicament for the treatment of abnormal cellular proliferation in a human subject wherein the compound is selected from Formula XIV and Formula XIV(1): <chemistry id="chem0957" num="0957"><img file="EP4470618A2_D0957.tif" /></chemistry> and <chemistry id="chem0958" num="0958"><img file="EP4470618A2_D0958.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in clause 15.</li></ol>
Contents8
969 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44 Sheet 45 Sheet 46 Sheet 47 Sheet 48 Sheet 49 Sheet 50 Sheet 51 Sheet 52 Sheet 53 Sheet 54 Sheet 55 Sheet 56 Sheet 57 Sheet 58 Sheet 59 Sheet 60 Sheet 61 Sheet 62 Sheet 63 Sheet 64 Sheet 65 Sheet 66 Sheet 67 Sheet 68 Sheet 69 Sheet 70 Sheet 71 Sheet 72 Sheet 73 Sheet 74 Sheet 75 Sheet 76 Sheet 77 Sheet 78 Sheet 79 Sheet 80 Sheet 81 Sheet 82 Sheet 83 Sheet 84 Sheet 85 Sheet 86 Sheet 87 Sheet 88 Sheet 89 Sheet 90 Sheet 91 Sheet 92 Sheet 93 Sheet 94 Sheet 95 Sheet 96 Sheet 97 Sheet 98 Sheet 99 Sheet 100 Sheet 101 Sheet 102 Sheet 103 Sheet 104 Sheet 105 Sheet 106 Sheet 107 Sheet 108 Sheet 109 Sheet 110 Sheet 111 Sheet 112 Sheet 113 Sheet 114 Sheet 115 Sheet 116 Sheet 117 Sheet 118 Sheet 119 Sheet 120 Sheet 121 Sheet 122 Sheet 123 Sheet 124 Sheet 125 Sheet 126 Sheet 127 Sheet 128 Sheet 129 Sheet 130 Sheet 131 Sheet 132 Sheet 133 Sheet 134 Sheet 135 Sheet 136 Sheet 137 Sheet 138 Sheet 139 Sheet 140 Sheet 141 Sheet 142 Sheet 143 Sheet 144 Sheet 145 Sheet 146 Sheet 147 Sheet 148 Sheet 149 Sheet 150 Sheet 151 Sheet 152 Sheet 153 Sheet 154 Sheet 155 Sheet 156 Sheet 157 Sheet 158 Sheet 159 Sheet 160 Sheet 161 Sheet 162 Sheet 163 Sheet 164 Sheet 165 Sheet 166 Sheet 167 Sheet 168 Sheet 169 Sheet 170 Sheet 171 Sheet 172 Sheet 173 Sheet 174 Sheet 175 Sheet 176 Sheet 177 Sheet 178 Sheet 179 Sheet 180 Sheet 181 Sheet 182 Sheet 183 Sheet 184 Sheet 185 Sheet 186 Sheet 187 Sheet 188 Sheet 189 Sheet 190 Sheet 191 Sheet 192 Sheet 193 Sheet 194 Sheet 195 Sheet 196 Sheet 197 Sheet 198 Sheet 199 Sheet 200 Sheet 201 Sheet 202 Sheet 203 Sheet 204 Sheet 205 Sheet 206 Sheet 207 Sheet 208 Sheet 209 Sheet 210 Sheet 211 Sheet 212 Sheet 213 Sheet 214 Sheet 215 Sheet 216 Sheet 217 Sheet 218 Sheet 219 Sheet 220 Sheet 221 Sheet 222 Sheet 223 Sheet 224 Sheet 225 Sheet 226 Sheet 227 Sheet 228 Sheet 229 Sheet 230 Sheet 231 Sheet 232 Sheet 233 Sheet 234 Sheet 235 Sheet 236 Sheet 237 Sheet 238 Sheet 239 Sheet 240 Sheet 241 Sheet 242 Sheet 243 Sheet 244 Sheet 245 Sheet 246 Sheet 247 Sheet 248 Sheet 249 Sheet 250 Sheet 251 Sheet 252 Sheet 253 Sheet 254 Sheet 255 Sheet 256 Sheet 257 Sheet 258 Sheet 259 Sheet 260 Sheet 261 Sheet 262 Sheet 263 Sheet 264 Sheet 265 Sheet 266 Sheet 267 Sheet 268 Sheet 269 Sheet 270 Sheet 271 Sheet 272 Sheet 273 Sheet 274 Sheet 275 Sheet 276 Sheet 277 Sheet 278 Sheet 279 Sheet 280 Sheet 281 Sheet 282 Sheet 283 Sheet 284 Sheet 285 Sheet 286 Sheet 287 Sheet 288 Sheet 289 Sheet 290 Sheet 291 Sheet 292 Sheet 293 Sheet 294 Sheet 295 Sheet 296 Sheet 297 Sheet 298 Sheet 299 Sheet 300 Sheet 301 Sheet 302 Sheet 303 Sheet 304 Sheet 305 Sheet 306 Sheet 307 Sheet 308 Sheet 309 Sheet 310 Sheet 311 Sheet 312 Sheet 313 Sheet 314 Sheet 315 Sheet 316 Sheet 317 Sheet 318 Sheet 319 Sheet 320 Sheet 321 Sheet 322 Sheet 323 Sheet 324 Sheet 325 Sheet 326 Sheet 327 Sheet 328 Sheet 329 Sheet 330 Sheet 331 Sheet 332 Sheet 333 Sheet 334 Sheet 335 Sheet 336 Sheet 337 Sheet 338 Sheet 339 Sheet 340 Sheet 341 Sheet 342 Sheet 343 Sheet 344 Sheet 345 Sheet 346 Sheet 347 Sheet 348 Sheet 349 Sheet 350 Sheet 351 Sheet 352 Sheet 353 Sheet 354 Sheet 355 Sheet 356 Sheet 357 Sheet 358 Sheet 359 Sheet 360 Sheet 361 Sheet 362 Sheet 363 Sheet 364 Sheet 365 Sheet 366 Sheet 367 Sheet 368 Sheet 369 Sheet 370 Sheet 371 Sheet 372 Sheet 373 Sheet 374 Sheet 375 Sheet 376 Sheet 377 Sheet 378 Sheet 379 Sheet 380 Sheet 381 Sheet 382 Sheet 383 Sheet 384 Sheet 385 Sheet 386 Sheet 387 Sheet 388 Sheet 389 Sheet 390 Sheet 391 Sheet 392 Sheet 393 Sheet 394 Sheet 395 Sheet 396 Sheet 397 Sheet 398 Sheet 399 Sheet 400 Sheet 401 Sheet 402 Sheet 403 Sheet 404 Sheet 405 Sheet 406 Sheet 407 Sheet 408 Sheet 409 Sheet 410 Sheet 411 Sheet 412 Sheet 413 Sheet 414 Sheet 415 Sheet 416 Sheet 417 Sheet 418 Sheet 419 Sheet 420 Sheet 421 Sheet 422 Sheet 423 Sheet 424 Sheet 425 Sheet 426 Sheet 427 Sheet 428 Sheet 429 Sheet 430 Sheet 431 Sheet 432 Sheet 433 Sheet 434 Sheet 435 Sheet 436 Sheet 437 Sheet 438 Sheet 439 Sheet 440 Sheet 441 Sheet 442 Sheet 443 Sheet 444 Sheet 445 Sheet 446 Sheet 447 Sheet 448 Sheet 449 Sheet 450 Sheet 451 Sheet 452 Sheet 453 Sheet 454 Sheet 455 Sheet 456 Sheet 457 Sheet 458 Sheet 459 Sheet 460 Sheet 461 Sheet 462 Sheet 463 Sheet 464 Sheet 465 Sheet 466 Sheet 467 Sheet 468 Sheet 469 Sheet 470 Sheet 471 Sheet 472 Sheet 473 Sheet 474 Sheet 475 Sheet 476 Sheet 477 Sheet 478 Sheet 479 Sheet 480 Sheet 481 Sheet 482 Sheet 483 Sheet 484 Sheet 485 Sheet 486 Sheet 487 Sheet 488 Sheet 489 Sheet 490 Sheet 491 Sheet 492 Sheet 493 Sheet 494 Sheet 495 Sheet 496 Sheet 497 Sheet 498 Sheet 499 Sheet 500 Sheet 501 Sheet 502 Sheet 503 Sheet 504 Sheet 505 Sheet 506 Sheet 507 Sheet 508 Sheet 509 Sheet 510 Sheet 511 Sheet 512 Sheet 513 Sheet 514 Sheet 515 Sheet 516 Sheet 517 Sheet 518 Sheet 519 Sheet 520 Sheet 521 Sheet 522 Sheet 523 Sheet 524 Sheet 525 Sheet 526 Sheet 527 Sheet 528 Sheet 529 Sheet 530 Sheet 531 Sheet 532 Sheet 533 Sheet 534 Sheet 535 Sheet 536 Sheet 537 Sheet 538 Sheet 539 Sheet 540 Sheet 541 Sheet 542 Sheet 543 Sheet 544 Sheet 545 Sheet 546 Sheet 547 Sheet 548 Sheet 549 Sheet 550 Sheet 551 Sheet 552 Sheet 553 Sheet 554 Sheet 555 Sheet 556 Sheet 557 Sheet 558 Sheet 559 Sheet 560 Sheet 561 Sheet 562 Sheet 563 Sheet 564 Sheet 565 Sheet 566 Sheet 567 Sheet 568 Sheet 569 Sheet 570 Sheet 571 Sheet 572 Sheet 573 Sheet 574 Sheet 575 Sheet 576 Sheet 577 Sheet 578 Sheet 579 Sheet 580 Sheet 581 Sheet 582 Sheet 583 Sheet 584 Sheet 585 Sheet 586 Sheet 587 Sheet 588 Sheet 589 Sheet 590 Sheet 591 Sheet 592 Sheet 593 Sheet 594 Sheet 595 Sheet 596 Sheet 597 Sheet 598 Sheet 599 Sheet 600 Sheet 601 Sheet 602 Sheet 603 Sheet 604 Sheet 605 Sheet 606 Sheet 607 Sheet 608 Sheet 609 Sheet 610 Sheet 611 Sheet 612 Sheet 613 Sheet 614 Sheet 615 Sheet 616 Sheet 617 Sheet 618 Sheet 619 Sheet 620 Sheet 621 Sheet 622 Sheet 623 Sheet 624 Sheet 625 Sheet 626 Sheet 627 Sheet 628 Sheet 629 Sheet 630 Sheet 631 Sheet 632 Sheet 633 Sheet 634 Sheet 635 Sheet 636 Sheet 637 Sheet 638 Sheet 639 Sheet 640 Sheet 641 Sheet 642 Sheet 643 Sheet 644 Sheet 645 Sheet 646 Sheet 647 Sheet 648 Sheet 649 Sheet 650 Sheet 651 Sheet 652 Sheet 653 Sheet 654 Sheet 655 Sheet 656 Sheet 657 Sheet 658 Sheet 659 Sheet 660 Sheet 661 Sheet 662 Sheet 663 Sheet 664 Sheet 665 Sheet 666 Sheet 667 Sheet 668 Sheet 669 Sheet 670 Sheet 671 Sheet 672 Sheet 673 Sheet 674 Sheet 675 Sheet 676 Sheet 677 Sheet 678 Sheet 679 Sheet 680 Sheet 681 Sheet 682 Sheet 683 Sheet 684 Sheet 685 Sheet 686 Sheet 687 Sheet 688 Sheet 689 Sheet 690 Sheet 691 Sheet 692 Sheet 693 Sheet 694 Sheet 695 Sheet 696 Sheet 697 Sheet 698 Sheet 699 Sheet 700 Sheet 701 Sheet 702 Sheet 703 Sheet 704 Sheet 705 Sheet 706 Sheet 707 Sheet 708 Sheet 709 Sheet 710 Sheet 711 Sheet 712 Sheet 713 Sheet 714 Sheet 715 Sheet 716 Sheet 717 Sheet 718 Sheet 719 Sheet 720 Sheet 721 Sheet 722 Sheet 723 Sheet 724 Sheet 725 Sheet 726 Sheet 727 Sheet 728 Sheet 729 Sheet 730 Sheet 731 Sheet 732 Sheet 733 Sheet 734 Sheet 735 Sheet 736 Sheet 737 Sheet 738 Sheet 739 Sheet 740 Sheet 741 Sheet 742 Sheet 743 Sheet 744 Sheet 745 Sheet 746 Sheet 747 Sheet 748 Sheet 749 Sheet 750 Sheet 751 Sheet 752 Sheet 753 Sheet 754 Sheet 755 Sheet 756 Sheet 757 Sheet 758 Sheet 759 Sheet 760 Sheet 761 Sheet 762 Sheet 763 Sheet 764 Sheet 765 Sheet 766 Sheet 767 Sheet 768 Sheet 769 Sheet 770 Sheet 771 Sheet 772 Sheet 773 Sheet 774 Sheet 775 Sheet 776 Sheet 777 Sheet 778 Sheet 779 Sheet 780 Sheet 781 Sheet 782 Sheet 783 Sheet 784 Sheet 785 Sheet 786 Sheet 787 Sheet 788 Sheet 789 Sheet 790 Sheet 791 Sheet 792 Sheet 793 Sheet 794 Sheet 795 Sheet 796 Sheet 797 Sheet 798 Sheet 799 Sheet 800 Sheet 801 Sheet 802 Sheet 803 Sheet 804 Sheet 805 Sheet 806 Sheet 807 Sheet 808 Sheet 809 Sheet 810 Sheet 811 Sheet 812 Sheet 813 Sheet 814 Sheet 815 Sheet 816 Sheet 817 Sheet 818 Sheet 819 Sheet 820 Sheet 821 Sheet 822 Sheet 823 Sheet 824 Sheet 825 Sheet 826 Sheet 827 Sheet 828 Sheet 829 Sheet 830 Sheet 831 Sheet 832 Sheet 833 Sheet 834 Sheet 835 Sheet 836 Sheet 837 Sheet 838 Sheet 839 Sheet 840 Sheet 841 Sheet 842 Sheet 843 Sheet 844 Sheet 845 Sheet 846 Sheet 847 Sheet 848 Sheet 849 Sheet 850 Sheet 851 Sheet 852 Sheet 853 Sheet 854 Sheet 855 Sheet 856 Sheet 857 Sheet 858 Sheet 859 Sheet 860 Sheet 861 Sheet 862 Sheet 863 Sheet 864 Sheet 865 Sheet 866 Sheet 867 Sheet 868 Sheet 869 Sheet 870 Sheet 871 Sheet 872 Sheet 873 Sheet 874 Sheet 875 Sheet 876 Sheet 877 Sheet 878 Sheet 879 Sheet 880 Sheet 881 Sheet 882 Sheet 883 Sheet 884 Sheet 885 Sheet 886 Sheet 887 Sheet 888 Sheet 889 Sheet 890 Sheet 891 Sheet 892 Sheet 893 Sheet 894 Sheet 895 Sheet 896 Sheet 897 Sheet 898 Sheet 899 Sheet 900 Sheet 901 Sheet 902 Sheet 903 Sheet 904 Sheet 905 Sheet 906 Sheet 907 Sheet 908 Sheet 909 Sheet 910 Sheet 911 Sheet 912 Sheet 913 Sheet 914 Sheet 915 Sheet 916 Sheet 917 Sheet 918 Sheet 919 Sheet 920 Sheet 921 Sheet 922 Sheet 923 Sheet 924 Sheet 925 Sheet 926 Sheet 927 Sheet 928 Sheet 929 Sheet 930 Sheet 931 Sheet 932 Sheet 933 Sheet 934 Sheet 935 Sheet 936 Sheet 937 Sheet 938 Sheet 939 Sheet 940 Sheet 941 Sheet 942 Sheet 943 Sheet 944 Sheet 945 Sheet 946 Sheet 947 Sheet 948 Sheet 949 Sheet 950 Sheet 951 Sheet 952 Sheet 953 Sheet 954 Sheet 955 Sheet 956 Sheet 957 Sheet 958 Sheet 959 Sheet 960 Sheet 961 Sheet 962 Sheet 963 Sheet 964 Sheet 965 Sheet 966 Sheet 967 Sheet 968 Sheet 969
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| WO0020358A2 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| EP0125678A1 | Cites | European Patent Office (EPO) | Applicant |
| WO02072576A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| EP0385850A2 | Cites | European Patent Office (EPO) | Applicant |
| WO2004108133A2 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2005060967A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2005113489A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2006058338A2 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2007041598A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2007065518A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2009050232A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2009135651A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2010023161A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2010085684A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2010108817A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2010130794A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2011035124A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2011130628A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2011156245A2 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2012021382A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2012061708A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2012174199A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2013020557A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2013063560A2 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2013106643A2 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2014134240A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2015160845A2 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2016011906A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2016040508A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2016105518A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2016176449A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2016176640A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2017007612A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2017024318A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2017046318A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2017117473A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2017197036A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2017197046A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2017197051A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2017197055A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2017197056A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2018093569A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2018115218A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2018220149A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2018237026A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2019099868A2 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2019121562A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2019149922A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2019191112A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO2019236483A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| US6045501A | Cites | United States of America | Applicant |
| US6315720B1 | Cites | United States of America | Applicant |
| US6395754B1 | Cites | United States of America | Applicant |
| US6561976B2 | Cites | United States of America | Applicant |
| US6561977B2 | Cites | United States of America | Applicant |
| US6755784B2 | Cites | United States of America | Applicant |
| US6869399B2 | Cites | United States of America | Applicant |
| US6908432B2 | Cites | United States of America | Applicant |
| US7141018B2 | Cites | United States of America | Applicant |
| US7230012B2 | Cites | United States of America | Applicant |
| US7820697B2 | Cites | United States of America | Applicant |
| US7874984B2 | Cites | United States of America | Applicant |
| US7959566B2 | Cites | United States of America | Applicant |
| US8204763B2 | Cites | United States of America | Applicant |
| US8315886B2 | Cites | United States of America | Applicant |
| US8589188B2 | Cites | United States of America | Applicant |
| US8626531B2 | Cites | United States of America | Applicant |
| US8673939B2 | Cites | United States of America | Applicant |
| US8735428B2 | Cites | United States of America | Applicant |
| US8741929B2 | Cites | United States of America | Applicant |
| US8828427B2 | Cites | United States of America | Applicant |
| US9056120B2 | Cites | United States of America | Applicant |
| US9101621B2 | Cites | United States of America | Applicant |
| US9101622B2 | Cites | United States of America | Applicant |
| ITO ET AL., SCIENCE, vol. 327, 2010, pages 1345 - 1350 | Non-patent | – | Applicant |
| BARTLETT ET AL., NAT. REV. CANCER, vol. 4, 2004, pages 314 - 322 | Non-patent | – | Applicant |
| MARTINIANI, R ET AL.: "Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma", ADV HEMATOL, vol. 2012, 2012, pages 842945 | Non-patent | – | Applicant |
| TERPOS, E ET AL.: "Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma", ONCOTARGETS AND THERAPY, vol. 6, 2013, pages 531 | Non-patent | – | Applicant |
| TEREFENK ET AL., BIOORG. MED. CHEM. LETT, vol. 15, no. 15, 2005, pages 3600 - 03 | Non-patent | – | Applicant |
| SMOLYAR ET AL., RUSSIAN JOURNALOF ORGANIC CHEMISTRY, vol. 47, no. 8, 2011, pages 119 - 3 | Non-patent | – | Applicant |
| JUN YON CHOI ET AL., J. MED. CHEM., vol. 55, no. 13, 2012, pages 852 - 70 | Non-patent | – | Applicant |
| "Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418 | Non-patent | – | Applicant |
| "IUPAC - Compendium of Chemical Terminology", 1997, BLACKWELL SCIENTIFIC PUBLICATIONS | Non-patent | – | Applicant |
| no. 813424-17-8 | Non-patent | – | Applicant |
12 members in 5 offices
Members12
| Document | Office | Kind | |
|---|---|---|---|
| WO2020181232A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO2020181232A8 | World Intellectual Property Organization (WIPO) | A8 | |
| CN113557235A | China | A | |
| EP3935050A1 | European Patent Office (EPO) | A1 | |
| EP3935050A4 | European Patent Office (EPO) | A4 | |
| US2023019060A1 | United States of America | A1 | |
| EP3935050B1 | European Patent Office (EPO) | B1 | |
| EP3935050C0 | European Patent Office (EPO) | C0 | |
| EP4470618A2This record | European Patent Office (EPO) | A2 | |
| ES2995214T3 | Spain | T3 | |
| EP4470618A3 | European Patent Office (EPO) | A3 | |
| CN113557235B | China | B |
26 legal events, as 3 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| First examination report despatched17Q | 17Q | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: EXAMINATION IS IN PROGRESSSTAA | STAA | EP | |
| Request for examination filed17P | 17P | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: REQUEST FOR EXAMINATION WAS MADESTAA | STAA | EP | |
| Requests to designate patent in hong kongDE | DE | HK | |
| Designated contracting statesAK | AK | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Amendment of ipc main classPREVIOUS MAIN CLASS: A61P0035000000R079 | R079 | DE | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION HAS BEEN PUBLISHEDSTAA | STAA | EP |
Numbers
- Publication
- 4470618
- Application
- 241940345
Titles3
- German
- HETEROCYCLISCHE VERBINDUNGEN ZUR MEDIZINISCHEN BEHANDLUNG
- English
- HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT
- French
- COMPOSÉS HÉTÉROCYCLIQUES POUR TRAITEMENT MÉDICAL
Classification
- CPC, 14
- C07D263/58
- C07D413/04
- C07D405/12
- C07D277/68
- C07D403/04
- C07D417/04
- C07D209/34
- C07D413/12
- C07D413/06
- C07D471/04
- C07D417/06
- C07D498/04
- C07D413/14
- A61P35/00
- IPC, 1
- A61P35 00
Designated states44
- Contracting states, 38
- Albania
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czechia
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Croatia
- Hungary
- Ireland
- Iceland
- Italy
- Liechtenstein
- Lithuania
- Luxembourg
- Latvia
and 14 moreShow fewer
- Monaco
- North Macedonia
- Malta
- Netherlands (Kingdom of the)
- Norway
- Poland
- Portugal
- Romania
- Serbia
- Sweden
- Slovenia
- Slovakia
- San Marino
- Türkiye
- Extension states, 2
- Bosnia and Herzegovina
- Montenegro
- Validation states, 4
- Cambodia
- Morocco
- Republic of Moldova
- Tunisia